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Abstract 
Chronic obstructive pulmonary disease (COPD) and severe asthma are progressive 
chronic inflammatory diseases of the airways.  Both diseases are characterised by 
airflow limitation and share some pulmonary symptoms.  However they have distinct 
inflammatory cell signatures and differ in response to corticosteroid (CS) treatment.  
Most asthmatic patients control their disease with CS, with a few showing a relative 
CS resistance; however COPD patients show little or no improvement with CS and 
are CS insensitive.  Macrophage migration inhibitory factor (MIF) is a pleiotropic pro-
inflammatory mediator whose function is yet to be fully elucidated.  MIF has been 
shown to counter-act the immunosuppressive action of CS.  MIF is elevated in 
chronic diseases such as asthma and atherosclerosis.  The role of MIF in COPD has 
not been investigated and its role in asthma is not fully understood. 
MIF inhibition attenuated ozone-induced airway inflammation and lung function in 
vivo but did not affect CS sensitivity. MIF expression did not vary between stable 
COPD patients and controls.  Pro-inflammatory effects of MIF were investigated in 
THP-1 monocytes and primary cells.  There was no clear role for MIF in LPS-
induced inflammation.  MIF modulated the transactivation functions of CS in THP-1 
cells.  Finally I took an unbiased approach to generate new hypotheses for MIF 
function using proteomic and transcriptomic techniques.  The RIG-I-like pathway was 
identified by proteomics as a novel target pathway and was investigated in THP-1 
cells and human BAL macrophage samples following viral infection. 
The role of MIF in airway inflammation remains unclear and results demonstrated 
here show MIF function does not necessarily translate from mouse to humans.  MIF 
does not seem to have a role in the inflammation of stable disease.  The proteomic 
data suggests that the association between viral infection, MIF and CS in regulating 
CS sensitivity in COPD and severe asthma should be investigated.   
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1.1 Chronic obstructive pulmonary disease (COPD) 
1.1.1 Definition, risk factors and prevalence 
COPD is a common, preventable and treatable disease of the lung airways, it is 
characterised by persistent and usually progressive, airflow limitation (GOLD, 2013).  
COPD is associated with an enhanced inflammatory response of the airways to 
noxious particles or gases, especially cigarette smoking, with some extra-pulmonary 
effects.  An acute exacerbation, which is a sudden worsening of symptoms and 
COPD comorbidities contribute to the severity of disease in individual patients 
(GOLD, 2013).  COPD is a major cause of morbidity and mortality worldwide (GOLD, 
2013) and is currently the 4th leading cause of death worldwide, it is predicted to 
become the 3rd leading cause of death by 2030 (Mathers and Loncar, 2006). 
Comorbidities with COPD include cardiovascular disease (Burrows et al., 1972) and 
diabetes mellitus (Rana et al., 2004).   
COPD is clinically diagnosed using lung function spirometry tests.  The Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) states a post-bronchodilator 
forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio of 
<0.70 and a FEV1 of ≤70% confirms the presence of persistent airflow limitation 
(Table 1.1) and thus a diagnosis of COPD (Rabe et al., 2007, GOLD, 2013).  
Disease severity can also be classified into four stages of COPD (GOLD stage A-D) 
incorporating symptoms and risk of exacerbations in a combined COPD assessment 
(Figure 1.1).  The impact of the patients symptoms are assessed using the COPD 
assessment test (CAT) that gives a score between 0-40; a score ≥10 indicates a 
high level of symptoms (Jones et al., 2009).  The exacerbation risk can be calculated 
from spirometry and FEV1 values or based on individuals’ patient history of 
exacerbations.  Two or more exacerbations in the preceding year indicate high risk 
(Hurst et al., 2010).  The presence of COPD symptoms such as dyspnoea, chronic 
cough and chronic sputum production along with exercise level (measured by 6-min 
walk test) and exposure to risk factors must also be taken into account (Mannino and 
Buist, 2007).    Exacerbations increase the rate of lung function decline and increase 
disease severity (Donaldson et al., 2002).  
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Table 1.1: Spirometry classifications of COPD airflow limitation 
GOLD Classification FEV1 % predicted 
Stage 1: Mild ≥80% 
Stage 2: Moderate 50% ≤ FEV1 < 80% 
Stage 3: Severe 30% ≤ FEV1 < 50% 
Stage 4: very severe <30% or <50%+chronic respiratory failure 
Disease severity can be classified by FEV1 % predicted in combination with a FVC ratio of 
<0.70 and presence of COPD symptoms such as chronic cough and sputum production. 
 
Figure 1.1: Combined COPD assessment 
A combined COPD assessment is used to understand the impact of COPD on individuals.  
This method takes into account the symptomatic assessment (CAT test) with patient’s 
spirometry (GOLD classification) and risk of exacerbations (adapted from (GOLD, 2013)). 
 
Tobacco smoke is the main aetiological factor in COPD development but other 
factors have been shown to be associated with disease prevalence, such as outdoor, 
occupational and indoor pollutants e.g. burning of biofuels for heat and cooking and 
a genetic predisposition (Mannino and Buist, 2007, Barnes and Adcock, 2009). 
COPD was previously more common in men compared to women.  However, as 
more women smoke and are given equal exposures the gender difference has 
reduced and COPD is now equally prevalent between genders (Mannino and Buist, 
2007).  COPD is generally accepted as a disease of the elderly and associated with 
accelerated ageing of the lung (Ito and Barnes, 2009).  COPD is associated with 
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significant economic burdens, in the European Union, 6% of total health care costs 
are spent on respiratory care, 56% of which accounts for spending on COPD.  The 
worldwide burden of COPD is predicted to increase due to continued exposure to 
COPD risk factors and ageing of the population (Lopez et al., 2006). 
1.1.2 Pathophysiology 
Varying contributions of small airways disease and parenchymal destruction cause 
the characteristic airflow limitation seen in COPD patients (Barnes, 2000a).  Small 
airways disease is the result of compression and narrowing of bronchioles due to 
chronic inflammation and structural changes such as fibrosis and scarring (airway 
remodelling) (Saetta et al., 1998).  The narrowing of the airways increases 
resistance and reduces airflow.  Parenchymal destruction is the permanent 
destruction of the lung parenchyma by chronic inflammation. This destruction results 
in the enlargement of airspaces distal to the terminal bronchioles and loss of alveolar 
attachments, lung elastic recoil (lung compliance) (Kim et al., 1991) and leads to 
airflow limitation, as there is an inability for the airways to remain open during 
expiration (Figure 1.2).  
     Healthy       COPD 
 
Figure 1.2: Illustration of healthy and COPD airways  
COPD presents with the characteristic airflow limitation due to chronic inflammation and 
fibrosis of the small airways narrowing the lumen of the airway and increasing the airflow 
resistance.  The airways are also obstructed due to increased mucus production again 
contributing to the reduced airflow.  Another feature that leads to airflow limitation is the 
destruction of lung parenchyma and the reduced ability of keeping the airway open.  
Reproduced with permission from (Barnes, 2000a), Copyright Massachusetts Medical 
Society.  
 
 
Introduction 
 
20 
 
Previous definitions of COPD have included emphysema and chronic bronchitis 
however these clinical terms are no longer used (GOLD, 2013).  Emphysema or the 
destruction of alveoli only describes a single structural abnormality seen in patients 
and therefore unsuitable for such a complex disease.  Chronic bronchitis or the 
presence of a persistent cough and sputum production (for at least 3 months in 2 
consecutive years) remains clinically important.  However, chronic bronchitis is not a 
pathophysiological feature of the characteristic airflow limitation as the cough and 
sputum production may precede the development of airflow limitation due to 
increased mucus production in the upper airways.  Although, there is also reduced 
mucociliary clearance with chronic bronchitis and this has been shown to contribute 
towards increased bacterial colonisation and infections leading to COPD 
exacerbations (Patel et al., 2002, Sethi et al., 2000). 
The decline in FEV1 and severity of disease correlates only with narrowing of small 
airways and not with chronic bronchitis or emphysema, suggesting a predominant 
role of airway remodelling in airflow limitation and COPD development (Hogg et al., 
2004).   
1.2 Asthma 
1.2.1 Definition, risk factors and prevalence 
Asthma is one of the most common chronic diseases in the world, with 235 million 
people worldwide being treated for the disease (WHO, 2013) and its prevalence is 
increasing, especially among children (GINA, 2012).  Asthma is associated with 
persistent inflammation, bronchoconstriction and airway hyper-responsiveness that 
presents clinically as recurrent episodes of wheezing, breathlessness, chest 
tightness and coughing (GINA, 2012).  However, unlike COPD, asthma is 
characterised by reversible expiratory airflow limitation.   
Asthma is a significant burden on healthcare costs with increased hospital 
admissions and care visits costing an estimated £2.5 billion in the UK and resulting 
in about 20 million working days lost annually (Masoli et al., 2004).  The quality of life 
of patients is also compromised by disease-associated comorbidities (Wenzel, 
2006).  
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Asthma is an umbrella term for a heterogeneous disease that is divided into 
phenotypic subgroups with multiple physiological and clinical characteristics (Bel, 
2013, Wenzel, 2006).  However these phenotypes are not fully characterised and the 
distinction between the groups is continually evolving and remains controversial 
(Wenzel, 2012).  
Due to the complexity of the disease, risk factors can be categorised into asthma 
development risks and asthma triggers.  Developmental risks include genetic 
predisposition (Holgate, 1999, Holloway et al., 1999), sensitisation to indoor 
allergens such as house dust mite and fungi (Gelber et al., 1993), tobacco smoking 
(Lange et al., 1998) and respiratory infections (Zambrano et al., 2003).  The triggers 
that can induce an exacerbation or ‘asthma attack’ include exposure to allergens e.g. 
house dust mites (Sporik et al., 1990), exercise (Parsons and Mastronarde, 2005), 
stress and smoke (GINA, 2012). 
1.2.2 Pathophysiology 
The characteristic airway narrowing (bronchoconstriction) in asthma is a result of 
persistent inflammation; airway hyper-responsiveness and airway remodelling in 
asthma and can become relatively irreversible in some patients (Figure 1.3).  
In asthmatic patients the inflammation is more pronounced in the medium-sized 
bronchi within the lung and causes thickening of the airway wall (GINA, 2012).  It is 
also important to note that the airway inflammation is persistent even though the 
symptoms are episodic.  During the inflammatory response bronchoconstrictor 
mediators such as histamine and prostaglandin D2 are released from mast cells and 
stimulate the constriction of airway smooth muscle cells (ASMCs) resulting in airway 
narrowing; this is largely reversed by bronchodilators (Manning and O'Byrne, 1988).   
Airway hyper-responsiveness is the functional characteristic of asthma and results in 
airway narrowing after an innocuous stimulus for a non-asthmatic individual (GINA, 
2012).  Airway hyper-responsiveness is associated with both inflammation and repair 
mechanisms of the airway; however its mechanisms are not fully understood.  
Constriction stimulated by the release of bronchoconstrictor mediators may result in 
excessive narrowing of the airways presenting asthmatic symptoms of dyspnoea 
(Wang et al., 2003).  Another contributing feature to airway hyper-responsiveness is 
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epithelial shedding, which is the loss of barrier function to prevent allergen 
penetration and the initiation of an allergic response (Montefort et al., 1992). 
Airway remodelling is a characteristic structural feature of asthma and corresponds 
to the severity of disease and the relative irreversibility of airway narrowing (Chetta 
et al., 1997).  Contributing towards airway remodeling is sub-epithelial fibrosis, which 
is the thickening of airway walls and a reduction in the airway lumen (Bousquet et al., 
2000).   
Other pathophysiological changes that may give rise to the airway remodelling and 
ultimately the airway narrowing of asthma include, hypertrophy and hyperplasia of 
ASMCs by increasing the thickness of the airway walls and mucus hypersecretion 
leading to ‘mucus plugging’ and increased resistance within the airways (Bousquet et 
al., 2000, James and Wenzel, 2007).  Also, mucosal oedema due to vascular 
leakage during the inflammatory response is associated with asthmatic airway 
narrowing (Wenzel, 2012, Chung et al., 1990, Bousquet et al., 2000). 
 
 
Figure 1.3: Illustration of normal and asthmatic airway 
The airways of asthmatic patients are characteristically narrowed with a smaller airway 
lumen and increased resistance to airflow.  The wall of the airway in asthmatics is thicker 
due to inflammation and hyperplasia and hypertrophy of ASMCs.  Airway hyper-
responsiveness increases the sensitivity to allergens and stimuli, resulting in excessive 
airway narrowing on bronchoconstriction. Adapted from: (NIH, 2013). 
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1.3 Inflammation 
1.3.1 Inflammation in health 
The inflammatory response is a protective mechanism against tissue injury by 
restricting the tissue damage at an affected site.  The hallmarks of inflammation were 
first described over 2000 years ago by the Roman medical writer Aulus Cornelius 
Celsus (30BC-38AD) and are calor (heat), rubor (redness), dolor (pain) and tumor 
(swelling): functio laesa (loss of function) was only included as a cardinal sign of 
inflammation by Galen years later (Kindt et al., 2007).  Within minutes of the injury, 
there is vasodilation resulting in increased blood volume but reduced blood flow at 
the site of injury.  This increase in blood, heats up the surrounding tissue and causes 
the area to redden; this inflammatory sign is only visible at injury sites near to the 
skin (Kindt et al., 2007).  Increased vascular permeability is another trait of the 
inflammatory response that leads to leakage of fluid from the blood vessel into 
tissue.  This accumulation of fluid contributes to the swelling/oedema and redness of 
the injury site.  Pain is felt after the release of mediators stimulating nerve endings 
and pain receptors; again this sign is only apparent where nerves and receptors are 
present (Kindt et al., 2007).  Histamine a potent mediator released from activated 
cells causes further vasodilation and smooth muscle contraction (Manning and 
O'Byrne, 1988). 
Part of the inflammatory response is the activation of the immune response, which is 
split between two systems, the innate and the adaptive systems.  Importantly, these 
two systems do not act independently but collaboratively.  Inflammation is also 
characterised by cells within these systems with recruitment of leukocytes, 
circulating monocytes and tissue macrophages releasing inflammatory mediators 
(Ryan and Majno, 1977) and lymphocytes amplifying inflammation, killing cells or 
producing antibodies (Ennis et al., 1977, Verbonitz et al., 1978).   
1.3.1.1 Innate immunity 
The innate response is the first line of defence against infection and is activated 
within a few hours of infection; however it is less specific than adaptive immunity.  
Initially pathogens have to overcome the hosts’ barriers, which include the skin and 
mucosal membranes (Abbas and Lichtman, 2006).  Phagocytic cells such as tissue 
macrophages and neutrophils are front-line cells of the innate response and reside 
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close to the barriers; some pathogens get phagocytosed and destroyed.  These 
resident innate cells also have pattern recognition receptors (PRR) and recognise 
specific molecules, pathogen-associated molecular patterns (PAMPS) that are 
unique to the microbes (Mogensen, 2009).  Toll-like receptors (TLRs) are a type of 
PRR and are found on the surface and within the cytoplasm of innate immune cells 
such as macrophages.  
One way the innate response is initiated is by the detection of PAMPs by the TLRs 
leading to the release of pro-inflammatory mediators such as cytokines, chemokines 
and lipid mediators and the resulting activation, recruitment and/or migration of cells 
to the site of infection (Akira et al., 2001).  TLRs belong to the IL-1 receptor (IL-1R) 
family, however the TLR and IL-1R have very different extracellular domains and 
distinct ligands but have a conserved intracellular domain that is known as the 
Toll/IL-1R (TIR) domain (Slack et al., 2000).  TLR activation leads to the recruitment 
of adapter proteins (e.g. MyD88) and kinases (e.g. IRAK) (Wesche et al., 1997, Akira 
and Takeda, 2004) (Figure 1.4). 
Directly or indirectly, transcription factors (AP-1, CREB, NF-B and IRF3) are 
activated and translocate to the nucleus, where they bind to promoters of pro-
inflammatory genes and induce gene transcription (Karin, 1995, Ghosh and Karin, 
2002, Park et al., 2005).  Target genes for these pro-inflammatory transcription 
factors include the common inflammatory cytokines IL-1 and TNF that act in a feed 
forward loop to drive and amplify the inflammatory response as well as more specific 
cytokines such as IL-6, IL-12 and type 1 interferon (IFN) and their receptors (Hiscott 
et al., 1993, Collart et al., 1990, Murphy et al., 1995). 
The inflammatory response is not only driven and maintained by the control of gene 
transcription but also by post-transcriptional modifications including modulating 
mRNA turnover, transport and translation (Winzen et al., 2004, Dean et al., 2004).  
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Figure 1.4: Schematic diagram for toll-like receptor (TLR) signalling to initiate 
inflammatory response  
A) Cells with pattern recognition capability identify non-self antigens and these; in turn bind 
to pattern recognition receptors (PRR) such as Toll-like receptors (TLR) to initiate an 
immune response.  The Toll/IL-1R (TIR) domain recruits adapter proteins MyD88 and 
members of the IL-1R-associated kinase (IRAK) family (Suzuki et al., 2002).  B) 
Phosphorylation (P) of IRAK1 by IRAK4 recruits TNF receptor-associated factor-6 (TRAF6). 
C) The IRAK1-TRAF6 complex dissociates and binds transforming growth factor-β-activated 
kinase (TAK1) (Arch et al., 1998, Baud and Karin, 2001, Takeda et al., 2003); both IRAK1 
and TRAF6 are then degraded by ubiquitination (UUU).  D) TAK1 auto-phosphorylates 
(Takeda et al., 2003) and activates either E) IKK (Ghosh and Karin, 2002) or F) MAPK 
(Chang and Karin, 2001) and pathways leading to changes in the transcriptional activity and 
potentiating the inflammatory response. (Schematic adapted (Akira and Takeda, 2004)). 
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1.3.1.2 Adaptive immunity 
The adaptive immune response is a stronger, more effective and highly specific 
mechanism for clearing pathogens and, importantly, has memory compared to the 
innate immune system (Alberts et al., 2002b).  Nonetheless, this immunity can take 
days to develop after the initial exposure. The specificity of the adaptive immunity 
allows for subtle differences among antigens to be detected and the memory ability 
allows for a much quicker and heightened response to occur on a second challenge 
(Kindt et al., 2007).  
Lymphocytes are antigen-presenting cells (APC) and are the main cell type in 
adaptive immunity.  APCs present antigens on the cell surface that are recognised 
by the T cell receptor on T lymphocytes (Abbas and Lichtman, 2006, Kindt et al., 
2007). 
There are two types of adaptive immunity that are mediated by different lymphocytes 
and have different methods to defend against different types of infection.  Humoural 
immunity is mediated by B-lymphocytes that respond by secreting antibodies to 
neutralise and eliminate microbes in the blood and lumen of organs such as the 
respiratory tract (extracellular) (Abbas and Lichtman, 2006, Kindt et al., 2007, Alberts 
et al., 2002b).  In contrast, when cells have taken up microbes intracellularly by 
either phagocytosis or are infected i.e. viruses are dividing within cells, then T-
lymphocytes mediate a cell-mediated response.  T-lymphocytes sub-divide into T 
helper (TH) cells and T cytotoxic (TC) cells, the former are involved in activating 
macrophages to kill the phagocytosed microbes and the latter induce cell death of 
infected cells (Abbas and Lichtman, 2006, Kindt et al., 2007, Alberts et al., 2002b). 
This is summarised in Figure 1.5. 
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Figure 1.5: Types of adaptive immunity 
Adaptive immunity is split into two types, humoural and cell-mediated.  The latter is further 
divided into different cell types.  Each has specific cell types that mediate the immunity and 
each has different effects and functions to eliminate and remove the microbes from the body. 
(Abbas and Lichtman, 2006). 
 
1.3.2 Resolution of inflammation 
Once an inflammatory process and the resulting immune response have been 
initiated the response requires resolution to reduce excessive tissue damage and 
restore tissue function (Lawrence and Gilroy, 2007).  Historically, the resolution of 
inflammation was understood to be achieved by macrophage phagocytosis of 
neutrophils (Savill et al., 1989).  However, resolution has more recently been 
accepted to be an active, complex and coordinated process that has many 
mechanisms to resolve the inflammation quickly and efficiently with minimal damage 
(Gilroy et al., 2004, Serhan, 2011).  
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Chemokines are crucial in recruiting cells such as neutrophils and macrophages to 
the inflamed site and augmenting the inflammatory response.  To resolve the 
inflammation, cells must be cleared and numbers must be returned to basal levels.  
There are many mechanisms to achieve this such as reducing cellular recruitment by 
chemokine truncation (McQuibban et al., 2000, Dean et al., 2008), removal of cells 
without spilling cytotoxic content by neutrophil apoptosis (van den Berg et al., 2001) 
and macrophage re-programming from pro- to anti-inflammatory phenotypes (Fadok 
et al., 1998).  Other mechanisms demonstrated include efferocytosis, where 
macrophages phagocytose cells, such as neutrophils (Henson, 2003), macrophage 
regression via the lymphatic drainage system (Llodra et al., 2004) and induction of 
tissue repair to reduce fibrosis for example by tumour growth factor-β (TGF-β) 
(Rappolee et al., 1988).   
Mechanisms for the negative regulation of the pro-inflammatory mediators include 
mitogen activated protein kinase phosphatases (MKP) that inhibit mitogen activated 
protein kinase (MAPK) signalling (Clark, 2003) and inhibiting the degradation of IB 
that sequesters Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
B) in the cytoplasm and prevent transcription (Baeuerle and Baltimore, 1988).  
Binding of TRAF3 instead of TRAF6 to IRAK1 leads to the induction of IL-10 gene 
expression, which is an anti-inflammatory cytokine (Hacker et al., 2006).  
Alternatively, there is an increasing literature regarding the role of anti-inflammatory 
lipids such as resolvins (Serhan, 2011).  These were not measured in this thesis and 
so are not discussed any further. 
1.3.3 Immune dysfunction and the consequences  
Failure to resolve inflammation leads to immune dysfunction and pathogenesis of 
inflammatory diseases (Lawrence and Gilroy, 2007).  Disorders due to excessive or 
aberrant immune responses to an antigen challenge are collectively known as 
hypersensitivity diseases (Abbas and Lichtman, 2006, Kindt et al., 2007).  Chronic 
inflammation can also develop when an antigen or stimulus persists and this is 
common in autoimmune diseases in which self-antigens continually activate the 
immune response. 
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1.3.3.1 Chronic inflammation 
Continually activated immune cells will constantly release pro-inflammatory 
mediators and will result in a persistent and chronic inflammatory response.  
Continual stimulation of fibroblast proliferation and collagen production will promote 
fibrosis and induce the development of scarring, which can impede normal tissue 
function (Diegelmann and Evans, 2004).  Chronic inflammation can result in 
numerous diseases effecting different tissues and organs and either being systemic 
or localised, such as COPD, asthma, rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE). 
1.3.3.1.1 Chronic inflammation in COPD and asthma 
Asthma and COPD are chronic inflammatory diseases of the airways, however the 
characteristics of the chronic inflammation differ, this is summarised in Table 1.2.    
Elevated numbers of neutrophils have been found in bronchoalveolar lavage fluid 
(BALF) (Thompson et al., 1989) and induced sputum samples from COPD patients 
(Keatings et al., 1996, Hill et al., 1999, Barnes, 2000a).  At sites of destroyed 
parenchyma a predominance of macrophages and CD8+ (TC) lymphocytes have 
been observed (Barnes, 2000a).  These COPD-associated cells release cytokines 
and chemokines to drive and amplify inflammation; elevated cytokine and chemokine 
levels have been detected in BALF and induced sputum from COPD patients 
compared to healthy controls, reviewed in (Barnes, 2008a).   
Levels of the chemokines CCL2 and CCR2 correlate with number of neutrophils, 
macrophages and mast cells in the lung (de Boer et al., 2000).  During 
exacerbations, chemokines are further induced, resulting in more macrophages 
recruited to the inflammation site and augmenting the immune response (Norzila et 
al., 2000). 
Elevated levels of TNF have been reported especially during exacerbations and in 
patients with COPD-associated weight loss (Eagan et al., 2012).  In addition, TNF 
has been shown to act on ASMCs to increase contractibility and have a role in 
airway hyper-responsiveness (Kips et al., 1993).  Inhibition of TNF has been shown 
to have therapeutic benefits in other chronic inflammatory diseases but has limited 
efficacy in asthma despite improvement in lung function and reduced exacerbations 
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being demonstrated in early small studies (Berry et al., 2006).   Indeed, blocking 
TNF is not now considered therapeutically beneficial in asthma since there is no 
clinical benefit of golimumab and its use is associated with severe adverse side 
effects including death (Wenzel et al., 2009).  A similar lack of efficacy associated 
with detrimental effects is seen in COPD (Barnes, 2008a). 
Allergic asthma is immunoglobulin E (IgE)-dependent and the binding of sensitised-
IgE to mast cells orchestrates a rapid asthmatic inflammatory response on second 
exposure of the specific allergen (Gould and Sutton, 2008).  Allergic asthma is also 
accepted to have a predominant TH2 response and levels of eosinophils are 
increased in the sputum (Barnes, 2008a), however asthma is a multifactorial disease 
and other subsets of asthma have been described (Wenzel, 2006).  For example, 
severe asthmatics have neutrophil-mediated inflammation compared to the 
conventional eosinophil-rich inflammation in allergic asthmatics, also a mix of 
TH1/TH2 or principally TH17 phenotypes of asthma have been described (Cosmi et 
al., 2011).  The characteristic bronchoconstriction seen in asthmatic patients is a 
result of histamines and mediators released from activated mast cells and 
eosinophils.   
Numbers of TH17 cells have been shown to be increased in the airways of asthmatic 
patients compared to healthy controls and these cells release IL-17A (Bullens et al., 
2006, Pene et al., 2008).  The expression of IL-17 is also increased in the epithelium 
of asthmatic patients (Chang et al., 2011).  The TH2 response is further amplified by 
increased release of IL-33 and activity of GATA3 (Smithgall et al., 2008), a 
transcription factor that controls the transcription of typical TH2-associated cytokines.  
Increased IL-17F release, a mediator secreted from TH17 cells, is also associated 
with neutrophil-mediated inflammation and induces further chemokine release; this is 
also seen in severe asthmatic patients (Schmidt-Weber et al., 2007).   
The levels of CXCL8 correlate with the number of neutrophils in the sputum of 
severe asthmatics (Norzila et al., 2000) and have been shown to be elevated during 
a viral exacerbation (Fujimoto et al., 2005, Spruit et al., 2003).  IL-10, an anti-
inflammatory cytokine has significantly reduced transcription and secretion levels; 
again, this is common between COPD and asthmatic patients (Takanashi et al., 
1999, John et al., 1998). 
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Growth factors promote the differentiation, survival and proliferation of neutrophils, 
eosinophils, macrophages and fibroblasts, augmenting the inflammation and 
instigating fibrosis of the small airways in COPD (Minshall et al., 1997).  Increased 
levels of growth factors, such as TGF-β from eosinophils have been associated with 
the characteristic sub-epithelial fibrosis seen in the airways of asthmatic patients 
(Minshall et al., 1997).  
The inflammation in COPD and asthma is maintained due to the induction of 
cytokine signalling pathways, which induce the production of further pro-
inflammatory mediators from activated cells in a feed-forward mechanism.   This 
results in chronic inflammation as the acute inflammation is not resolved due to 
mechanisms not fully elucidated.   The inflammatory cycle therefore continues and 
the phenotypes of disease develop.  
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Table 1.2: Inflammatory characteristics of COPD and asthma 
 COPD Asthma 
Histopathology 
  
Structural changes ↑↑↑ Fibrosis (A) 
↑ Airway smooth muscle  
Loss of alveolar attachments 
(emphysema) (B) 
Enlargement of airspaces 
(loss of lung compliance) (C) 
↑ Fibrosis (A) 
↑↑↑ Airway smooth muscle 
(B) 
↑↑ Thickened basement 
membrane (C) 
Inflammation location Small airways 
Lung parenchyma 
Larger airways 
 
Cells types Neutrophils 
Alveolar macrophages 
Epithelial cells 
TH1 and TC lymphocytes 
Eosinophils  
Epithelial cells 
Activated mast cells  
TH2 and TH17 lymphocytes 
Airway smooth muscle 
Associated-cytokines 
(elevated in disease 
patients vs. healthy 
controls) 
TNF, IL-6, IL-1β, IFN-, IL-
17F 
TNF, IL-1β, IL-6, IL-4, IL-5, 
IL-9, IL-13, IL-17A and IL-33 
Associated chemokines CXCL8, CCL2 CXCL8 
Associated growth factors GM-CSF, TGF-β TGF-β 
Airways from a COPD patient and asthmatic patient show overall difference in histology 
between diseases, locations of structural changes are shown on histology image.  The major 
cell types that are involved in orchestrating and driving inflammation in the diseases differ.  
There are some common but also disease specific cytokines, chemokines and growth 
factors that are released (Keatings and Barnes, 1997, Saetta et al., 1993, Aaron et al., 2001, 
Gajewska et al., 2003, Traves et al., 2002, Schmidt-Weber et al., 2007, de Boer et al., 2000). 
Reproduced with permission from (Hogg et al., 2004), Copyright Massachusetts Medical 
Society. 
 
1.3.4 Macrophages  
Macrophages play an important role in the inflammatory response of COPD 
(Shapiro, 1999) and asthma (Peters-Golden, 2004) and are the major cell type in 
recognising infection or injury in the hosts’ innate response.  The numbers of 
macrophages are far greater in COPD than in asthma (Saetta et al., 1993).   Once 
the macrophages are activated, for example by cigarette smoke or other inhaled 
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irritants; they release reactive oxygen species (ROS) and neutrophillic chemotactic 
factors along with prostaglandins, cytokines and extracellular matrix proteins 
orchestrating the inflammatory response (Shapiro and Senior, 1999).  In addition, 
macrophages are detected in higher numbers in COPD BALF samples compared to 
healthy controls (5-10 fold increase) and the numbers in the bronchial submucosa 
increase with disease severity (Barnes, 2000a, Hogg et al., 2004, Saetta et al., 
1993).  The presence of monocyte-attracting chemokines such as MCP-1 (monocyte 
chemotactic protein or CCL2) is elevated in sputum and BALF of patients with COPD 
(de Boer et al., 2000) and may account, in part, for the increased recruitment of 
circulating monocytes into the airways.  
Increased proliferation of cells, including alveolar macrophages and fibroblasts, has 
been associated with fibrosis of the small airways and the progression of COPD 
(Barnes, 2008b).  Similarly, large clusters of macrophages in the small airways may 
be associated with the emphysema observed in some COPD patients (Fraig et al., 
2002).  In asthmatics, pulmonary macrophages have long been recognised to induce 
histamine release from mast cells and basophils to modulate the contraction of 
ASMCs (Schulman et al., 1985) and they are therefore intimately involved in the 
airway hyper-responsiveness seen in asthma. 
Macrophages are also phagocytic and there is a reduction in the ability of 
macrophages to clear apoptotic and dying cells in COPD and asthma (Hodge et al., 
2003).  This may result in secondary necrosis and exacerbation of the inflammatory 
process (Vandivier et al., 2006, Huynh et al., 2005).  Alveolar macrophages show 
impaired phagocytosis of neutrophils if exposed to cigarette smoke (Kirkham et al., 
2004) and express reduced levels of recognition receptors such as CD44 and CD31 
(Hodge et al., 2007).  The clearance of apoptotic cells by macrophages is termed 
efferocytosis and this function has been reported to be defective in clearing epithelial 
cells in COPD (Hodge et al., 2003). 
Alveolar macrophages also release the anti-inflammatory cytokine IL-10 in response 
to inflammatory stimuli.  However there are markedly decreased in levels of sputum 
IL-10 in COPD patients compared to healthy controls (Takanashi et al., 1999). 
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1.3.5 Inflammatory signalling 
1.3.5.1 MAPK signalling cascade 
MAPKs are a family of signal transduction enzymes and one of the major signalling 
systems used by cells to initiate a response.  There are three classes of MAPK, p38, 
extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK).  
MAPKs are organised into three hierarchal levels and they all operate via the 
phosphorylation of both threonine (Thr) and tyrosine (Tyr) residues converting them 
into the activated form and finally resulting in the interaction with cytoplasmic 
substrates and the translocation into the nucleus (Ferrell and Bhatt, 1997).  All p38, 
ERK and JNK signalling pathways have been implicated in inflammatory processes; 
ERK MAPK is involved in cell proliferation, differentiation and survival, whereas p38 
and JNK MAPKs are mainly involved in mediating pro-inflammatory responses and 
apoptosis (Herlaar and Brown, 1999).  Disease initiation and progression has been 
shown to correlate with the activation status of p38 MAPK in severe asthmatics 
(Bhavsar et al., 2008) and smokers with COPD have increased activated p38 MAPK 
in lung alveolar spaces and walls (Renda et al., 2008).  Recent evidence from a 
small placebo-controlled clinical trial indicates that the orally available p38 MAPK 
inhibitor PH-797804 is well tolerated by COPD patients and has some beneficial 
effects on lung function and dyspnoea (MacNee et al., 2013).  Alternatively, p38 
MAPK inhibition in combination with an inhaled CS (ICS) has been proposed to be of 
potential benefit in severe asthma and COPD (Armstrong et al., 2011). 
1.3.5.2 Proliferation and p53 
Proliferation of alveolar macrophages and their role in activating surrounding tissues 
and cells has been implicated in the development of fibrosis of the small airways and 
overall progression of COPD (Barnes, 2004).  In asthma, a pathophysiological 
feature of disease is the hypertrophy of ASMCs; this may be the result of the cells 
being stimulated by growth factors secreted by activated inflammatory cells (Barnes, 
1996).  
The p53 gene (TP53) is a tumour-suppressor gene; its fundamental role is to protect 
against cellular damage by controlling cell cycle or inducing apoptosis (Alberts et al., 
2002a).  Baseline levels of p53 are kept low until its activation when the levels are 
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dramatically increased and its functional targets, such as p21WAF1 are induced 
(Mirzayans et al., 2012).  
Proliferation, cell growth and apoptosis are not only driven via p53-dependent 
pathways but through the pro-inflammatory MAPK pathways (Tamemoto et al., 1992, 
Pedram et al., 1998, Takenaka et al., 1998, Zhang and Liu, 2002). 
1.4 Corticosteroids 
Corticosteroids (CSs) are potent anti-inflammatory substances used as therapeutics 
in many inflammatory diseases including inflammatory bowel disease, RA and 
autoimmune diseases.  CSs are used to control asthma and COPD and although the 
majority of asthmatic patients are relatively well controlled with CS, a small 
percentage of severe asthmatics do not see any therapeutic benefits even with high 
doses of oral CS (Wenzel et al., 1999).  Most COPD patients show little or no benefit 
to CSs (Barnes, 2000b).  Severe asthmatics and COPD patients are said to be 
relatively steroid insensitive with respect to their anti-inflammatory properties.  
Understanding the mechanisms in which CS function has aided in elucidating the 
mechanisms of steroid insensitivity.  
CSs diffuse across the plasma membrane and bind to the glucocorticoid receptor 
(GR) complex in the cytoplasm (Rhen and Cidlowski, 2005).  GR has two isoforms; 
GRα and GRβ.  In its inactivated form GR is chaperoned by a number of proteins 
including heat shock protein 90 (HSP90).  CS bind to GR resulting in conformational 
changes and release from HSP90 and chaperone proteins (Kang et al., 1999).  The 
GR-CS complex translocates into the nucleus, where two distinct pathways are 
activated, transrepression and transactivation, reviewed in (Barnes and Adcock, 
2003).   
Transrepression results in the suppression of inflammation by turning off activated 
genes that encode for cytokines, chemokines, adhesion molecules and receptors 
(Barnes and Adcock, 2003) via the regulation of transcription factors AP-1 and NF-
B (Barnes and Adcock, 1998).  Activated GR monomers bind to the activated DNA-
bound pro-inflammatory transcription factors and results in changes of the chromatin 
structure through the recruitment of co-repressors with histone deacetylase (HDAC) 
activity (Ito et al., 2000).  HDAC proteins prevent DNA acetylation and reduce 
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transcriptional activity.  More recently the concept of assisted loading whereby the 
previous presence of other transcription factors can prime chromatin and direct the 
activated GR or other transcription factors to select regions in the genome has been 
proposed as key to GR function (Biddie et al., 2011, Voss et al., 2011). 
Transactivation is DNA-dependent and induces the expression of anti-inflammatory 
genes such as MKP-1 (Kassel et al., 2001), IκBα (Heck et al., 1997) and the anti-
inflammatory cytokine IL-10 (Rea et al., 2000).  MKP-1 de-phosphorylates MAPK 
proteins and therefore suppresses the inflammatory response (Lasa et al., 2002) and 
IκBα is a protein that retains the NF-B complex in the cytoplasm preventing its 
translocation into the nucleus (Verma et al., 1995).  Mechanistically, initial data 
suggested that binding of the GR-CS complex to the GR response element (GRE) 
within the promoter of GR-inducible genes leads to the recruitment of co-activators 
with histone acetyltransferase (HAT) activity and changes in the chromatin structure, 
enabling increased gene transcription (Barnes and Adcock, 2003).  More recent 
evidence has indicated that the assisted loading process may also occur at GREs 
with preloading of AP-1 allowing a more amenable chromatin structure for GR 
activation to form (Voss et al., 2011).   
Transcriptional activity is also affected by epigenetic regulators and unrecognised 
regulatory proteins suggesting that GR may not directly participate in the ultimate 
regulation of gene transcription (Uhlenhaut et al., 2013). 
1.4.1 Corticosteroid insensitivity 
Severe asthma and COPD are diseases that are uncontrolled and show poor 
treatment responses due to lack of novel therapeutics and steroid insensitivity. 
Disease-associated burdens include major health care costs but also lost 
productivity, reduced participation in family life and CS side effects (GINA, 2012, 
GOLD, 2013).   
Persistent asthma in both adults and children is successfully treated in the majority 
of cases with CSs and people lead normal lives with improved lung function and 
quality of life and reduced frequency of exacerbations (Barnes, 1996, O'Byrne and 
Parameswaran, 2006).  However about 10% of asthmatic patients require the 
maximum inhaled CS dose and 1% of these patients require oral CSs (Barnes, 
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2013) despite evidence for compliance with treatment.  These patients are described 
as CS insensitive and present with poor disease control and no reduction in the 
inflammation (Adcock and Lane, 2003).  Smoking asthmatics also show CS 
insensitivity and require higher doses (Thomson and Spears, 2005, Ahmad et al., 
2008); biopsies of steroid insensitive asthmatics have revealed the typical 
eosinophilic inflammation of asthma (Szefler and Leung, 1997). 
COPD patients prescribed with high doses of ICS or orally available CSs show little 
improvement in lung function or reduction in numbers of inflammatory cells or 
mediators within the lung (Adcock et al., 2006, Keatings et al., 1997).  However, a 
25% reduction in COPD exacerbation rate was seen with inhaled CSs (ICS) (Yang et 
al., 2007).  There is small clinical benefit of CS monotherapy and the increasing 
evidence that high doses are potentially harmful (Walters et al., 2009). 
Increasing doses of CSs also result in deleterious side-effects despite failure to 
inhibit the pro-inflammatory cytokine release (Keatings and Barnes, 1997) leaving no 
treatment available for these patients.  Steroid insensitivity has been reported in 
many other inflammatory diseases such as RA and cystic fibrosis (Barnes and 
Adcock, 2009). 
There are many mechanisms implicated in causing steroid insensitivity in COPD and 
severe asthma.  These mechanisms are also reported in other chronic inflammatory 
diseases indicating common impairments causing CS insensitivity and not specific 
disease traits.   
1.4.1.1 Mechanisms of CS insensitivity 
1.4.1.1.1 Genetics 
It was first reported that “CS-resistant asthma” was more common within families, 
indicating a strong genetic role in the development of CS insensitivity (Carmichael et 
al., 1981).  Genetic studies using microarrays and genome wide association studies 
have identified polymorphisms within GR and differentially expressed genes in CS-
insensitive/resistant asthmatics compared to healthy controls (Donn et al., 2007, van 
den Akker et al., 2006).  One gene, bone morphogenetic protein receptor type II 
(BMPRII) was found to enhance the CS-effect when transfected into CS insensitive 
cells (Donn et al., 2007).  To date, a link between COPD patients and genetic 
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susceptibility has not been established however there is evidence that genetics may 
play a role in COPD development.  
1.4.1.1.2 GRβ 
Another proposed mechanism leading to CS-insensitivity is the elevated expression 
of GRβ, the dominant negative isoform of GR (Webster et al., 2001), which has been 
reported in steroid-resistant asthmatic patients (Hamid et al., 1999, Sousa et al., 
2000).  There is no evidence of increased expression of GRβ in COPD but GR is 
reduced (Gagliardo et al., 2000).  This change in GRβ to GR ratio within the 
inflammatory cells may impair the CS function (Marwick and Chung, 2010), although 
there have been no studies into the functional effects of an increased GRβ ratio.  
Moreover, knockdown of GRβ in alveolar macrophages resulted in enhanced nuclear 
translocation of GR and increased CS sensitivity (Goleva et al., 2006).    
1.4.1.1.3 HDAC2 
Removal of acetyl groups on core histones or on non-histone proteins by HDACs 
results in the suppression of gene transcription and a ‘closed’ chromatin structure.  
Reports have shown steroid insensitive COPD patients have significantly reduced 
HDAC expression by more than 95% compared to non-smokers and have enhanced 
inflammatory response (Ito et al., 2005).  HDAC is essential for GR transrepression 
of some inflammatory genes and therefore reduced HDAC expression and activity 
may impair CS function either through altering GR acetylation status or modifying 
histone or other non-histone proteins (Ito et al., 2006).  Restoring HDAC function 
correlates with improved CS ability to suppress the expression of select inflammatory 
genes (Cosio et al., 2004).  
1.4.1.1.4 p38 MAPK 
Kinase signalling amplifies the inflammatory response and p38 MAPK has been 
shown to be elevated in peripheral lungs and alveolar macrophages from COPD 
patients compared to smokers (Renda et al., 2008) and in patients with severe 
asthma compared to non-severe disease (Bhavsar et al., 2008).  In support of this 
enhanced pro-inflammatory response, reduced expression of MKP-1 was reported in 
severe asthmatics (Bhavsar et al., 2008).  However, few reports have shown CS-
induced MKP-1 or related genes in asthmatics or COPD patients (Kelly et al., 2012).  
Therefore, it is unknown whether the CS insensitivity is due to impaired MKP-1 
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production and activity or altered CS-signalling in disease.  IL-2, IL-5 and IL-4 
expression is increased in the airways of patients with CS-insensitive asthma (Leung 
et al., 1995) and in vitro the combination of IL-2 and IL-4 induces steroid insensitivity 
by enhancing p38 MAPK activation (Irusen et al., 2002).  The increased p38 MAPK 
activation leads to the phosphorylation of GR and reduces CS affinity binding within 
nucleus (Irusen et al., 2002).  More recently direct phosphorylation of GR by p38 
MAPK induced by stress responses and/or prolonged inflammation has been shown 
(Galliher-Beckley et al., 2011).  
1.4.1.1.5 Oxidative stress 
COPD patients have increased oxidative stress in their lungs and airways compared 
to healthy patients, (Brindicci et al., 2005, Montuschi et al., 2000, Rahman et al., 
2002) which may be augmented by exogenous cigarette smoke or endogenous 
sources such as respiratory burst of cells (Park et al., 2009).  Both the cigarette 
smoke and increased oxidative stress have an inhibitory effect on HDAC function 
and reduces HDAC expression (Adcock et al., 2005, Ito et al., 2001, Ito et al., 2004, 
Yang et al., 2006) and this, in part, may explain the reduced action of CSs (Barnes, 
2000b).  In COPD patients, steroid sensitivity is not restored upon smoking cessation 
as once instigated ROS stress self-perpetuates for many years or even decades 
(Keatings and Barnes, 1997, Rahman et al., 2002).  Studies investigating the 
production of antioxidants have demonstrated that COPD patients have reduced 
capacity to induce antioxidant defences (Smolonska et al., 2009).  Furthermore, the 
oxidative stress caused by cigarette smoking enhances the need for efficient 
antioxidant defences and if due to genetic reasons the production is altered then the 
development of COPD is more likely (Mak et al., 2007). 
1.5 Macrophage migration inhibitory factor (MIF) 
MIF was one of the first cytokines to be discovered; it was originally described in 
1966 as a soluble mediator released from activated T-lymphocytes that inhibited the 
random migration of macrophages, in the delayed-type hypersensitivity (DTH) 
reaction (Bloom and Bennett, 1966, David, 1966).  However MIF remained unstudied 
until the cloning of human MIF complementary DNA (cDNA) in 1989 (Weiser et al., 
1989) and its rediscovery as a pituitary-derived peptide released in response to 
endotoxin in mice in 1993 (Bernhagen et al., 1993). 
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Subsequently, MIF has been shown to be constitutively expressed by an extensive 
variety of cells (Calandra et al., 1994, Donnelly et al., 1997).  Although previously 
thought of as a MIF target, monocytes/macrophages have been shown to be the 
predominant source of MIF both constitutively and in response to LPS (Calandra et 
al., 1994).  Other immune cells secreting MIF include; lymphocytes (Bacher et al., 
1996) neutrophils (Daryadel et al., 2006), eosinophils (Rossi et al., 1998) and 
structural cells include; ASMCs (Verschuren et al., 2005), epithelial  (Imamura et al., 
1996) and endothelial cells  (Nishihira et al., 1998).  MIF is also expressed in many 
tissues such as the brain, lung, heart, kidney and liver (Calandra and Roger, 2003). 
MIF is pre-formed and stored within vesicles in the cytoplasm of cells, allowing for 
rapid release, in contrast to other pro-inflammatory mediators like IL-1β that require 
de novo synthesis before being secreted (Calandra et al., 1994).  The MIF gene 
does not encode for a N-terminal signal sequence and therefore the MIF protein 
cannot translocate to the endoplasmic reticulum (ER) for the classical pathway of 
secretion (Flieger et al., 2003).  Similarly to IL-1β but conversely to other pro-
inflammatory mediators like CXCL8 and TNF, MIF is released from cells via a non-
classical pathway involving ATP-binding cassette transporters (ABCA1) (Flieger et 
al., 2003).  After secretion MIF stimulates and activates many target cells in an 
autocrine and paracrine fashion such as macrophages, lymphocytes, epithelial and 
ASMCs.   
1.5.1 From genome to protein 
The MIF gene is located on chromosome 22q11.2 of the human genome (Paralkar 
and Wistow, 1994, Budarf et al., 1997).  MIF mRNA encodes a 115-amino acid non-
glycosylated protein with a molecular weight of 12.5kDa. The MIF gene consists of 3 
exons, 205bp, 173bp and 183bp in length and 2 introns (189bp and 95bp) (Weiser et 
al., 1989).  There is 90% homology between the human MIF and mouse Mif gene at 
the amino acid level and MIF is a highly conserved protein across many mammalian 
species (human, rat, mouse and cattle), despite this, genetic deletion of Mif in mice 
results in no immunological or physiological abnormalities (Bozza et al., 1999).  
The control of MIF expression is not fully understood but the MIF gene is known to 
contain several putative DNA-binding sequences for transcription factors including, 
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AP-1, NF-B, GATA and cyclic adenosine 3’,5’-monophosphate (cAMP)-responsive 
element binding (CREB) protein (Calandra and Roger, 2003). 
Three-dimensional X-ray crystallography studies of human and rat showed that MIF 
exists as a homotrimer (Figure 1.6) (Suzuki et al., 1996, Sun et al., 1996a).  Each 
monomer consists of 2 anti-parallel α-helices and six β-strands, the trimer is a barrel 
structure with a solvent-accessible channel running through the centre of the protein 
(Suzuki et al., 1996, Sun et al., 1996a).  It has been suggested that MIF action is 
either via the monomer or dimer form of the protein, dependent upon its 
concentration however this is controversial with no clear evidence either way 
(Tomura et al., 1999, Mischke et al., 1998).  
Recent studies have shown there is one gene that is homologous with MIF that 
encodes a protein known as D-dopachrome tautomerase (D-DT).  MIF and D-DT are 
both located on chromosome 22 and also share a structural homology and functional 
activities (Merk et al., 2012).  D-DT recently has been described as a member of the 
MIF superfamily and designated MIF-2 (Merk et al., 2012) however studies into the 
role of D-DT in severity and augmentation of disease and its association with MIF will 
need elucidating. 
 
Figure 1.6: Ribbon structure of MIF protein 
Ribbon diagram of three-dimensional structure of the MIF trimer. Red, yellow and blue 
represent the monomers of the trimer.  In the monomer, two -helices pack against the β-
sheets. In the trimer, the β-stranded barrel is surrounded by six -helices. (Lolis, 2001). 
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1.5.2  Genetic polymorphisms 
Mutations in the MIF gene may predispose affected individuals to altered 
susceptibility to, or severity of inflammatory/infectious diseases.  Polymorphisms 
within the MIF gene have been associated with disease severity and poor clinical 
manifestations (Plant et al., 2005). 
To date, four polymorphisms within the MIF gene and promoter have been reported: 
a 5-8-CATT tetranucleotide repeat at position -794 (-794 CATT(5-8)) and 3 single-
nucleotide polymorphisms (SNPs) at positions -173 (-173*G/C), +254 (+254*T/C) 
and +656 (+656*C/G).  The +254 and +656 SNPs are positioned in introns and 
therefore do not affect the coding sequence of MIF gene (Baugh and Bucala, 2002, 
Donn et al., 2001, Donn et al., 2002).  Gene reporter assays and human clinical 
studies have shown that the increased number of the CATT(5-8) repeats in the 
promoter region is associated with increased MIF expression (Baugh et al., 2002).  
Studies on inflammatory diseases including asthma and RA have shown the 
presence of more CATT repeats, thus high-expression of MIF, is related to disease 
severity (Mizue et al., 2005, Radstake et al., 2005). 
1.5.3 Role of MIF in the immune response 
Although MIF was originally discovered as a factor secreted from activated T-
lymphocytes in delayed-type hypersensitivity (DTH) reactions, the current view 
favours a predominant role in innate immunity.  The role of MIF in adaptive immunity 
is not completely defined and most reports are from mouse cells or models.   
1.5.3.1 MIF in the innate response 
MIF has been shown to act in an autocrine and paracrine fashion, directly and 
indirectly acting on its own synthesis induction and other pro-inflammatory mediators 
induction, along with activating and recruiting inflammatory cells and inducing 
phagocytosis (Bacher et al., 1996, Bozza et al., 1999, Donnelly et al., 1997, Makita 
et al., 1998, Mitchell et al., 2002, Mitchell et al., 1999).  Overall it is understood that 
MIF initiates the inflammatory response (Calandra et al., 1994, Bernhagen et al., 
1993).  MIF is rapidly released from various immune cells on exposure to pathogens, 
microbes, pro-inflammatory cytokines or during antigen-specific activation (Calandra 
et al., 1998)  
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In mouse models, MIF treatment augments LPS-induced toxicity and anti-MIF 
neutralisation protects the mice from lethal endotoxic shock (Bernhagen et al., 1993).  
Genetically deleted MIF mice are likewise resistant to LPS-lethality (Bozza et al., 
1999).  The inflammatory role of MIF and the attenuation of toxicity, by anti-MIF 
antibodies and MIF knockout mice, were also seen with bacterial exotoxin (Calandra 
et al., 1998, Bacher et al., 1996).  The innate response of MIF is not species specific 
and has also been demonstrated in rats with endotoxemia (Bacher et al., 1997).  The 
importance of MIF in LPS signal transduction and gram-negative bacteria recognition 
was studied in RAW 264.7 mouse macrophages, where MIF-induced up-regulation 
of the TLR4 receptor was shown, allowing for quick recognition of gram-negative 
bacteria and endotoxin activating the innate immune response (Roger et al., 2001). 
1.5.3.2 MIF in the adaptive response 
Mouse T-cells constitutively express MIF with TH2 cells producing more MIF than 
TH0 and TH1 cells (Bacher et al., 1996).  In vitro, MIF is induced from primary mouse 
T-cells by anti-CD3 and super-antigen and is associated with IL-2 secretion and 
proliferation, both of which were decreased with anti-MIF antibodies (Bacher et al., 
1996). 
In vivo mouse studies confirm the role of MIF in DTH reactions, with exogenous MIF 
potentiating the reaction and MIF-neutralising antibodies resulting in reduced 
antigen-specific T-cell proliferation and IgG production (Santos et al., 2001, 
Bernhagen et al., 1996).  This reduced DTH reaction was further supported in 
genetically deleted MIF mouse studies (Santos et al., 2008). 
More recently MIF has been associated with other cell-mediated immunity roles 
including activating T cells in contact hypersensitivity and mixed lymphocyte 
reactions (Shimizu et al., 2003).  MIF is also able to stimulate IL-17 secretion from 
mouse lymph node cells (Stojanović et al., 2009).  A mitogenic effect of MIF on T-
cells has not been shown and therefore MIF may exert its role in adaptive immunity 
as a co-factor. 
1.5.4 Mechanism of action 
MIF is yet to be fully understood functionally and its roles within the immune system 
are still to be fully elucidated.  MIF belongs to no known protein superfamily and has 
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hence been described as a cell-specific cytokine, chemokine, hormone and/or 
enzyme to explain its plethora of cellular functions, summarised in Figure 1.7. 
1.5.4.1 Cytokine 
Cytokines are soluble factors that react with receptors on various cell types to exert a 
signalling cascade to perform functions and coordinate immune responses. 
MIF released into the circulation behaves as a classic pro-inflammatory cytokine by 
activating MAPK and modulating the gene transcription of various mediators 
including cytokines (TNF, IFN, IL-6 and IL-1β), chemokines (CXCL8 and CXCL2), 
and prostaglandin and leukotrienes (prostaglandin E2 (PGE2) and cyclooxygenase 2 
(COX-2)) in mice (Calandra et al., 1994, Bozza et al., 1999, Mitchell et al., 1999, Lue 
et al., 2006).  Furthermore, MIF was shown to directly induce TNF in human 
monocytes (THP-1 cells) and mouse macrophages (RAW264.7 cells) (Senter et al., 
2002, Calandra et al., 1995) but not in murine peritoneal macrophages (de Jong et 
al., 2001).  Mixed results have been reported regarding MIF induction of IL-6, IL-12, 
IL-1β and COX-2 as well (Onodera et al., 2004, Santos et al., 2004). 
Other MIF cytokine-like functions include the enhancement of proliferation and 
activation of T-lymphocytes (Calandra et al., 1998) and the suppression of p53-
induced apoptosis (Mitchell et al., 1999).  MIF was first implicated in cellular 
proliferation as an essential regulatory mediator in T-lymphocyte and endothelial cell 
proliferation and modulating the immune response after activation of lymphocytes 
(Bacher et al., 1996).  Association between MIF and p53 was proposed in 1999 
(Hudson et al.) and MIF inhibiting p53 activation in mice macrophages was 
demonstrated a few years later (Mitchell et al., 2002).  MIF cysteine residue (Cys81) 
directly binds to two cysteine residues on p53 (Cys242 and Cys238), confirmed by co-
imunnoprecipitation and results in inhibition of many p53 targets including p21waf1 
and the pro-apoptotic BAX gene expression (Jung et al., 2008).  MIF has also been 
suggested to drive inflammation through its proliferative effects as shown in ex vivo 
vascular smooth muscle cells in atherosclerosis mice, causing hypertrophy and 
artery remodelling (Chen et al., 2004). 
MIF is generally accepted to be a pro-inflammatory mediator maintaining the 
inflammatory response; although some bacterially expressed MIF reagents have 
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been shown to contain various levels of LPS contamination (Bernhagen et al., 1994, 
Calandra et al., 1995, Lubetsky et al., 2002) and hence some reports give 
controversial results. 
MIF concentrations in the serum of healthy individuals (0.1-100ng/ml) (Petrovsky et 
al., 2003) are much higher than those of other pro-inflammatory cytokines (TNF 
and IL-6) at baseline that can barely be detected, questioning the potency of MIF.  
Also the lack of homology between other pro-inflammatory cytokines and the ability 
of MIF to signal via non-receptor endocytosis and to bind and inactivate c-Jun 
activation domain-binding protein (JAB1) do not support the cytokine-like function of 
MIF. 
1.5.4.2 Chemokine  
Chemokines are low molecular weight proteins that activate and cause leukocytes to 
migrate to the site of injury or infection.  In contrast to its name, reports have 
demonstrated the direct induction of classical chemokines by MIF, including CXCL8 
(Onodera et al., 2004, Santos et al., 2004), CCL5 (RANTES) and CCL2 (MCP-1) 
(Gregory et al., 2006).  MIF has been classified as having a ‘chemokine-like function’ 
(CLF) chemokine (Bernhagen et al., 2007, Gregory et al., 2006, Ren et al., 2003), 
other CLF chemokines include thioredoxin (TRX) (Bertini et al., 1999) and 
complement factor 5a (C5a) (Sozzani et al., 1995).  Much of the current 
understanding of the chemokine-like functions of MIF have been elucidated through 
vascular research such as in atherosclerosis (Burger-Kentischer et al., 2002), 
although this is a major comorbidity of COPD (Burrows et al., 1972). 
The involvement of MIF in cellular migration, recruitment and promoting trafficking 
has been demonstrated in the following in vivo models and in vitro systems.  
Intravital microscopy was used to report that exogenous MIF recruited more 
macrophages via MIF induced-CCL2 (Gregory et al., 2006).  MIF-induced CCL2 and 
MAPK activation was also shown in vitro to increase migration of mouse neutrophils 
and macrophages (Fan et al., 2011, Santos et al., 2011). 
Gregory and colleagues have also shown that genetically deleted MIF mice have 
reduced leukocyte-endothelial cell interactions in response to stimuli (Gregory et al., 
2004).  In human in vitro studies using umbilical vein endothelial cells (HUVECs), 
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exogenous MIF was shown to increase TNF-induced leukocyte rolling and 
adhesion via the up-regulation of p-selectin expression (Cheng et al., 2010, Simons 
et al., 2011). 
Increased numbers of neutrophils present in a mouse model of LPS-induced airway 
inflammation was shown to be MIF dependent (Makita et al., 1998) and MIF 
neutralisation of an ovalbumin (OVA)-challenged mouse model resulted in reduced 
recruitment of neutrophils and eosinophils to the lung (Kobayashi et al., 2006).  MIF 
was found to exert its chemotactic properties on neutrophils, monocytes and T-cells 
via binding to receptor complexes involving CD74/CXCR2/CXCR4 (Bernhagen et al., 
2007). 
MIF also contributes to cellular recruitment and migration in non-immune cells, by 
promoting the migration of rat smooth muscle cells (Okamoto et al., 2008) and up-
regulating the migration of mouse fibroblasts in a model of wound healing (Dewor et 
al., 2007). 
 
Figure 1.7: Schematic of MIF cellular functions 
MIF has been reported to function in many ways including as a cytokine, chemokine, 
hormone and enzyme.  At the cellular level, MIF has been shown to induce cytokine and 
chemokine production, induce cellular proliferation and recruitment and to inhibit 
macrophage migration and p53-induced apoptosis. 
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1.5.4.3 Hormone 
Based on rodent models, MIF is considered a mediator of the hypothalamic-pituitary-
adrenal (HPA) axis (Bucala, 1996, Bernhagen et al., 1993).  MIF is released in a 
hormone-like fashion from the hypothalamus, pituitary gland and adrenal gland in 
response to stress or stimuli (Bernhagen et al., 1993, Nishino et al., 1995, Bacher et 
al., 1998).  The levels of MIF have been reported to rise with adrenocorticotropic 
hormone (ACTH), a hormone released from the pituitary to stimulate the adrenal 
release of CSs acting to counteract the immunosuppressive function (Calandra et al., 
1994, Nishino et al., 1995) (See Section 1.6).   
In human studies, MIF release is secreted in a diurnal rhythm corresponding to that 
of endogenous CSs with a plasma concentration of 0.1-100ng/ml (Petrovsky et al., 
2003).  However, an effect of exogenous CSs on MIF secretion from pituitary cells 
and subsequent systemic effects have not been demonstrated (Isidori et al., 2002) 
although MIF can override the hydrocortisone induced-inhibition of NF-B activation 
(Daun and Cannon, 2000).  The doses of hydrocortisone used in this latter study 
were physiological and therefore MIF was shown to antagonise the effect of naturally 
occurring steroids at circulating levels, enabling an immune response to occur (Daun 
and Cannon, 2000).  Although MIF is released in a hormone-like fashion the function 
of MIF may be mediated through its cytokine-like or catalytic activity. 
1.5.4.4 Enzyme 
MIF shares a similarity in protein structure with enzymes such as the human D-DT 
(Sugimoto et al., 1997) and some prokaryotic enzymes for example the 4-
oxalocrotonate tautomerase.  Interestingly, MIF not only shows structural similarity to 
but also functional activity with these enzymes.  Reports show different catalytic 
activities of MIF; including that of a phenylpyruvate keto-enol isomerase (Rosengren 
et al., 1996), D-DT (Rosengren et al., 1996) and a thiol-mediated oxidoreductase 
(Kleemann et al., 1998) that may be involved in the biological function of MIF.   
Similar to its recently demonstrated homologue D-DT, MIF is capable of 
tautomerising non-physiological substrates such as D-dopachrome into 5,6-
dihydroxyindole-2-carboxylic acid (DHICA) (Rosengren et al., 1996).  Inhibition of the 
tautomerase activity of MIF with (S,R)3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole 
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acetic acid methyl ester (ISO-1) (Lubetsky et al., 2002) has been reported to 
attenuate inflammation (See Section 1.5.7).  The immune function of MIF regarding 
mouse endotoxemia and its protective effects towards LPS-lethality is comparable to 
that of D-DT, although further investigations into the role of D-DT are required (Merk 
et al., 2012). 
MIF possesses a CXXC motif that is also present in thiol-mediated oxidoreductase 
enzymes, like thioredoxin (TRX).  These enzymes function in cellular 
oxidation/reduction processes acing as anti-oxidants (Sun et al., 1996b).  A positive 
correlation between the anti-oxidant TRX and MIF in plasma of sepsis patients has 
been reported (Leaver et al., 2010).  However the relationship between TRX, MIF 
and oxidative stress in COPD and severe asthma has not been investigated. 
The amino-terminal proline (Pro-1) residue has been shown to be essential for MIF 
catalytic activity (Bendrat et al., 1997).  However it remains to be established if this 
enzymatic activity is required for the biological function of MIF. 
1.5.5 MIF receptors  
Before 2003, no receptor for MIF was known and the precise MIF/receptor complex 
profiles are yet to be fully resolved.  To date the receptors appear to be cell and 
function specific and these are being extensively researched. 
1.5.5.1 Membrane-bound receptors 
Leng and colleagues identified CD74 as a cell surface binding protein for MIF by 
using an expression cloning strategy in THP-1 monocytes (Leng et al., 2003).  CD74 
is the cell surface form of the major histocompatibility class II-associated invariant 
chain, however CD74 has no signal transduction ability (Stumptner-Cuvelette and 
Benaroch, 2002).  Pathways and mechanisms to transduce the signal have been 
suggested, such as regulated intramembrane cleavage, recruitment of cytosolic 
proteins and recruitment of membrane signalling proteins (Leng and Bucala, 2006). 
A signal transduction molecule that has been shown to complex with CD74 is CD44.  
CD44 as a co-receptor is needed to elicit a response through Src tyrosine kinase 
activation (Meyer-Siegler et al., 2004).  Activation of CD74-CD44 by MIF leads to 
subsequent pro-survival signals in B-lymphocytes, for example proliferation and anti-
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apoptotic protein production (Gore et al., 2008), activation of the MAPK pathways 
ERK1/2 (Mitchell et al., 1999, Lue et al., 2006), which is most characterised and p38 
MAPK (Santos et al., 2004), inhibition and activation of JNK (Lue et al., 2011) and 
production of PGE2 (Mitchell et al., 2002) as well as activation of 
phosphatidylinositide 3-kinase (PI3K) (Lue et al., 2007, Amin et al., 2003).  
MIF/CD74 signalling has been associated with both the pro-inflammatory and anti-
apoptotic functions of MIF.  
CD74 has also been shown to complex with chemokine receptors.  CXCR2 and 
CD74 binding on monocytes, increases the MIF-induced adhesion of monocytes 
(Bernhagen et al., 2007), whilst CD74/CXCR4 binding activates JNK MAPK via 
Src/PI3K/JNK/AP1 pathway and induces CXCL8 production (Kleemann et al., 2000, 
Lue et al., 2011). 
It has also been postulated that extracellular MIF binds to chemokine receptors, 
CXCR4/CXCR2 complexes or CXCR4 and CXCR2 alone (Bernhagen et al., 2007) 
and more recently CXCR7 (Tarnowski et al., 2010) to elicit its CLF. 
MIF and CXCR2 binding has been shown to mediate the CLF and indirectly affect 
leukocyte adhesion.  Inhibitor studies have shown the MIF/CXCR2 binding mediates 
monocyte and T-lymphocyte arrest and PI3K activation leading to neutrophil 
adhesion (Lue et al., 2007, Smith et al., 2006) and modulating expression of 
adhesion proteins via NF-B and gene transcription (Lee et al., 2012).  
CXCR4 is widely expressed on immune cells including T-lymphocytes, monocytes 
and structural fibroblasts (Murphy et al., 2000) and has been implicated in cell 
recruitment processes.  MIF induces T-lymphocyte recruitment and arrest through 
CXCR4 binding (Bernhagen et al., 2007).  MIF/CXCR4 binding also activates AKT 
signalling in monocytes and fibroblasts, which was confirmed by inhibiting receptor 
binding (Schwartz et al., 2009).   
1.5.5.2 Intracellular signalling 
MIF has also been shown to interact and directly bind with c-Jun activation domain-
binding protein-1 (JAB1).  Both endogenous intracellular MIF and exogenous MIF 
after endocytosis, bind to JAB1 (Kleemann et al., 2000).  MIF antagonises JAB1-
stimulated AP-1 transcription and JAB1-induced JNK activity (Kleemann et al., 
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2000).  JAB1 also binds to p27Kip1, stopping the cell cycle, and promoting its 
degradation.  MIF inhibits this function and p27Kip1 levels rise, reducing cell 
proliferation (Hudson et al., 1999).  MIF/JAB1 complexes have been detected in 
atherosclerotic plaque tissue (Burger-Kentischer et al., 2002) and pituitary tumours 
(Pyle et al., 2003). 
JAB1 has also been shown to serve as a ‘molecular sink’, where MIF/JAB1 
complexes prevent MIF secretion (Kleemann et al., 2000) and therefore inhibit MIF-
induced PI3K/Akt activation.  Genetic inhibition of JAB1 by RNA interference resulted 
in a significant increase in secreted MIF in human embryonic kidney cells (HEK293) 
(Lue et al., 2007). MIF-induced PI3K/Akt signalling promotes cell growth and survival 
and inhibits apoptosis by inactivating pro-apoptotic proteins (BAD and FOXO3a); 
MIF/JAB1 complexes therefore prevent an excessive pro-survival response of cells 
(Lue et al., 2007). 
It has been suggested that at low MIF concentrations, MIF would signal through 
membrane bound receptors (CD74) functioning in a pro-inflammatory fashion.  
However at higher concentrations of MIF it could act via the non-receptor based 
JAB1-mediated signalling pathway and thus have a negative effect on inflammation 
and cell growth (Bucala, 2000) (Figure 1.8). 
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Figure 1.8: Overview of exogenous MIF signalling to control inflammation and cell 
growth 
MIF can initiate signalling cascades via membrane-bound receptor complexes or via non-
receptor binding to modulate the pro-inflammatory processes and growth of cells. A) MIF 
binding to membrane bound CD74 in complex with CD44 leads to activation of MAPK and 
PI3K signalling pathways and increased production of pro-inflammatory cytokines.  MIF-
CD74/CD44 binding also enhances cell cycle progression by inhibiting apoptosis.  B) MIF 
signalling through CXCR7 has been stipulated but downstream signalling is not fully 
elucidated.  C) MIF signals via chemokine receptors to initiate chemokine functions such as 
inducing cellular adhesion and migration to site of injury.  D) MIF binds chemokine receptors 
in complex with CD74 to activate cytokine and chemokine functions.  E) At high 
concentrations of exogenous MIF, the protein is endocytosed into the cytoplasm of the target 
cell where it binds and inactivates JAB1.  Inactive JAB1 inhibits anti-apoptotic processes and 
results in reduced pro-inflammatory mediator production.  Adapted from (Bucala, 2000, 
Tillmann et al., 2013). 
 
1.5.6 Molecular tools for MIF blockade 
Neutralising anti-MIF antibodies have been used in various animal models of disease 
to demonstrate the anti-inflammatory efficacy of inhibiting MIF, for example in 
endotoxemia and exotoxemia (Bernhagen et al., 1993, Calandra et al., 1998), 
arthritis (Leech et al., 1998) and cancer (Meyer-Siegler and Hudson, 1996). 
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However, neutralising antibodies make poor therapeutic agents due to the loss of 
efficacy over time, the inconvenient administration and the cost of production, 
therefore small molecule inhibitors are preferred (Chames et al., 2009).  The lack of 
evidence for specific MIF functions and, at the time, no MIF receptor being identified 
made testing inhibitors challenging.  However, the enzymatic activity of MIF and the 
identification of MIFs catalytic domain allowed the design of selective low molecular 
weight inhibitors.  The dopachrome tautomerisation assay was mainly used to 
measure potency of potential MIF inhibitors, however functions including MIF-
dependent phosphorylation of ERK1/2 in fibroblasts (Mitchell et al., 1999) and MIF 
overriding CS suppression of TNF in murine cells (Calandra et al., 1994) was also 
used to confirm the efficacy of MIF inhibitors. 
ISO-1 is a small molecule antagonist of MIF tautomerase activity that binds to the 
enzymatic active site (Lubetsky et al., 2002) and is the best characterised MIF 
inhibitor (Figure 1.9).  ISO-1 has been shown to inhibit the D-DT conversion and to 
prevent the CS-mediated suppression to TNF, PGE2 and COX-2 release in a 
concentration-dependent manner in vitro (Lubetsky et al., 2002).  ISO-1-treated mice 
have enhanced survival in a model of sepsis following caecal ligation and puncture 
(Al-Abed et al., 2005).  Furthermore, ISO-1 was shown to attenuate OVA-induced 
lung inflammation in a mouse model of allergic asthma to comparable levels seen 
with dexamethasone pre-treatment (Chen et al., 2010). 
Other compounds have been shown to inhibit MIF function, albeit at differing 
potencies and acting via different mechanisms, for example irreversible inhibition of 
MIF by acetaminophen metabolites (Senter et al., 2002) or isothiocyanate-based 
molecules (Ouertatani-Sakouhi et al., 2009) or reversible inhibition by 
benzisothiazolones (Jorgensen et al., 2011). 
More recently, a newer irreversible inhibitor of MIF was reported, 4-iodo-6-
phenylpyrimidine (4-IPP) (Winner et al., 2008) (Figure 1.9).  Similarly to ISO-1, the 4-
IPP compound was shown the block MIF-dependent tautomerase activity, MIF-
dependent cell migration and MIF-dependent cell growth although demonstrating ≈5x 
to 10x more potency than ISO-1 (Winner et al., 2008).  This compound has been 
proposed as a potential anti-cancer agent (Winner et al., 2008). 
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A)        B) 
 
Figure 1.9: MIF inhibitors 
Chemical structures of small molecule inhibitors of MIF A) ISO-1 ((S,R)3-(4-hydroxyphenyl)-
4,5-dihydro-5-isoxazole acetic acid methyl ester) and B) 4-IPP (4-iodo-6-phenylpyrimidine) 
(Winner et al., 2008) 
 
MIF has also been successfully deleted from the genome of mice by removing exon 
3 of the Mif gene.  Genetically deleted MIF mice present normal growth, fertility and 
development (Bozza et al., 1999) and have been used to confirm the involvement of 
MIF in many disease models (Leech et al., 2003, Mizue et al., 2005, Santos et al., 
2004). 
1.5.7 MIF association with diseases 
MIF expression is elevated and implicated in the pathophysiology of a plethora of 
diseases including asthma (Rossi et al., 1998), RA (Leech et al., 1999), 
atherosclerosis (Burger-Kentischer et al., 2002, Lin et al., 2000), SLE (Rovensky et 
al., 1975) and many cancers such as prostate, brain and non-small cell lung cancer 
(Brock et al., 2012, Wang et al., 2011a, Meyer-Siegler et al., 2002).  Studies 
investigating the role of MIF in these diseases have revealed MIF functioning in 
many of the ways discussed above.  Although the role and purpose of MIF in these 
diseases are not fully understood it remains to be determined if the role of MIF is 
beneficial or detrimental in a particular disease.   
Of major interest to this study, Rossi and colleagues first reported that MIF was 
significantly elevated in BALF from asthmatic patients compared to healthy controls 
and eosinophils were a major source of MIF release (Rossi et al., 1998, Yamaguchi 
et al., 2000).  The understanding that MIF is predominantly secreted from TH2 cells 
compared to TH1 cells (Bacher et al., 1996), expressed by both immune and lung 
structural cells (Donnelly et al., 1997) and in the absence of MIF, an inefficient 
Introduction 
 
54 
 
control of helminthic infection (Rodriguez-Sosa et al., 2003) supports the suggestion 
that MIF has a role in the pathogenesis of allergic asthma. 
Increased serum levels of MIF in SLE patients compared to healthy controls 
correlated with SLE-related tissue damage scores and CS exposure (Foote et al., 
2004, Mizue et al., 2005).  Further evidence of the involvement of MIF in chronic 
inflammatory diseases was found when a single polymorphism in the MIF promoter 
region (-173*C) was reported to not only correlate with increased prevalence of SLE 
(Sanchez et al., 2006) but was also associated with the acceleration of radiological 
damage and increased disease severity in RA (Radstake et al., 2005).  The role of 
MIF in the pathogenic events of RA is best characterised and well accepted (Morand 
et al., 2006).  There are many reports demonstrating increased MIF in the serum or 
synovial fluid of RA patients compared to controls and that MIF expression correlates 
with disease severity (Baugh and Bucala, 2002, Leech et al., 1999, Onodera et al., 
1999, Morand et al., 2002).  In support of this, antagonism of MIF by an anti-MIF 
antibody resulted in prolonged survival or reduced disease severity in a rat adjuvant 
arthritis model (Leech et al., 1998), a mouse antigen-induced arthritis (AIA) model 
(Santos et al., 2001) and in a mouse collagen-induced arthritis model (Mikulowska et 
al., 1997).  The involvement of MIF in RA was further confirmed in MIF deficient mice 
in an AIA model (Leech et al., 2003).  Many RA-associated cells have been shown to 
express MIF (macrophages, endothelial cells and fibroblast-like synoviocytes) 
(Leech et al., 1999, Onodera et al., 1999) and in turn MIF has been shown to 
stimulate the release of RA-related cytokines and pro-inflammatory mediators 
(TNF, IL-1 and CXCL8) (Onodera et al., 2004, Calandra et al., 1995, Santos et al., 
2004, Donnelly et al., 1997). 
MIF has been shown to be elevated during the progression of atherosclerosis, a 
chronic inflammatory disease characterised by the chemokine-mediated influx of 
cells to site of injury in the arterial wall (Burger-Kentischer et al., 2002).  In a similar 
manner to RA, many pathogenic events involved in atherosclerosis can be mediated 
by or induce the release of MIF.  For example MIF is implicated in plaque 
destabilisation due to MIF-induced matrix metalloproteinase release in the artery wall 
(Schober et al., 2004, Kong et al., 2005).  
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Interestingly, cardiovascular disease (CVD) and the risk of atherosclerosis is 
increased in patients with SLE (Bruce, 2005) and RA (Goodson, 2002).  COPD 
patients have many systemic burdens and comorbidities caused by many factors 
including chronic inflammation and long-term smoking that increase the risk of 
further complications.  COPD patients also have increased risk of developing CVD 
(Burrows et al., 1972); however, the role of MIF in either potentiating or causing CVD 
in COPD patients has not been investigated. 
1.6 MIF and CS insensitivity 
As previously discussed, relative CS insensitivity is a great burden on patients with 
severe asthma and COPD, resulting in loss of disease control.  The discovery that 
MIF counter-regulates the anti-inflammatory actions of CS has driven MIF research 
in several chronic inflammatory diseases, where relative CS insensitivity is a major 
clinical concern (Calandra et al., 1995).  The relationship between CSs and MIF also 
differs compared to other pro-inflammatory cytokines as MIF expression is induced 
by low concentrations of CSs (Calandra et al., 1995, Bacher et al., 1996).  However 
this MIF induction was not seen at the gene level and a role for post-translational 
mechanisms has been proposed (Fingerle-Rowson et al., 2003).  It has also been 
reported that CSs positively regulate the expression and secretion of MIF (Petrovsky 
et al., 2003).  
MIF-mediated CS-antagonistic effects have been shown in vivo, where exogenous 
MIF overrode CS inhibition of lethality by endotoxic shock in mice (Calandra et al., 
1995).  Similarly, Santos and colleagues demonstrated that exogenous MIF inhibited 
dexamethasone suppression of inflammation in an allergen-induced arthritis model in 
MIF deficient mice (Santos et al., 2001).  MIF counter-regulation of CSs has also 
been shown in rat models of RA, where neutralisation of MIF showed reduced joint 
inflammation and histological severity of diseases was reversed (Leech et al. 2000). 
In 2006 it was reported that MIF expression levels are raised in colonic mononuclear 
cells from patients with CS resistant ulcerative colitis, and the anti-inflammatory 
response of CSs was restored with anti-MIF antibodies (Ishiguro et al., 2006).  These 
data suggest that together MIF and CSs reciprocally control the regulation of 
inflammation.  
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The mechanisms behind this reciprocal regulation have not been fully elucidated but 
include inhibition of MKP-1 (Roger et al., 2005) and induction of IB (Daun and 
Cannon, 2000).  MKP-1 is up-regulated by CSs and negatively regulates all MAPK 
pathways (Flaster et al. 2007), addition of MIF inhibits MKP-1 induction in a 
concentration-dependent manner (Roger et al., 2005).  IB binds and inhibits the 
translocation of NF-B into the nucleus, therefore retaining the transcription factor in 
the cytoplasm and reducing inflammation (Karin, 1999). 
In human studies, genetic polymorphisms in the MIF gene have been associated 
with CS insensitivity and reduced clinical response in RA (De Benedetti et al., 2003), 
nephrotic syndrome in children (Berdeli et al., 2005), SLE (Baugh and Bucala, 2002) 
and asthma (Rossi et al., 1998).  Although this has been disputed (Ayoub et al., 
2008), the evidence still warrants investigation of MIF counter-regulating CS 
function. 
There is currently relatively little research into MIF and its associations with asthma 
and/or COPD compared to the other chronic inflammatory diseases despite 
advances in MIF biology and the development of newer antagonists.  Due to the 
comparable chronic inflammatory status and the similar pathophysiology of these 
diseases with COPD and severe asthma, measuring MIF and investigating its effect 
on CS function in lung diseases may provide a rationale for novel therapies in these 
diseases. 
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1.7 Hypothesis 
Patients with chronic obstructive pulmonary disease (COPD) and severe asthma 
have elevated levels of macrophage migration inhibitory factor (MIF) that drives the 
chronic airway inflammation.  MIF also counter-regulates the immune-suppressive 
action of corticosteroids and therefore is a mechanism for the relative corticosteroid 
insensitivity seen in COPD and asthma. 
1.8 Aims 
i. Investigate the role of MIF in a CS insensitive in vivo model of COPD and 
determine whether MIF antagonism can restore this CS sensitivity. 
ii. Establish expression profiles of MIF in COPD patient samples. 
iii. Investigate the role of MIF at baseline and in a LPS-induced inflammation 
model in both primary and immortalised human cells. 
iv. Confirm the counter-regulatory role of MIF on CS function and investigate 
potential mechanisms in human THP-1 cells. 
v. Investigate global mRNA and protein expression changes to identify novel 
pathways and protein interactions involved in human MIF signalling.  
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2.1 Materials 
Table 2.1: Cell culture reagents 
REAGENT SUPPLIER 
Dialysed foetal bovine serum Sigma-Aldrich, Dorset, UK 
Heat-inactivated, foetal bovine serum (FBS) Sigma-Aldrich, Dorset, UK 
L-Arginine:HCL (U-13C6) CK gas products, Hampshire, UK 
L-Arginine:HCL (U-13C6, U-15N4) CK gas products, Hampshire, UK 
L-Glutamine Sigma-Aldrich, Dorset, UK 
L-Lysine:2HCL (4,4,5,5-D4) CK gas products, Hampshire, UK 
L-Lysine:2HCL (U-13C6, U-15N2) CK gas products, Hampshire, UK 
L-Methionine Sigma-Aldrich, Dorset, UK 
Phosphate-buffered saline (PBS) Sigma-Aldrich, Dorset, UK 
Roswell park memorial institute (RPMI-1640 
medium 
Sigma-Aldrich, Dorset, UK 
RPMI 1640 medium without arginine, leucine, lysine, 
and phenol red 
Sigma-Aldrich, Dorset, UK 
Sterile tissue culture grade water Sigma-Aldrich, Dorset, UK 
TIB-202 (THP-1 cells) ATCC, Rockville, MD, USA  
Trypan Blue Sigma-Aldrich, Dorset, UK 
 
Table 2.2: Laboratory Reagents 
REAGENT SUPPLIER 
5x siRNA Buffer Dharmacon, Colorado, USA 
ACCUSPINTM System-Histopaque®-1077 Sigma-Aldrich, Dorset, UK 
AMV reverse transcriptase enzyme Promega, Southampton, UK 
AMV reverse transcriptase reaction buffer Promega, Southampton, UK 
BD OptEIA™ TMB substrate reagent  BD sciences, Erembodegem, Belgium 
Bovine serum albumin (BSA) Sigma-Aldrich, Dorset, UK 
Bradford solution Bio-Rad Laboratories, Hertfordshire, UK 
Calcium chloride Sigma-Aldrich, Dorset, UK 
Deoxynucleotide triphosphates (dNTPs) Promega, Southampton, UK 
Diff-Quick Reagena, Toivala, Finland 
Dimethylsulphoxide (DMSO) Sigma-Aldrich, Dorset, UK 
ECF substrate GE Healthcare, Buckinghamshire, UK 
Fura-2AM Invitrogen, Paisley, UK 
Hanks buffered salt solution (HBSS) Sigma-Aldrich, Dorset, UK 
Marvel Milk Powder Waitrose, Berkshire, UK 
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Methylthiazolydiphenyl-tetrazolium bromide 
(MTT) 
Sigma-Aldrich, Dorset, UK 
MIF ON-TARGETplus non-targeting pool siRNA Dharmacon, Colorado, USA 
Novex® Sharp pre-stained protein standard Invitrogen, Paisley, UK 
NuPAGE® LDS sample buffer (4x) Invitrogen, Paisley, UK 
NuPAGE® MES SDS running buffer (20x) Invitrogen, Paisley, UK 
NuPAGE® MOPS SDS running buffer (20x) Invitrogen, Paisley, UK 
NuPAGE® Novex® Bis-Tris 10% mini gels Invitrogen, Paisley, UK 
ON-TARGETplus SMARTpool MIF siRNA Dharmacon, Colorado, USA 
Phosphate-buffer solution with Tween® 20 Sigma-Aldrich, Dorset, UK 
Pluronic acid Invitrogen, Paisley, UK 
QIAshredders™ homogenisers Qiagen, West Sussex, UK 
Quantitect SYBR® Green PCR mastermix Qiagen, West Sussex, UK 
Random primers Promega, Southampton, UK 
ReBlot™ Plus antibody stripping solution Millipore, MA, USA 
Recombinant RNasin ribonuclease inhibitor Promega, Southampton, UK 
RNase-free water Sigma-Aldrich, Dorset, UK 
Sodium chloride  Sigma-Aldrich, Dorset, UK 
TaqMan® Gene Expression Master Mix Invitrogen, Paisley, UK 
Trizma Sigma-Aldrich, Dorset, UK 
Tween® 20 Sigma-Aldrich, Dorset, UK 
β-mercaptoethanol Sigma-Aldrich, Dorset, UK 
 
 
Table 2.3: Assay kits 
KIT SUPPLIER 
Amaxa® cell line nucleofector® kit V Lonza, Cologne, Germany 
Cell proliferation BrdU kit Roche diagnostics, West Sussex, UK 
DuoSet ELISA kits  R&D Systems, Abingdon, UK 
Nuclear extraction kit Active Motif, Rixensart, Belgium 
PhosphoTracer ELISA Abcam, Cambridge, UK 
Proteome Profiler Human Phospho-MAPK 
Array Kit R&D Systems, Abingdon, UK 
RNeasy mini kit Qiagen, West Sussex, UK 
TransAM™ assays Active Motif, Rixensart, Belgium 
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Table 2.4: PCR primers and annealing temperatures  
GENE OLIGO SEQUENCE 
ANNEALING 
TEMPERATURE 
MIF forward  5’-CGGCAAGCCCGCACAGTACATC-3’ 
58ºC 
MIF reverse  5’-CACGTTGGCAGCGTTCAT-3’ 
18S forward 5’-CTTAGAGGGACAAGTGGCG-3’ 
60ºC 
18S reverse 5’-ACGCTGAGCCAGTCAGTGTA-3’ 
DUSP1 forward 5’-ACCACCACCGTGTTCAACTT-3’ 
60ºC 
DUSP1 reverse 5’-GAGGTCGTAATGGGGCTCTG-3’ 
IL8 forward 5’-TTTTGCCAAGGAGTGCTAAAG-3’ 
60ºC 
IL8 reverse 5’-TTTCTGTGTTGGCGCAGTGTGG-3’ 
 
The following Taqman® probes were commercially ordered from Applied 
Biosystems® at Invitrogen, Paisley, UK. 
Table 2.5: TaqMan Gene Expression Assaysprobes 
GENE PRODUCT CODE  DYE 
18S  4310893E VIC™ TAMRA™ 
MIF Hs00236988 FAM 
DUSP1 Hs00610256 FAM 
DDX58 Hs00204833 FAM 
IFIH1 Hs01070332 FAM 
TNF Hs01113624 FAM 
IL8 Hs00174103 FAM 
TP53 Hs01034249 FAM 
CD74 Hs00269961 FAM 
 
Table 2.6: Primary antibodies for Western blotting 
PRIMARY ANTIBODY FINAL CONC SUPPLIER 
β-actin Anti-Mouse 1/20000 Abcam, Cambridge, UK 
MDA5 Anti-Rabbit 1/1000 Cell signaling, Danvers, MA, USA 
MIF Anti-Goat 1/2500 Abcam, Cambridge, UK 
Total IRF3 Anti-Rabbit 1/2000 Cell signaling, Danvers, MA, USA 
p-IRF3 Anti-Rabbit 1/1000 Cell signaling, Danvers, MA, USA 
RIG1 Anti-Rabbit 1/1000 Cell signaling, Danvers, MA, USA 
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Table 2.7: Secondary alkaline phosphatase conjugated antibodies for Western 
blotting 
SECONDARY ANTIBODY FINAL CONC SUPPLIER 
Polyclonal goat anti-rabbit 25ng/ml Millipore, MA, USA 
Polyclonal rabbit anti-goat 25ng/ml Millipore, MA, USA 
Polyclonal rabbit anti-mouse 25ng/ml Millipore, MA, USA 
 
Table 2.8: Compounds 
COMPOUND STOCK SOLUTION SUPPLIER 
Anti-CD74 (c-16) 200µg/ml 
Santa Cruz, Heidelburg, 
Germany 
Dexamethasone 5×10-2M in sterile H2O Sigma-Aldrich, Dorset, UK 
ISO-1 5mg/ml in 10% DMSO 
VWR International,  
Leicestershire, UK 
Ketaset (Ketamine) 100mg/ml  
Fort Dodge Animal Health, Fort 
Dodge, IA, USA 
Lipopolysaccharide (LPS)  1mg/ml Sigma-Aldrich, Dorset, UK 
Pentobarbital sodium 20% w/v JM Loveridge, Hampshire, UK  
Poly (I:C) 1mg/ml in sterile H2O InvivoGen, San Diego, CA, USA 
Recombinant human MIF 0.1mg/ml eBioscience, Hatfield, UK  
Xylacare (Xylazine) 2% w/v 20mg Animalcare, York, UK 
 
Table 2.9: Equipment 
EQUIPMENT SUPPLIER 
7500 Real-time PCR systems Applied Biosystems, Invitrogen, Paisley, UK 
96-well MicroWell™ NUNC plates Fisher Scientific UK, Loughborough, UK 
Aeroneb® Lab Micropump Nebulizer EMMS, Hants, UK 
Biotek Instuments microplate reader Winooski, VT, USA 
Corning® clear bottom 96-well plates Sigma-Aldrich, Dorset, UK 
Fluostar Optima Fluorimeter BMG LabTech, Aylesbury, UK 
 G-storm Thermocycler LabTech International, East Sussex, UK 
iBlot® dry blotting system Invitrogen, Paisley, UK 
ImageQuant TL Software GE Healthcare, Buckinghamshire, UK 
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Inverted light microscope Leica Microsystems, Buckinghamshire, UK 
Microcentrifuge Hettich Mikro 22R DJB Labcare, Buckinghamshire, UK 
NanoDrop™ Lite LabTech International, East Sussex, UK 
Nucleofector® II device Lonza, Cologne, Germany 
Oesophageal catheter EMMS, Hants, UK            
Optical microscope  Olympus Optical Company Ltd., Tokyo, Japan 
Ozonizer (model 500) Sander, Wuppertal, Germany 
Pneumotachograph EMMS, Hants, UK 
RotorGene RG3000 Corbett Research, Crawley, UK 
Shandon cytospin 4 Thermo Electron Corporation, MA, USA 
Sigma 4-16K centrifuge SciQuip Ltd, Shropshire, UK 
SkanWasher 400 Skatron, Molecular Devices, CA, USA 
Storm 840 Phosphoimager Molecular Dynamics, New Jersey, USA 
Transducer EMMS, Hants, UK 
Ventilator (MiniVent 845) Hugo Sach Electronic, Germany 
2.2 In Vitro Methods 
2.2.1 In vitro cell culture 
THP-1 cells, a human leukaemia monocytic cell line, were purchased from the 
American Type Culture Collection (ATCC) and cultured in complete RPMI-1640 
growth medium supplemented with 10% FBS and 2mM L-glutamine at a density of 
0.3×106 cells/ml.  Sub-culturing every 2-3 days ensured that the cell density did not 
exceed 1×106 cells/ml.  Cells were cultured in a humidified 5% CO2 atmosphere, kept 
at 37°C and counted using trypan blue (1:10 dilution) and a haemocytometer.  Prior 
to stimulation and experiments, cells were cultured in starvation media (phenol red-
free RPMI-1640 medium supplemented with 0.5% FBS and 2mM L-glutamine) at a 
cell density of 0.5x106 cells/ml 
2.2.2 Isolation of peripheral blood mononuclear cells (PBMCs) 
Venous blood (60 ml) was collected into three 20 ml syringes containing 1 ml of acid 
citrate dextrose (ACD) solution.  PBMCs were isolated using the ACCUSPINTM 
System-Histopaque®-1077 that utilises a porous high-density polyethylene barrier. 
Anticoagulated blood (20ml) was poured into each tube and then centrifuged at 
1000×g for 10 min at room temperature.  After centrifugation the plasma layer “upper 
layer” was carefully removed and the opaque interface, containing mononuclear cells 
(PBMCs) was transferred into a clean tube.  PBMCs were washed with Hank’s 
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buffered saline solution (HBSS) and centrifuged at 250×g for 10 min at room 
temperature this was repeated twice. PBMCs were then resuspended in the 
appropriate volume of complete RPMI-1640 medium.  PBMCs were counted using a 
cell counting chamber and seeded onto 96-well plates for further experiments to be 
carried out. 
2.2.3 Cell viability 
2.2.3.1 MTT 
Cell viability was determined by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) assay.  The assay measures the ability of the mitochondria within 
living cells to reduce the yellow MTT dye to its purple formazan product.  This 
product is then dissolved with DMSO; the absorbance reading of the resulting 
solution is proportional to the number of viable cells.    
Briefly, cells were plated in 96-well tissue culture plates (0.1×106 cells/well) and 
stimulated according to the specific experimental procedure.  At the end of the 
experiment, the plates were spun down and the supernatants were carefully 
removed.  The cells were then incubated in 100µl of 0.5mg/ml MTT solution in 
serum-free RPMI medium for 3 hours.  Confirmation of the purple product within the 
cells was observed using a light microscope, 100µl DMSO was added to each well to 
lyse cells and dissolve the formazan product. The plates were placed on a plate 
shaker for a few minutes to ensure the product is dissolved. The absorbance at 
550nm was measured using a microplate reader.  The effect of treatment on cell 
viability was calculated as a percentage of OD relative to the untreated control.  
2.2.4 Transient Transfection  
Knockdown of MIF was achieved using the nucleofection process developed by 
Amaxa AG Biosystems.  The effects of siRNA on the MIF gene were temporary and 
loss of gene expression was reversed as the cells proliferated. 
2.2.4.1 Nucleofection  
THP-1 cells were transiently transfected with MIF siRNA following Amaxa protocols 
specific for THP-1 cells.  Transfection efficiency is reported by Lonza to be ≈70%, 
measured by transfecting 0.5μg of a plasmid encoding enhanced green fluorescent 
protein. 
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Transfection experiments had three controls: Naïve- untransfected cells, Mock 
transfection- cells which were subjected to nucleofection but in the absence of any 
siRNA and Scramble- cells which were subjected to nucleofection with functional 
non-targeting siRNA. 
THP-1 cells (2×106) were either resuspended in nucleofector solution with 
supplement (100µl per control and treatment) or 10% FBS complete RPMI media. 
MIF On-target siRNA (200nM) was carefully added to 100µl of cell suspension to 
each specific electroporation cuvettes; was then added to each cuvette to be 
electroporated.  All samples, apart from the naïve- untransfected control, were 
electroporated with the pre-set program V-001 on the nucleofector device.  
Transfected cells were then resuspended in 10% FBS complete RPMI media and 
reseeded into 6-well, 24-well and 96-well plates for 24, 48 and 72 hours. The 
seeding density was empirically determined as 750µl for 6-well plates, 200µl for 24-
well plates and 50µl (in triplicate) for 96-well plates.  The cells from the 6-well and 
24-well plates were for protein (Section 2.2.6) and mRNA (Section 2.2.5) extraction 
respectively to determine the MIF protein knock down, whereas the cells from the 
96-well plates were for treatment and stimulant experiments.  
2.2.5 Determination of mRNA expression 
The determination of mRNA expression was achieved by extracting total RNA from 
the cells, preparing complementary DNA (cDNA) by reverse transcription (RT) and 
then measuring by real-time quantitative PCR (RT-qPCR) 
2.2.5.1 RNA extraction 
Total RNA was isolated from THP-1 cells using the RNeasy Mini Kit; all 
centrifugation was performed at room temperature.  Lysis and disruption of cells was 
achieved by the addition of RLT buffer with 1% β-mercaptoethanol (β-ME), which 
immediately inactivated RNases and maintained integrity of RNA.  Homogenisation 
of lysate was performed using QIAshredder spin columns and centrifuged for 2 
minutes at 12000×g.  An equal volume of ethanol (70%) was mixed, with the 
homogenised lysate and the sample transferred to RNeasy spin columns.  The 
columns were centrifuged for 15s at 12000×g; spin columns were washed with Buffer 
RW1, and then washed twice with Buffer RPE, after the final wash step the 
remaining RPE buffer is removed by centrifuge for 2 minutes at 12000×g.  Total RNA 
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was then eluted from the spin column in 50µl RNase-free water by centrifugation for 
1 min at 12000×g.   
Total RNA was then stored at -80°C until use, quantification and purity was achieved 
using a Nanodrop™ Lite.  RNA concentration was given in ng/µl and purity was 
determined by ratio of absorbance at 260nm and 280nm (A260/A280), mRNA used 
had a value ≥1.6 and ≤2. 
2.2.5.2 Reverse transcription 
Total RNA (0.5µg) was resuspended in 10µl of RNase free water and was denatured 
at 70°C for 5 minutes.  Single stranded cDNA was then synthesised by addition of a 
master mix containing relevant components to complete the RT reaction, shown in 
Table 2.10.  Samples were then incubated at 42°C for 1hr followed by an enzyme 
inactivation step at 90°C for 4 minutes.  After the RT reaction, 40µl of DEPC-treated 
water was added to the RT-product to dilute magnesium present in sample.  cDNA 
was stored at -20°C until use. 
Table 2.10: Master mix components for reverse transcription (RT) reaction 
REAGENT VOLUME/ REACTION (µL) FINAL CONCENTRATION 
5x AMV buffer 
 
4 1x 
dNTPs 2 1mM 
Random primers 1 1µg 
RNasin 1 40U 
AMV RTase 1 10U 
H2O-DEPC 1 N/A 
cDNA product Up to 10µl in DEPC-H2O  
 
2.2.5.3 Real time quantitative polymerase chain reaction (qPCR) 
Gene transcript levels of specific genes were quantified by Real Time- qPCR using 
either QuantitTect SYBR® Green performed on a Rotor-Gene 3000 machine and 
Rotor-Gene 6 software (Corbett Research; Australia) or TaqMan® performed on an 
ABI systems model and analysed using 5700 software.  The total reaction volume 
was 20µl for both protocols; see Table 2.11 & 2.12 for reagents and concentrations.  
To account for variations within the protocol, gene transcript levels of 18S RNA, a 
housekeeping gene, was also quantified and used for normalisation.  Primer 
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sequence and optimal annealing temperatures used in the SYBR® green method are 
in Table 2.4.  For the SYBR® green method, the reaction involved an initial heat step 
of 95°C for 15 minutes to activate the DNA polymerase followed by 30-40 cycles of 
denaturation (94°C for 15 seconds), annealing (55-60°C for 30 seconds) and 
extension (72°C for 30 seconds). Similarly, the TaqMan® protocol consisted of an 
initial 50ºC step for 2 minutes followed by 95ºC for 10 minutes then 40 cycles of 
95ºC for 15 seconds and 60ºC for 1 minute (acquisition step); the commercially 
available probes are designed to all anneal at 60ºC. 
Table 2.11: Components for Sybr® green RT-qPCR master mix  
COMPONENT VOLUME 
2x QuantiTect SYBR Green PCR Master Mix 1X 
Forward primer 1µl 
Reverse primer 1µl 
RNase-free water 3µl 
Total master mix reaction volume 15µl 
cDNA product 5µl 
 
Table 2.12: Components for TaqMan® RT-qPCR master mix 
COMPONENT VOLUME 
TaqMan® Master Mix 10µl 
18S Probe 1µl 
Gene of interest Probe 1µl 
RNase-free water 3µl 
Total master mix reaction volume 15µl 
cDNA product 5µl 
 
2.2.6 Determination of intracellular protein expression 
Changes in intracellular protein content of THP-1 cells were determined from protein 
lysates extracted from the cells.  THP-1 cells were seeded into 6-well plates at a 
density of 0.5×106 cells/ml and treated according to the specific experiment being 
performed.  After completion of the experiment the plates were kept on ice and 
intracellular proteins isolated.  Differences between treatment groups were either 
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measured by Western blotting or quantitatively by sandwich enzyme linked 
immunosorbent assays (ELISA), see Section 2.7. 
2.2.6.1 Whole cell extraction 
At completion of the experiment the cells were transferred to pre-chilled 15ml 
centrifuge tubes and pelleted by centrifugation at 14,000×g for 3 minutes at 4°C.  
Briefly, the cells were washed with ice-cold PBS containing phosphatase inhibitors to 
maintain the phosphorylation state of the proteins.  After the removal of all 
supernatant the cell pellet was resuspended in complete lysis buffer containing lysis 
buffer, 10mM DTT and 1X protease inhibitor cocktail, thorough mixing was ensured 
with a 10-second vortex.  Samples were incubated on ice for 10 minutes followed by 
a 30-second vortex.  Finally samples were centrifuged at 14,000×g for 20 minutes in 
a 4°C pre-chilled microcentrifuge, the supernatant (whole cell extract) was 
transferred into pre-chilled tube and stored at -80°C.  
2.2.6.2 Cytoplasmic and nuclear extraction 
THP-1 cells were plated in 6-well plates at a seeding density of 0.5×106 cells/ml 
before being subjected to specific conditions.  Cells were then collected and 
transferred to pre-chilled 15ml centrifuge tubes, pelleted and washed in ice-cold 
phosphatase inhibitors in PBS.  After a second spin, the pellet was gently 
resuspended in 1X hypotonic buffer, transferred to a pre-chilled 1.5ml tube and 
incubated on ice for 15 minutes.  After detergent was added and samples were 
vortex for 10 seconds, the samples were centrifuged for 30 seconds at 14,000×g at 
4°C.  The supernatant (cytoplasmic fraction) was collected and transferred into a 
new tube.  The pellet was resuspended in complete lysis buffer, containing 1X lysis 
buffer, 10mM DTT and 1X protease inhibitor cocktail, the tube was then scraped 
against a metal tube rack to break down the nuclear membrane.  The samples were 
then incubated for 30 minutes on ice, vortex before centrifugation at 14,000×g for 10 
minutes at 4°C; the resulting supernatant (nuclear extract) was transferred into a 
new pre-chilled tube and stored at -80°C until further analysis. 
2.2.6.3 Bradford protein assay 
Protein concentrations of whole cell, cytoplasmic and nuclear extracts were 
determined by using a Bradford assay.  This assay is based on an absorbance shift 
of Coomassie brilliant blue dye, the red form of the dye is converted into the blue 
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form with the addition of proteins.  Bradford reagent (200μl/well) was dispensed in a 
96-well microtitre plate.  A curve, using a stock of 2mg/ml BSA standard solution and 
1µl of the unknown samples was added in duplicate to the wells.  After 5 minutes, 
the absorbance was read at 595nm using a microtitre plate reader and a standard 
curve generated using GraphPad Prism and this was used to determine the 
concentrations of the extracts. 
2.2.6.4 Western blotting 
Protein extracts (30-50μg) were transferred into new tubes and gently mixed with the 
correct volume of 4X NuPAGE® LDS sample buffer containing 4% β-ME.  The 
samples were then boiled for 5 minutes at 95°C to denature the proteins. The 
samples were then loaded onto a 10% Bis-Tris Novex® pre cast mini-gel along with 
Novex® Sharp pre-stained protein standard to allow for band size comparisons.  The 
precast gel were placed in electrophoresis gel tanks and filled with either 1X 
NuPAGE® MES SDS running buffer, for small molecular weight proteins, or 1X 
NuPAGE® MOPS SDS running buffer, for larger molecular weight proteins.  The tank 
was connected to a power supply and the gel was electrophoresed for 35-55 minutes 
at 200V.   
2.2.6.5 Semi-dry transfer 
After electrophoresis, the proteins were transferred from the polyacrylamide gel onto 
a nitrocellulose membrane by a semi-dry method using the iBlot™ Dry Blotting 
system.  Briefly, the gel cassettes were opened with a gel knife and the gel was 
transferred to the nitrocellulose membrane on the ‘bottom’ stack of the iBlot™ gel 
transfer stacks.  This ‘bottom’ stack contains a copper anode (positive) and a 
nitrocellulose membrane.  Filter paper soaked in deionised water was then placed on 
top of the gel before a ‘top’ stack was added, a copper cathode (negative).  The 
sandwich of layers was placed on the iBlot™ device in addition to a sponge and 
tightly closed.  A mini roller was used to remove any bubbles between all the layers.  
The iBlot™ device was used on program 3 at 20V and run for 7 minutes.  After the 
transfer had completed, the sandwich of layers was dissembled and the 
nitrocellulose membrane, on which the proteins had now transferred, was cut to size 
using a scalpel.  The membrane was rinsed in TBS-Tween® (0.1% Tween®) before 
immunodetection. 
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2.2.6.6 Immunodetection 
Membranes were incubated in blocking buffer, 5% milk in TBS-Tween®, for at least 1 
hour at room temperature on a rocker, to prevent non-specific binding of proteins.  
Membranes were then incubated in a suitable concentration of primary antibody (see 
Table 2.6) diluted in 5% milk in TBS-Tween® for 1 hour at room temperature or at 
4°C overnight on a rocker.  After incubation the membranes were washed three 
times in TBS-Tween® for 5 minutes on rocker, followed by 1 hour incubation with a 
secondary antibody diluted in 5% milk in TBS-Tween®, the secondary antibodies 
were conjugated with alkaline phosphatase (AP) (Table 2.7).  The membranes were 
again washed three times in TBS-Tween® for 10 minutes each and then gently 
blotted to remove excess wash buffer.  The blotted dry membranes were placed on 
Saran wrap, protein side up and ECF substrate solution pipetted to cover them 
(24µl/cm2), they were then incubated for 1 minute protected from light; again they 
were blotted to remove excess substrate and then placed between plastic sheets 
and scanned on a storm phosphoimager.  Membranes can be re-probed for the 
detection of different proteins by incubating in reBlot™ stripping buffer for 15-20 
minutes.  The membranes are then re-blocked in 5% milk in TBS-Tween® and the 
process repeated with the new primary antibody. 
2.2.6.7 Band quantitation 
Band density is quantified using ImageQuant TL software and the rolling ball method 
was used for background subtraction.  Densitometric data of phosphorylated proteins 
were normalised to levels of total protein and levels of endogenous control β-actin. 
2.2.7 Determination of protein release 
Concentrations of cytokine detected (human- CXCL8, MIF, and TNF) (murine- KC, 
MIF and TNF) in sample or the concentration of MIF protein in extracted protein 
lysates (Section 2.2.6) were measured by species-specific sandwich ELISA.  THP-1 
cells were seeded into tissue culture 96-well plates at a final concentration of 
0.1×106 cells/ml and treated or stimulated according to the specific experiment in a 
final volume of 200µl/well.  After the required time, the plates were spun down 
(300×g for 5 mins) and supernatants removed and transferred to new 96-well plates 
where they were stored at -20°C.   
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DuoSet ELISA kits for particular cytokines or chemokines were used according the 
manufacturer’s instructions, the MIF ELISA kit was cross-reactive with human and 
mouse unlike the other mediators that were species specific.  Briefly, 96-well 
microtitre plates were coated with 100µl of capture antibody (Table 2.13) at the 
working concentration in PBS for 16 hours at room temperature. The capture 
antibody is aspirated off and the plate washed three times with 300µl of wash buffer 
(PBS-Tween) using an ELISA plate washer.  The plate was then blocked with 300µl 
blocking buffer (1% BSA in PBS) for at least 1 hour followed by a further three 
washes as described above.  Eight recombinant protein standards including a blank 
were then prepared by a 2-fold serial dilution of the stock protein standard in reagent 
diluent buffer, 100µl (in duplicate) of these were then dispensed into the wells along 
with 100µl of diluted sample supernatant in triplicate, for protein lysates 1µg of total 
protein was diluted into 100µl of reagent diluent.  The plates were incubated at room 
temperature for 2 hours followed by another wash step.  Detection antibody diluted 
to the working concentration (Table 2.13) in reagent diluent (100µl) was dispensed 
into the wells and incubated for a further 2 hours at room temperature.  The plate 
was again washed and 100µl of Streptavidin-Horseradish peroxidase (HRP) solution, 
diluted to the working concentration in reagent diluent, was added to the wells and 
incubated for 20 minutes at room temperature avoiding direct light.  A final wash step 
was performed before 100µl of the substrate solution, prepared by mixing equal 
volumes of colour reagents A (H2O2) and B (Tetramethylbenzidine), were added to 
wells and incubated for 10 minutes to allow colour to develop. The substrate reaction 
was stopped by the addition of 50µl of stop solution (2N H2SO4).  The absorbance of 
each well was measured at 450nm and 540nm (correction) using a microtitre 
spectrophotometer.  A four-parameter logistic standard curve was generated using 
GraphPad Prism (GraphPad Software, San Diego, CA, USA) and the cytokine 
concentrations of each sample calculated from this, the concentrations were 
corrected for dilution by multiplying by the dilution factor. 
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Table 2.13: Antibodies, concentrations and standard curves for ELISA 
CYTOKINE ANTIBODY 
STOCK 
CONCENTRATION 
STANDARD 
CURVE 
MIF 
Capture- mouse anti-human MIF 
Detection- goat anti-human MIF 
(biotinylated) 
Standard- recombinant human MIF 
2.0µg/ml 
100ng/ml 
 
30ng/ml 
2000- 
7.81pg/ml 
CXCL8 
Capture- mouse anti-human CXCL8 
Detection- goat anti-human CXCL8 
(biotinylated) 
Standard- recombinant human CXCL8 
4.0µg/ml 
20ng/ml 
 
100ng/ml 
2000- 
15.63pg/ml 
TNF 
(Human) 
Capture- mouse anti-human TNF 
Detection- goat anti-human TNF 
(biotinylated) 
Standard- recombinant human TNF 
2.0µg/ml 
100ng/ml 
 
370ng/ml 
1000- 
3.91pg/ml 
KC 
Capture- rat anti-mouse KC 
Detection- goat anti-mouse KC 
(biotinylated) 
Standard- recombinant human KC 
360µg/ml 
36µg/ml 
 
210ng/ml 
1000- 
3.91pg/ml 
TNF 
(Mouse) 
Capture- goat anti-mouse TNF 
Detection- goat anti-mouse TNF 
(biotinylated) 
Standard- recombinant mouse TNF 
144µg/ml 
36µg/ml 
 
310ng/ml 
2000- 
15.63pg/ml 
 
Table 2.14: Reagents used in ELISA 
CYTOKINE WASH BUFFER BLOCK BUFFER REAGENT DILUENT 
MIF 
0.05% Tween® 20 in 
PBS 
1% BSA in PBS 1% BSA in PBS 
CXCL8 
0.05% Tween® 20 in 
PBS 
1% BSA in PBS 
with 0.05% NaN3 
0.1% BSA, 0.05% Tween® 
20 in Tris-buffered saline 
(20mM Tris HCL pH 7.4, 
150mM NaCl) 
TNFα 
(Human) 
0.05% Tween® 20 in 
PBS 
1% BSA in PBS 1% BSA in PBS 
KC 
0.05% Tween® 20 in 
PBS 
1% BSA in PBS 1% BSA in PBS 
TNFα 
(Mouse) 
0.05% Tween® 20 in 
PBS 
1% BSA in PBS 1% BSA in PBS 
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2.2.8 Cell proliferation Assay 
The proliferation of THP-1 cells was determined by BrdU colorimetric ELISA-based 
assay. When cells are cultured with labelling medium that contains 5-bromo-2’-
deoxyuridine (BrdU), this pyrimidine analog is incorporated in place of thymidine into 
the newly synthesised DNA of proliferating cells.  The assay analyses the 
incorporation of BrdU into the cellular using an anti-BrdU antibody.  Briefly 1×104 
THP-1 cells/well were seeded into black tissue culture 96-well plate and treated with 
various dilutions of compounds/stimulants to a final volume of 100µl for 48 hours.  
BrdU labelling reagent was added to a final concentration of 10µM and re-incubated 
for 24 hours at 37ºC, after this the plate was spun down (300×g for 5 mins), all 
supernatant removed and wells gently blotted dry.  The cells were fixed with the 
manufacturer’s fix/denaturing solution followed by an incubation of 90 minutes with a 
working concentration of anti-BrdU-POD at room temperature.  The antibody solution 
was removed and the plate washed three times with 1X wash buffer, finally substrate 
solution was added and incubated for 3 minutes.  Luminescence was read on a plate 
reader at 460nm.  Data was normalised as a percentage of untreated cells. 
2.2.9 TransAM™ Transcription factor ELISAs 
To detect and quantify transcription factor activation the TransAM™ ELISA-based 
assay was used.  The basic protocol was the same for each transcription factor (p53, 
GR and NFAT) although specific kits were used for each transcription factor, any 
differences between the kits are detailed in Table 2.15.  Each TransAM™ kit 
contained a 96-well plate on which oligonucleotides that contain the specific 
transcription factors consensus DNA binding site had been immobilised, any 
transcription factors present in the sample nuclear extract would specifically bind to 
these and would be detected. 
THP-1 cells were treated with compounds according to specific experiments, at 
completion of treatments nuclear proteins were extracted (Section 2.2.6.2) and 
quantified (Section 2.2.6.3).  First, binding buffer was added to each well to be used 
before a set amount of nuclear extract, diluted in lysis buffer, was added; negative 
and positive controls were included in each assay.  The plate was then incubated for 
1 hour at room temperature with mild agitation followed by three washes with wash 
buffer.  Primary antibody diluted in antibody binding buffer (Table 2.16) was 
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dispensed into all wells and incubated for 1 hour at room temperature without 
agitation; followed by three wash steps.  Secondary antibody conjugated with HRP, 
diluted in antibody binding buffer (Table 2.16) was added to the wells and then 
incubated for 1 hour at room temperature without agitation.  The plate was washed a 
final time with 4 washes before developing solution was added and incubated for 5-
10 minutes, protected from light.  The reaction was then stopped with kit supplied 
stop solution; the absorbance of each well was then read by a plate reader at 450nm 
with a background reading at 655nm.  These absorbance readings were normalised 
to the background reference and the negative control values were also subtracted.  
The measurements were then calculated as a percentage of naïve cells. 
Table 2.15: DNA consensus sequences for transcription factors in TransAM® kit 
 P53 GR NFAT 
DNA 
consensus 
motif 
5’-GGACATGCCC 
GGGCATGTCC-3’ 
5’-GGTACAnnn   
TGTTCT-3’ 
5’-AGGAAA-3’ 
Nuclear 
extract (µg) 
10 20 10 
Sample 
volume (µl) 
10 20 10 
 
Table 2.16: TransAM® antibody dilutions 
 P53 GR NFAT 
Primary 
Antibody 
1:1000 1:1000 1:500 
Secondary 
Antibody 
1:1000 1:1000 1:1000 
 
2.2.10 Proteome profilerTM Array 
For the parallel determination of relative levels of phosphorylation of MAPKs and 
other serine/threonine kinases, a human phospho-MAPK array was used.  
Nitrocellulose membranes were spotted with 26 capture and control antibodies in 
duplicate, these were then used to analyse the amount of phosphorylated protein for 
each corresponding spot detected in the sample. 
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THP-1 cells were treated with compounds for specific lengths of time at a cell density 
of 0.5×106/ml.  Protein lysates were prepared by rinsing cells in PBS followed by 
lysing in Lysis buffer (1×107 cells/ml) and incubating at 2-8ºC for 30 minutes.  The 
suspension was then centrifuged at 14000×g for 5 minutes and supernatant 
transferred to clean tubes, quantitation of sample protein was completed (Section 
2.2.6.3).  The membranes, already dotted with specific phospho-antibodies, were 
blocked in Array buffer 5 for 1 hour at room temperature on a rocking platform 
shaker, during this time samples were prepared.  Samples (300µg protein in a 
maximum volume of 400µl) were diluted in 1.5ml Array Buffer 1 along with 20µl of 
detection antibody cocktail; this mixture was incubated for 1 hour at room 
temperature to form complexes.  Array buffer 5 was aspirated from the 4-well multi 
dish and the prepared sample/antibody mix added to the membranes and incubated 
overnight at 2-8ºC on a rocking platform shaker.  The following day, membranes 
were washed three times in 1X wash buffer for 10 minutes each and then incubated 
for 30 minutes at room temperature in streptavidin-HRP diluted in array buffer 5.  
Membranes were then washed as described above and then blotted dry, to remove 
excess buffer; finally Chemi Reagent mix was evenly pipetted over the membranes 
and incubated for 1 minute, protected from light.  Again, excess liquid was blotted 
from the membranes before they were wrapped in plastic, placed into 
autoradiography films cassettes and then exposed to X-ray films for 1-10 minutes.  
The developed film showed the phosphorylated kinase signals and the spots could 
be identified using the transparency overlay provided in the kit.  Pixel densitometry 
was used to quantify the differences in kinase activity.  The average density of the 
duplicate spots was normalised to the negative control within the array and then 
calculated as a percentage of untreated control.   
2.2.11 MAPK PhosphoTracer ELISA 
For the semi-quantitative measurement of ERK 1/2 (pT202/Y204), p38 MAPK 
(pT180/Y182) and JNK 1/2/3 (pT183/Y185) concentrations in cell culture extracts a 
PhosphoTracer ELISA was used, the all-in-one method was followed. 
THP-1 cells (20µl at 10×106 cells/ml) were incubated at 37ºC in wells of a kit 
provided 96-well plate for a few hours to allow handling-mediated pathway activation 
to subside.  rhMIF (2X final concentration) was then dispensed to each well and 
incubated at 37ºC for specific time points.  At completion of experiment the cells 
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were lysed with 5X lysis mix concentrate and incubated for 10 minutes at room 
temperature on a plate shaker; 1X lysis mix was used for negative and positive 
controls.  Antibody mix (50µl) was then added onto this extract suspension, the plate 
sealed and then incubated for 1 hour at room temperature on a plate shaker.  The 
wells were then washed with wash buffer and the plate tapped dry to remove excess 
fluid.  Prior to its use, substrate mix was prepared and then added 100µl/well and 
incubated for 10 minutes at room temperature, protected from light, on a plate 
shaker.  The reaction was then stopped with the addition of kit supplied stop solution; 
before the fluorescence signal was read on a plate spectrophotometer 
(Excitation:530nm / Emission:590nm) the plate was briefly mixed.  Fluorescence 
readings for negative controls were subtracted from sample values and then these 
were calculated as a percentage of time 0. 
2.2.12 Stable Isotope Labelling with Amino acids in cell Culture 
Stable isotope labelling with amino acids in cell culture (SILAC) is a global proteomic 
technique (Ong et al., 2002).  THP-1 cells were cultured as normal with standard cell 
densities but using special designated complete SILAC RPMI-1640 media, see 
Table 2.17.  The cells were cultured for five divisions to ensure that full incorporation 
of heavy amino acids (13C6-Arg and 
2H4- Lys) into the proteins was achieved.  The 
cells were then spun down, resuspended in fresh designated SILAC media and 
seeded into new flasks.  The cells were then treated with compounds for 24 hours 
before whole cell protein extractions were prepared. 
Liquid chromatography-mass spectrometry-mass spectrometry (LC-MS-MS) analysis 
was performed at the University of Bristol.  Briefly, cell extracts were run on an SDS-
PAGE gel and the equivalent gel lanes were cut into 10 slices.  Each slice was 
subjected to in-gel tryptic digestion using a ProGest automated digestion unit 
(Digilab UK).  The resulting peptides were fractionated using a Dionex Ultimate 3000 
nanoHPLC system in line with an LTQ-Orbitrap Velos mass spectrometer (Thermo 
Scientific, MA, USA).  In brief, peptides in 1% (vol/vol) formic acid were injected onto 
an Acclaim PepMap C18 nano-trap column (Thermo Scientific Dionex, MA, USA). 
After washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides were 
resolved on a 250mm × 75μm Acclaim PepMap C18 reverse phase analytical 
column (Thermo Scientific Dionex, MA, USA) over a 150 min organic gradient, using 
7 -gradient segments (1-6% solvent B over 1min., 6-15% B over 58min., 15-32% B 
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over 58min., 32-40% B over 3min., 40-90% B over 1min., held at 90% B for 6min 
and then reduced to 1% B over 1min.) with a flow rate of 300nlmin−1.  Solvent A was 
0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic acid.  
Peptides were ionised by nano-electrospray ionisation at 2.1kV using a stainless 
steel emitter with an internal diameter of 30μm (Thermo Scientific, MA, USA) and a 
capillary temperature of 250°C.  Tandem mass spectra were acquired using an LTQ- 
Orbitrap Velos mass spectrometer controlled by Xcalibur 2.1 software (Thermo 
Scientific, MA, USA) and operated in data-dependent acquisition mode.  The 
Orbitrap was set to analyse the survey scans at 60,000 resolution (at m/z 400) in the 
mass range m/z 300 to 2000 and the top six multiply charged ions in each duty cycle 
selected for MS/MS in the LTQ linear ion trap.  Charge state filtering, where 
unassigned precursor ions were not selected for fragmentation, and dynamic 
exclusion (repeat count, 1; repeat duration, 30s; exclusion list size, 500) were used.  
Fragmentation conditions in the LTQ were as follows: normalised collision energy, 
40%; activation q, 0.25; activation time 10ms; and minimum ion selection intensity, 
500 counts. 
Full incorporation of the labelled isotopes to cellular proteins is essential.  Results 
were calculated as a ratio of light media. 
 
Table 2.17: Components for SILAC media 
Light: R0K0 Heavy: R6K4 
12C6 Arginine 
13C6 Arginine 
12C6 Lysine 
2H4 Lysine 
10% dialysed FBS 10% dialysed FBS 
2mM L-glutamine 2mM L-glutamine 
Methionine Methionine 
  
2.2.13 Calcium signalling 
THP-1 cells were resuspended in 1% BSA in phenol red free RPMI-1640 medium at 
a cell density of 5×106cells/ml and incubated for 30mins (37ºC, 5% CO2) with FURA-
2 AM and pluronic acid to fluorescently label the intracellular calcium.  Cells were 
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then washed with HBSS and the labelled cells resuspended in calcium buffer (50ml 
Hanks Buffer, 0.5% BSA, 0.5ml HEPES, 50μl CaCl, titrated with NaOH to pH 7.4).  
Cells were immediately loaded (100µl/well of cell suspension) into a black 96-well 
plate.  Maximum and minimum calcium release was measured before each 
experiment using digitonin (5µg/ml final concentration) and EDTA (50mM final 
concentration), fluorescence was measured at excitation 340-10nm and emission 
520-35nm with a gain of 2150.  Stimulants and compounds were made up in calcium 
buffer at 10X final concentration and injected into wells accordingly; the fluorescence 
was measured every 2.8 seconds.  Calcium concentration was calculated using the 
following the equation, R represents 380/340nm ratio and Rmin and Rmax was 
empirically determined from cells.  Sf2 and sb2 represents the averages of the 
380nm values at Rmin and Rmax respectively. 
[Ca2+] = (R - Rmin)/(Rmax - R) × 224 × (sf2/sb2) 
2.2.14 RNA microarrays 
Global mRNA expression profiles were determined using the SurePrint G3 Human 
microarrays V2 (Agilent Technologies, CA, USA).  Arrays were run according to 
manufacturer’s instructions at the University of Manchester.  Raw data files were 
returned to Imperial College London for further analysis. 
2.3 In vivo animal models 
Male C57/BL6 mice (Harlan, UK) were purchased and housed in specific pathogen 
free conditions within the CBS facility at Imperial College London, South Kensington 
campus.  Mice were housed in groups of four for the duration of the experiment and 
each experiment group had six mice (n=6).  All experiments were conducted when 
the mice were 6-8 weeks old and were performed under a Project License (70/7581) 
from the British Home Office, UK, under the Animals (Scientific Procedures) Act 
1986.   
2.3.1 Mouse ozone exposure- COPD model 
C57/BL6 mice were exposed to ozone generated from an ozonizer, which was mixed 
with air to a 3 part per million (ppm) concentration.  Mice were exposed for 3 hours 
twice a week for 6 weeks and anaesthetised 24 hours after the last exposure using 
ketamine and xylazine for airway hyper-responsiveness (AHR) analysis and 
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subsequent BALF collection.  Control groups were exposed to normal air in an 
identical experimental setup.  Groups were pre-treated with ISO-1 or ISO-1 and 
dexamethasone in combination intraperitoneally (i.p.) 30 minutes before exposure to 
ozone/air with a dose of 35mg/kg (ISO-1) and 2mg/kg (dexamethasone). 
2.3.2 Measuring airway hyper-responsiveness 
Twenty-four hours after ozone exposure the mice were anesthetised with Ketamine 
and xylene to measure airway hyper-response (AHR).  Once all reflexes were absent 
the mice were tracheostomised and ventilated at a rate of 250 breaths/minute and 
with a tidal volume of 250l.  Mice were continuously monitored in a whole body 
plethysmograph with a pneumotachograph connected to a transducer.  
Transpulmonary pressure was assessed via an oesophageal catheter.  Pulmonary 
resistance (RL) was recorded for 3 minute periods during increasing concentrations 
of acetylcholine (4-256mg/ml) administered with an Aeroneb® Lab Micropump 
Nebulizer.  RL was expressed as percentage change from baseline RL with nebulised 
PBS.  The concentration of acetylcholine required to increase RL by 200% from 
baseline was calculated (PC200) and –log PC200 was taken as a measure of airway 
responsiveness. 
2.3.3 Sample collection and preparation 
After AHR measurements the mice were sacrificed by overdose of pentobarbital 
sodium (500μl). 
2.3.3.1 Bronchoalveolar lavage fluid  
BALF samples were collected by rinsing the lungs three times with 0.8ml ice-cold 
PBS via an endotracheal tube and retrieved as BALF.  BALF samples were 
centrifuged to isolate cells from fluid (1500×g for 10 minutes at 4°C); the cell pellets 
were then resuspended in 200l PBS and counted on a haemocytometer (total cell 
count).  BALF was frozen at -80°C until analysis.  Inflammatory mediators (KC, 
TNF MIF) in BALF were determined by ELISA. 
2.3.3.2 Differential cell count 
BALF cell samples were centrifuged at 480rpm for 6 minutes, onto glass slides using 
a cytospin.  Cells on glass slides were stained using Diff-Quick kit and differential cell 
counts obtained using an optical microscope.  
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2.4 Statistical analysis 
Results are expressed as mean±standard error of mean (SEM) (n≥3) for in vitro work 
and mean±standard deviation (SD) for in vivo studies.  EC50 values were calculated 
from concentration response curves, and considered to be the concentration of 
compound that inhibits or induces the effect by 50% of the maximal response.  
GraphPad Prism® was used for statistical analysis, analysis of variance (ANOVA) 
was performed by Kruskal-Wallis analysis (non-parametric)  and for significant 
results; Dunn’s post-test was used.  The comparisons of individual samples were 
analysed using Mann-Whitney t-test.  p values less than 0.05 were considered 
statistically significant.  
 
 
 81 
 
 
 
Chapter 3  
3 Macrophage migration inhibitory 
factor inhibition in a steroid 
insensitive ozone-exposed in vivo 
murine model 
 
 
 
  
MIF inhibition on steroid insensitive ozone-induced in vivo model 
 
82 
 
3.1 Introduction 
MIF is a critical regulator of inflammation and has been shown to be involved in 
various inflammatory conditions such as RA (Bernhagen et al., 1996), sepsis (Bozza 
et al., 1999), atherosclerosis (Burger-Kentischer et al., 2002), acute respiratory 
distress syndrome (ARDS) (Donnelly et al., 1997) and asthma (Rossi et al., 1998).  
Whilst COPD is associated with elevated levels of pro-inflammatory cytokines there 
have been no reports of MIF associated with human COPD to date.  CSs are the 
gold standard treatment for many of these inflammatory diseases as they control 
disease progression and relieve symptoms.  COPD and a subset of severe 
asthmatics patients show CS insensitivity and hence have less control of the 
disease, presenting more severe symptoms and co-morbidities (Keatings and 
Barnes, 1997).  Similarly to other cytokines, MIF is suppressed by CSs at therapeutic 
concentrations however, unique to MIF; low physiological concentrations of CSs 
have been shown to induce MIF (Calandra et al., 1994).  In addition to the pro-
inflammatory functions, MIF has also been shown to counter-regulate the anti-
suppressive actions of CSs (Calandra et al., 1995, Bucala, 1996).  Anti-MIF and MIF 
inhibition strategies have therefore been of major interest to restore CS sensitivity 
and potentially reduce the prescribed doses needed for efficacy. 
Animal models are invaluable to research, not only for investigating the effects within 
a whole living system but also for proof-of-concept and from drug safety aspects.  
The ozone model used in this study has previously been reported as a model of 
COPD showing some phenotypes of disease (Triantaphyllopoulos et al., 2011, 
Wiegman et al., 2013).  Cigarette smoking is regarded as a major risk factor of 
developing COPD and has been shown to be the major cause of emphysema 
(Barnes, 2007).  However, in vivo models of cigarette smoke exposure depend upon 
the dose and timing of cigarette smoke exposure and may result in both pro- and 
anti-inflammatory outcomes.  Cigarette smoke contains >4000 distinct chemical 
entities along with >1015 reactive oxygen species per puff (Pryor and Stone, 1993).  
Ozone is an oxidant and the inflammatory profile that is induced by ozone is 
comparable to that induced by cigarette smoke.  The ozone-induced lung 
inflammation model shows enlargement of alveolar space with evidence of 
emphysema, induced pro-inflammatory cytokines like IL-13, IFN and KC and 
reduced anti-apoptotic proteins such as Bcl-2 reflecting several important COPD 
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traits (Triantaphyllopoulos et al., 2011).  Induced sputum samples from COPD 
patients have elevated levels of CXCL8 and TNF (Keatings et al., 1996) and the 
ozone-induced inflammation model here also shows increased levels of KC (a 
murine CXCR2 agonist) and TNF.  The elevated cytokine release has been 
associated with high numbers of neutrophils and macrophages also found in the 
sputum of COPD patients (Keatings et al., 1996) in support of this, the ozone-
induced mouse model shows significantly increased macrophages, neutrophils and 
lymphocytes detected in the BALF.  The advantage of the ozone-induced model 
compared to the cigarette smoke-induced inflammation model is that the former 
model induces these COPD-like characteristics more rapidly, 6 weeks of twice 
weekly exposure compared to possible 6-8 months of daily smoke exposure 
(Guerassimov et al., 2004).  
In addition to the current model showing characteristics of human COPD, the anti-
inflammatory functions of dexamethasone are not seen suggesting that this model 
also demonstrates relative CS insensitivity.  Although the mechanism of the CS 
insensitivity is not fully elucidated, it was demonstrated that the Nrf2-regulated 
haemeoxygenase-1 (HO-1) gene was suppressed after chronic exposure to ozone 
(Triantaphyllopoulos et al., 2011), suggesting an ozone-induced loss of anti-oxidant 
properties.   
ISO-1 is the best-characterised MIF inhibitor to date.  MIF has tautomerase activity 
and converts non-physiological substrate D-dopachrome into 5,6-dihydroxyindole-2-
carboxylic acid (DHICA) (Rosengren et al., 1996).  ISO-1 binds to the enzymatic 
active site irreversibly inhibiting MIF (Lubetsky et al., 2002).  Furthermore, 
attenuation of OVA-induced lung inflammation by ISO-1 has been reported in a 
mouse model of allergic asthma (Chen et al., 2010). 
To date, there are no reports on the effects of MIF inhibition on sensitivity to CSs 
within asthma or a COPD model; in this chapter I will investigate a CS insensitive 
COPD model and assess whether MIF inhibition by ISO-1, can improve the anti-
inflammatory effects of CSs. 
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3.2 Chapter hypothesis and aims 
Ozone exposure induces a steroid insensitive lung inflammation associated with 
elevated MIF expression.  Inhibition of MIF attenuates this ozone-induced 
inflammation and restores steroid sensitivity.  
1. Confirm inflammation and dexamethasone insensitivity induced by ozone-
exposure in in vivo mouse model 
2. Investigate the effects of MIF inhibition by ISO-1 pre-treatment on ozone-
induced inflammation in mouse in vivo model 
3. Investigate the effects of ISO-1 pre-treatment on ozone-induced 
dexamethasone insensitivity 
 
3.3 Results 
3.3.1 Ozone-induced CS insensitive COPD inflammation model 
Male C57/BL6 mice were pre-treated with ISO-1 i.p. (35mg/kg) or dexamethasone 
(2mg/kg) alone or in combination 30 minutes prior to being exposed to ozone (3ppm) 
or air for 3 hours, twice a week, for 6 weeks.  Bodyweights were measured before 
each exposure to assess the effects of ozone and compounds on overall health of 
the mice.  During the 6 week experiment there was a steady increase in the 
bodyweights of the mice in all groups, the compounds or ozone had no detrimental 
effects on overall health (Figure 3.1). 
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Figure 3.1: Drug and ozone effects on mouse body weights over the experimental time 
course 
C57BL/6 mice were injected i.p. with either ISO-1 (35mg/kg) or dexamethasone (Dex, 
2mg/kg) alone or in combination 30 minutes before 3-hour exposure to ozone (3ppm) or air.  
This occurred twice a week for 6 weeks and mice were weighed before each exposure.  The 
data are presented as mean±SD for 6 animals per group. 
 
Airway hyper-responsiveness was measured 24 hours after the final ozone/air 
exposure.  The mice were anaesthetised and once all reflexes were absent, they 
were tracheotomised and ventilated.  Pulmonary resistance (RL) was measured with 
increasing concentrations of acetylcholine (4-256mg/ml).  The concentration of 
acetylcholine required to increase RL by 200% compared to baseline was calculated 
(PC200) and –log PC200 was taken as a measure of airway hyper-responsiveness.  
Ozone alone significantly increased the RL compared to air control (326.5±29.8% vs. 
239.0±37.3% at 256mg/ml ACh, p<0.01) but dexamethasone pre-treatment had no 
effect on this (Figure 3.2A).  Ozone exposure significantly elevated the 
responsiveness of the airway (PC200) to acetylcholine and this was not affected by 
dexamethasone pre-treatment (2.30.2% vs. 2.30.2%, p=NS) indicating a relative 
CS insensitivity (Figure 3.2D).  
BALF samples were collected from all mice to assess the effect of ozone on lung 
inflammation; both total and differential cell counts were calculated.  Ozone exposure 
significantly increased the total number of BALF cells when compared to the air 
control 3-fold (4.11.8×105 cells vs. 12.34.0×105 cells, p<0.01).  This increase in 
cell numbers was seen for all cell-types counted; neutrophils increased by 3.5-fold 
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(0.60.2×105 cells vs. 2.10.5×105 cells, p<0.05), macrophages by 3.5-fold 
(1.00.4×105 cells vs. 3.20.7×105 cells, p<0.01) and lymphocytes increased by 3-
fold (2.91.8×105 cells vs. 8.42.4×105 cells, p<0.01) compared to air control (Figure 
3.3).  
In order to assess the inflammation occurring in the lungs, the levels of pro-
inflammatory mediators (MIF, KC and TNF) in BALF were measured.  BALF MIF 
levels were elevated 3-fold (2.50.9ng/ml vs. 7.01.6ng/ml, p<0.01) following ozone 
treatment compared to air control.  Ozone also induced BALF KC (46.420.2pg/ml 
vs. 10826.6pg/ml, p<0.01) and TNF (85.445.8pg/ml vs. 236.399.5pg/ml, 
p<0.01) levels 2.3-fold and 2.8-fold respectively.  Relative dexamethasone 
insensitivity was seen in this ozone-induced inflammation model.  Dexamethasone 
pre-treatment before ozone-exposure did not attenuate the levels of BALF MIF 
(7.01.6ng/ml vs. 5.60.7ng/ml, p=NS), KC (10826.6pg/ml versus 116.324.6pg/ml, 
p=NS) or TNF (236.399.5pg/ml vs. 19028.5pg/ml, p=NS) and none were 
significantly different to levels detected in mice exposed to ozone alone (Figure 3.4). 
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Figure 3.2: Effects of dexamethasone and ISO-1 on ozone affected pulmonary 
resistance and airway hyper-responsiveness 
C57BL/6 mice were injected (i.p.) with ISO-1 (35mg/kg) or dexamethasone (Dex, 2mg/kg) 
alone or in combination before being exposed to ozone (3ppm) or air for 3 hours, twice a 
week for 6 weeks.  Pulmonary resistance (RL) to acetylcholine (4-256mg/ml) was measured 
and presented as percentage change from baseline.  The pre-treatment effects on ozone-
affected pulmonary resistance were assessed (A) Dexamethasone alone, (B) ISO-1 alone, 
(C) ISO-1 and dexamethasone in combination.  (D) Airway hyper-responsiveness was 
calculated as –log PC200 (PC200 is the concentration of acetylcholine required to increase RL 
by 100% compared to baseline).  Data is presented as mean±SD for 6 animals per group. 
*p<0.05 vs. air control, **p<0.01 vs. air control, #p<0.05 vs. ozone, ##p<0.01 vs. ozone as 
calculated by individual Mann-Whitney t-test for graphs A-C and ANOVA with Dunns post-
hoc test for graph D. 
 
 
 
 
MIF inhibition on steroid insensitive ozone-induced in vivo model 
 
88 
 
A)           B) 
0
5
10
15
20
25
#
            Ozone
     ISO-1 -
+
+
+
+
-
-
-
**
T
o
ta
l 
C
e
ll
s
 (
c
e
ll
s
 x
 1
0
5
)
0
1
2
3
*
*
-
+
+
+
+
-
-
-
N
e
u
tr
o
p
h
il
s
 (
c
e
ll
s
 x
 1
0
5
)
 
C)          D) 
0
1
2
3
4
5
            Ozone
     ISO-1 -
+
+
+
+
-
-
-
**
M
a
c
ro
p
h
a
g
e
s
 (
c
e
ll
s
 x
 1
0
5
)
0
5
10
15
-
+
+
+
+
-
-
-
**
L
y
m
p
h
o
c
y
te
s
 (
c
e
ll
s
 *
 1
0
5
)
 
Figure 3.3: Effects of ISO-1 on ozone-induced BALF differential cell counts 
C57BL/6 mice were pre-treated with ISO-1 (35mg/kg) 30 minutes before a 3-hour ozone/air 
exposure twice a week, for 6 weeks.  BALF samples were collected and total cell (A), 
neutrophils (B), macrophages (C) and lymphocytes (D) numbers were counted.  Data is 
presented as mean±SD for 6 animals per group. *p<0.05 vs. air control, **p<0.01 vs. air 
control and #p<0.05 vs. ozone-exposed as calculated by ANOVA with Dunns post-hoc test. 
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Figure 3.4: Pro-inflammatory mediator levels in BALF supernatants from ozone-
exposed and dexamethasone- or ISO-1-treated mice 
Male C57BL/6 mice were injected (i.p) with ISO-1 (35mg/kg) or dexamethasone (Dex, 
2mg/kg) alone or in combination 30 minutes before being exposed to ozone/air for 3 hours 
this was repeated twice a week for 6 weeks.  BALF samples were collected and (A) MIF, (B) 
KC and (C) TNF levels measured.  Data is presented as mean±SD for 6 animals per group. 
*p<0.05 vs. air control, **p<0.01 vs. air control, #p<0.05 vs. ozone exposed as calculated by 
ANOVA with Dunns post-hoc test. 
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3.3.2 MIF inhibition on CS insensitive ozone-induced inflammation 
In this study, relative dexamethasone insensitivity was seen; dexamethasone pre-
treatment had no effect on the ozone-induced RL.  Ozone alone increased the RL 
with an enhanced acetylcholine concentration-dependent increase from baseline 
compared to air control.  In addition, dexamethasone did not suppress ozone-
induced BALF MIF, KC or TNF levels. 
The role of MIF in the ozone model was investigated by pharmacological inhibition 
using ISO-1.  Mice were pre-treated with ISO-1 (35mg/kg) 30 minutes prior to ozone 
or air-exposure.  Pre-treatment with ISO-1 before ozone exposure significantly 
reduced ozone-induced RL at the two highest concentrations of acetylcholine used 
(279.1±18.8% vs. 250±15.9% at 128mg/ml Ach, p<0.01; 326.5±29.8% vs. 
270.3±20.7% at 256g/ml Ach, p<0.01) (Figure 3.2B).  There was a significant 
difference seen between ozone alone and ozone plus ISO-1 treated animals with 
regards to –Log PC200 (2.3±0.2% vs. 2.7±0.3%, p<0.05) suggesting that ISO-1 had a 
protective effect on airway hyper-responsiveness (Figure 3.2D). 
ISO-1 pre-treatment attenuated the total BALF cell counts (12.3±4.0×105 cells vs. 
5.0±3.2×105 cells, p<0.05) although there was no significant effect seen on individual 
cell types.  Neutrophil levels were not affected by MIF inhibition as BALF neutrophilia 
was similar in the ozone-treated compared to ISO-1 pre-treated animals 
(2.1±0.5×105 cells vs. 1.9±0.4×105 cells, p=NS) with both levels being significantly 
greater than that seen in air controls (0.6±0.2×105 cells, p<0.05).  ISO-1 reduced the 
BALF numbers of both macrophages (3.2±0.7×105 cells vs. 1.86±1.3×105 cells, 
p=NS) and lymphocytes (8.4±2.4×105 cells vs. 5.6±2.3×105 cells, p=NS) induced by 
ozone although these differences did not reach significance (Figure 3.3). 
Ozone-induced BALF pro-inflammatory mediator expression was also attenuated by 
ISO-1 pre-treatment.  Ozone-induced BALF MIF levels were significantly reduced by 
1.6-fold with ISO-1 pre-treatment (7.0±1.6ng/ml vs. 4.5±1.1ng/ml, p<0.05).  In 
addition, KC (108±26.6pg/ml vs. 74.6±16.1pg/ml, p<0.05) and TNF 
(236.3±99.5pg/ml vs. 151.1±55.6pg/ml, p<0.05) levels were reduced 1.4-fold and 
1.6-fold respectively when compared to ozone alone-exposed.  However, the levels 
of ISO-1 pre-treated ozone-induced MIF and KC remained significantly increased 
compared to air control (p<0.05 for BALF MIF and p<0.05 for BALF KC) (Figure 3.4). 
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3.3.3 The effect of MIF inhibition on dexamethasone sensitivity 
As previously described, this ozone-induced model of COPD lung inflammation 
shows a relative CS insensitivity with a failure of dexamethasone to suppress AHR, 
BALF cell numbers and pro-inflammatory mediator expression.  MIF levels are 
significantly induced by ozone exposure and MIF has been shown to counteract the 
anti-inflammatory activity of CSs.  Therefore, to investigate if the relative 
dexamethasone insensitivity in this model could be reversed with MIF inhibition; the 
two compounds (ISO-1 and dexamethasone) were given in combination pre-ozone-
exposure.   
Ozone-induced RL was not affected by pre-treatment with ISO-1 and 
dexamethasone in combination.  The previously shown attenuation of RL with ISO-1 
alone was no longer evident when in combination with the CS (326.5±29.8% vs. 
306.9±40.3%, p=NS) (Figure 3.2C).  Ozone-induced airway hyper-responsiveness 
(PC200) was also not affected by the drugs in combination and remained elevated 
compared to the air control group (2.0±0.7% vs. 3.6±1.2%, p<0.05).  MIF inhibition 
by ISO-1 did not enhance the anti-inflammatory action of dexamethasone nor restore 
airway hyper-responsiveness to air controls levels (Figure 3.2D). 
MIF release induced by ozone-exposure was significantly suppressed by pre-
treatment with ISO-1 and dexamethasone in combination (7.0±1.6ng/ml vs. 
4.9±1.4ng/ml, p<0.05).  However, the effect was not enhanced compared to the 
actions of ISO-1 alone on ozone-induced BALF MIF levels.  Levels of MIF detected 
in the BALF remained significantly increased in the ISO-1 and dexamethasone pre-
treated ozone-exposed group compared to air control (4.9±1.4ng/ml vs. 
2.5±0.9ng/ml, p<0.01).  The ozone-induced BALF levels of KC (108.0±26.6pg/ml vs. 
86.0±19.9pg/ml, p=NS) and TNF (236.3±99.5pg/ml vs. 166.3±56.8pg/ml, p=NS) 
were also reduced in animals treated with the combination of ISO-1 and 
dexamethasone but again this did not reach significance and no additive effect was 
seen compared to that of the individual drugs on ozone induced mediator release.  In 
summary, I was unable to show that MIF inhibition enhanced the dexamethasone 
effects in this model (Figure 3.4). 
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3.4 Discussion 
3.4.1 ISO-1 attenuates ozone-induced inflammation 
There are various reports on the suppression of inflammation by MIF inhibition, in 
rodent models of inflammatory diseases.  Anti-MIF antibodies in rodents have been 
shown to be protective against endotoxemia (Calandra et al., 1995), arthritis (Leech 
et al., 1998) and sepsis (Al-Abed et al., 2005).  Mice with genetically deleted MIF 
also showed less inflammation in atopic dermatitis (Yoshihisa et al., 2011) and 
endotoxemia (Bozza et al., 1999). Most importantly to this study, reports of MIF 
inhibition on rodent models of allergen-induced asthma, led us to investigate the role 
of ISO-1, a small molecule antagonist of MIF, in a COPD inflammatory model.   
In previous reports eosinophil-rich inflammatory mouse and rat allergic asthma 
models that were induced by OVA-challenge showed attenuation of the inflammation 
by anti-MIF antibodies.  This was measured by reduced infiltration of inflammatory 
cells into BALF and by airway hyper-responsiveness (Amano et al., 2007, Kobayashi 
et al., 2006).  More recent studies have explored the association of MIF in mouse 
OVA-challenged models of inflammation and used ISO-1 (Chen et al., 2010).  In the 
Chen study, ISO-1 suppressed lung inflammation and airway remodelling, reduced 
BALF cell numbers, airway smooth muscle hypertrophy, sub-epithelial collagen 
deposition and TGF expression (Chen et al., 2010).  In support of this anti-
inflammatory action of MIF inhibition, I show here that ISO-1 pre-treatment 
attenuated ozone-induced inflammation with regards to RL and BALF cells and BALF 
MIF, KC and TNF mediator levels.  Nevertheless, the ozone-induced airway hyper-
responsiveness was not affected by ISO-1 pre-treatment and the ISO-1-suppressed 
ozone-induced MIF and KC remained significantly elevated compared to air and thus 
the inflammation was not fully repressed. 
In COPD, the inflammation is characterised as neutrophilic and models 
administrating low doses of LPS i.p. induce a neutrophil-rich lung inflammation 
(Hirano, 1996).  Anti-MIF antibodies attenuated the number of neutrophils recruited 
to the rat lung following LPS instillation in a model of lung injury/ARDS (Makita et al., 
1998).  LPS is a component of cigarette smoke, the major aetiological factor of 
COPD, which supports the potential relevance of this LPS model to human COPD.  
Ozone is also recognised as inducing a neutrophilic-rich inflammation 
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(Triantaphyllopoulos et al., 2011) and ISO-1 significantly suppressed the ozone-
induced cellular recruitment to the lung.  Although the ISO-1 effect on specific cell 
types was less obvious, macrophages and lymphocytes were reduced but this did 
not reach statistical significance and there was no effect of ISO-1 on BALF 
neutrophilia. 
In contrast to these studies, Korsgren and colleagues did not show attenuation of 
inflammation in OVA-challenged or LPS-treated mice models (Korsgren et al., 2000), 
and in this current study, the infiltration of neutrophils specifically, were not affected 
by ISO-1 pre-treatment.  There was also a disparity between this current study and 
that of Chen and colleagues who reported that ISO-1 attenuated lung inflammation; 
this may reflect the different inflammatory profiles induced by OVA and by ozone as 
the same strain of mice and dose of ISO-1 pre-treatment was used in both studies.  
OVA-treatment induces an eosinophil-rich inflammation in contrast to ozone, which 
induces a neutrophil-rich inflammatory response and therefore ISO-1 may have cell 
specific effects.  It is also noteworthy that the inflammation induced by OVA was 
twice as strong, with total cells reaching ≈30×105 with OVA (Chen et al., 2010) 
compared to the 12.30±1.6×105 with ozone, which may have concealed the ISO-1 
effect.   
Korsgren and colleagues used anti-MIF serum compared to Makita and colleagues 
using anti-MIF antibody (Korsgren et al., 2000, Makita et al., 1998), however the 
200μl-injected i.p. may not have been potent enough to suppress the inflammatory 
response.  There may also be a species difference seen as MIF inhibition of LPS-
induced neutrophillic inflammation has been demonstrated in rats (Makita et al., 
1998).  On the other hand there was also no suppression of OVA-induced eosinophil 
inflammation seen with anti-MIF serum (Korsgren et al., 2000).  However, this 
inflammation was milder than other studies and therefore could have masked the 
possible anti-inflammatory effects of MIF inhibition.  
3.4.2 ISO-1 does not restore dexamethasone sensitivity 
CS insensitivity is a major issue when treating COPD and severe asthma.  The 
unique function of MIF counter-regulating the function of CSs (Calandra et al., 1995) 
has driven research in many CS insensitive inflammatory diseases in an attempt to 
restore CS sensitivity, to improve disease control, to reduce exacerbations and 
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disease progression and lower the doses of oral CSs prescribed.  Anti-MIF studies 
have very recently started phase 1 studies for cancer treatment (Identifier 
NCT01765790) (ClinicalTrials, 2013) and pre-clinical studies are continuing for 
inflammatory and autoimmune diseases to fully elucidate its role within disease. 
To date, there is only one other report investigating ISO-1 and dexamethasone in a 
lung inflammatory model (Chen et al., 2010).  The authors report that the anti-
inflammatory effects of ISO-1 are comparable to those of dexamethasone in the 
OVA-induced murine asthma model; however unlike this current study they do not 
investigate the effects of the compounds in combination.  In contrast, ISO-1 and 
dexamethasone are non-comparable in my study and ISO-1 pre-treatment results in 
a more potent anti-inflammatory effect than seen with dexamethasone in the ozone 
model of COPD.  This reflects the fact that the ozone model is relatively CS 
insensitive, whilst OVA-induced inflammation is exquisitely CS sensitive.  Also, the 
dose of dexamethasone used in my study was 5-fold lower than that used by Chen 
and colleagues (2mg/kg vs. 10mg/kg) in the OVA-challenge model.   
ISO-1 and dexamethasone pre-treatment in combination showed no enhanced anti-
inflammatory effects on any of the ozone-induced parameters measured, pulmonary 
resistance, airway hyper-responsiveness or BALF MIF, KC and TNF levels.  The 
model remained CS insensitive with MIF inhibition.  However, it would be worth 
investigating if other inhibitors such as 4-IPP, a newer and more potent inhibitor of 
MIF (Winner et al., 2008) would restore the CS sensitivity in this model. 
In conclusion, this ozone-induced CS-insensitive murine model of COPD lung 
inflammation model was associated with increased BALF MIF levels.  RL, total BALF 
cell counts and BALF mediator levels were attenuated by pre-treatment with ISO-1.  
This supports a pro-inflammatory role for MIF in driving lung inflammation in this 
COPD model.  However, ISO-1 pre-treatment had no effect on suppressing ozone-
induced neutrophilia and did not reverse the CS insensitivity in the model, indicating 
that MIF is not the primary driver of CS insensitivity in this COPD model.  Further 
investigation into the role of MIF and its CS counter-regulatory function in CS 
insensitive COPD will be needed to understand if antagonism of MIF could be 
therapeutically beneficial. 
 95 
 
 
 
Chapter 4 
4 The effect of MIF on inflammation 
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4.1 Introduction 
COPD and asthma are both characterised by the infiltration of activated inflammatory 
cells and the subsequent release of cytokines (TNF) and chemokines (CXCL8) in 
the respiratory tract.  Despite some similar clinical features the underlying pattern of 
the chronic inflammation are markedly different between the diseases (Barnes, 
2008b).   
Most cells and organs constitutively express MIF; within the immune system it is 
released from monocytes/macrophages, lymphocytes and granulocytes and within 
the lungs, MIF is predominately found in macrophages and epithelial cells (Calandra 
and Roger, 2003).  
MIF is a pro-inflammatory cytokine involved in innate immunity to drive inflammation 
(Calandra et al., 1994).  MIF has been shown to induce TNF in human monocytes, 
mouse macrophages, Raw 264.7 cells and human THP-1 monocytes (Calandra et 
al., 1995, Senter et al., 2002) and also IL-1β, IL-6, CXCL8 and INF- (Calandra et al., 
1994, Bacher et al., 1996, Donnelly et al., 1997).  MIF has also been shown to be 
involved in other pro-inflammatory functions such as phagocytosis (Juttner et al., 
1998), proliferation (Hudson et al., 1999), MAPK signalling (Mitchell et al., 1999) and 
activating T lymphocytes (Bacher et al., 1996). 
Inhibition of MIF attenuates inflammation in murine inflammatory models in vivo 
(Lubetsky et al., 2002) and in vitro in mouse macrophages (Al-Abed et al., 2005).  
Suppression of inflammation by MIF-inhibition has also been shown in peripheral 
blood mononuclear cells (PBMCs) from healthy subjects (Lubetsky et al., 2002) and 
PBMCs from patients with cystic fibrosis (Adamali et al., 2012). 
MIF has been associated with the pathogenesis of allergic inflammation in mouse 
models of asthma (Mizue et al., 2005).  Differences between MIF levels of asthmatic 
patients and controls in BALF, serum and sputum samples have been reported 
(Rossi et al., 1998, Yamaguchi et al., 2000).  Whilst, there are correlations between 
MIF and severity of disease and differences between disease state seen in other 
chronic inflammatory diseases including RA (Mikulowska et al., 1997), ARDS 
(Donnelly et al., 1997) and more recently pulmonary hypertension (Zhang et al., 
2012).  To date there are no MIF expression profiles published from COPD patients. 
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Much of the knowledge and the functional role of MIF have resulted from mouse 
models and in murine cell lines with little information in human cells.  Accordingly, I 
have measured MIF in COPD human samples and investigated the function of MIF 
in human cell types. 
4.2 Chapter hypothesis and aims  
Macrophage migration inhibition factor released from monocytes/macrophages 
drives chronic inflammation.  Inhibition of MIF attenuates inflammation and 
stimulation with MIF enhances inflammation by increasing production of pro-
inflammatory cytokines and cellular proliferation through MAPK proteins.   
1. Compare MIF concentrations in non-smokers, smoker and COPD patient 
groups 
2. Investigate the pro-inflammatory action of MIF 
3. Compare the pharmacological (ISO-1) and biochemical (siRNA knockdown) 
inhibition of intracellular MIF on inflammatory processes in human primary 
(healthy, COPD and asthmatic patients) and immortalised cells 
4. Investigate MIF signalling pathways 
 
4.3 Results 
4.3.1 MIF expression profiles in COPD patient cohorts 
Concentrations of MIF expression were measured in sputum supernatants, serum, 
protein lysates from BAL macrophages and lung biopsies from non-smokers, 
smokers and COPD patients using ELISA and RT-qPCR.  The characteristics of the 
subjects included in these studies are shown in Tables 4.1-4.4.  MIF content in 
sputum supernatants was increased in patients with COPD compared to healthy 
non-smokers (p=0.007) however this difference between subject groups was not 
seen in circulating serum.  Intracellular MIF levels in proteins extracted from 
macrophages isolated from BALF did not change between subject groups and MIF 
gene expression levels also did not differ between groups (Figure 4.1).   
MIF was measured in BALF supernatants and was also detected in alveolar 
macrophages from the peripheral lung tissue of healthy smokers and COPD patients 
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by immunohistochemistry (work carried out by Dr Gaetano Caramori).  
Characteristics of the subjects recruited for this study are shown in Table 4.5.  There 
was no difference in MIF levels in BALF supernatants between healthy smokers and 
COPD patients (Figure 4.2).  MIF expression levels were not altered in COPD 
peripheral lung macrophages when compared to smokers with normal lung function 
(Figure 4.3).  
Table 4.1: Patient characteristics for sputum samples and protein lysates from BAL 
macrophages 
GROUP AGE 
SEX 
(M/F) 
N 
NUMBER 
PACK 
YEARS 
FEV1  
(% PRED) 
FEV1/FVC 
RATIO (%) 
Non 
smoker 
59(46-
71) 
9/10 19 N/A 106±4 79±1 
Smoker 
54(41-
66) 
8/7 15 32(21-51) 99±3 77±2 
COPD 
59(44-
72) 
13/5 18 39(25-57) 65±2 58±2 
COPD patients are GOLD stage 2 as diagnosed by the ATS guidelines.  Normally distributed 
data is represented as mean±SD and data not normally distributed is represented as median 
(25-75 quartiles)  
 
Table 4.2: Patient characteristics for serum samples 
GROUP AGE SEX (M/F) 
N 
NUMBER 
PACK 
YEARS 
FEV1  
(% PRED) 
FEV1/FVC 
RATIO (%) 
Non 
smoker 
51±2 8/6 14 N/A 105±4 98±3 
Smoker 59±2 14/8 22 28±3 86±3 84±3 
COPD 70±2 16/9 25 44±11 63±4 58±2 
COPD patients are GOLD stage 2 as diagnosed by the ATS guidelines.  Normally distributed 
data is represented as mean±SD  
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Table 4.3: Patient characteristics for lung biopsy samples 
GROUP AGE SEX (M/F) 
N 
NUMBER 
PACK 
YEARS 
FEV1  
(% PRED) 
FEV1/FVC 
RATIO (%) 
Non-
smoker 
60.5(58-
63) 
2/0 2 N/A 
107.5(99-
116) 
103.8(97.1-
110.5) 
Smoker 50.5±6.4 2/6 8 33.3±4.5 93.8±12.5 93.5±12.3 
COPD 56.5±6.2 4/6 10 36.1±9.1 80.7±10.4 78.6±4.9 
COPD patients are GOLD stage 2 as diagnosed by the ATS guidelines.  Normally distributed 
data is represented as mean±SD and data not normally distributed is represented as median 
(25-75 quartiles)  
 
Table 4.4: Patient characteristics for BALF supernatants 
GROUP AGE 
N 
NUMBER 
PACK YEARS 
FEV1 (% 
PRED) 
FEV1/FVC 
RATIO (%) 
Smoker 63.9±6.3 12 36.8±8.5 91.6±8.0 81.5±6.5 
COPD 66.8±5.5 12 36.5 (27-48.9) 61.2±10.8 
60.5 (52.6-
63.5) 
COPD patients are GOLD stage 1 or 2 as diagnosed by the ATS guidelines.  Normally 
distributed data is represented as mean±SD and data not normally distributed is represented 
as median (25-75 quartiles)  
 
Table 4.5: Patient characteristics for peripheral lung immunohistochemistry  
GROUP AGE 
SEX 
(M/F) 
N 
NUMBER 
PACK 
YEARS 
FEV1  
(% PRED) 
FEV1/FVC 
RATIO (%) 
Smoker 
74.1± 
5.9 
13/2 15 40 (30-50) 95.1± 17.0 78.1± 4.7 
COPD 
71.8± 
5.7 
15/0 15 
38.7± 
14.1 
74.5± 16.2 59.8± 8.7 
COPD patients are GOLD stage 1 or 2 as diagnosed by the ATS guidelines.  Normally 
distributed data is represented as mean±SD and data not normally distributed is represented 
as median (25-75 quartiles)  
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Figure 4.1: MIF expression profiles in human samples from non-smokers, smokers 
and COPD patients 
Concentrations of MIF were measured in various human samples from non-smokers (NS), 
smokers  with normal lung function and patients with COPD.  MIF levels detected by ELISA 
in (A) induced-sputum supernatants, (B) circulating serum, (C) protein lysates extracted from 
BAL macrophages, (D) MIF gene expression measured by RT-qPCR (relative to 18S mRNA 
control gene expression) in lung biopsy samples. **p<0.01 as calculated by ANOVA with 
Dunns post-hoc test 
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Figure 4.2: MIF expression in BALF supernatants 
MIF levels were measured by ELISA, in BALF supernatants from smokers (n=12) with 
normal lung function and COPD patients (n=12).  
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Figure 4.3: MIF expression in alveolar macrophages of peripheral lung from smokers 
and COPD patients 
MIF was detected using immunohistochemistry (magnification x400).  MIF expression was 
detected in alveolar macrophages of peripheral lung tissue sections. Representative images 
of MIF staining from (A) smokers and  (B) COPD patients Haematoxylin and eosin stain was 
used initially and anti-MIF antibody (brown staining) to highlight MIF protein.  (C) Graphical 
representation of MIF staining in smokers (n=15) and COPD patients (n=15).  
 
4.3.2 MIF regulation by LPS in THP-1 cells 
LPS is a pro-inflammatory component of cigarette smoke and was used to model 
COPD in vitro.  THP-1 monocytes were stimulated with LPS (1-20µg/ml) for 4 hours 
before total RNA was extracted and MIF gene expression measured by RT-qPCR.  
LPS significantly inhibited MIF expression in a concentration-dependent manner; the 
maximum suppression was by 71.1±5.6% of naïve with 10µg/ml LPS (Figure 4.4).   
20µm 20µm 
The effect of MIF on inflammation 
102 
 
A concentration curve of LPS (0.1-20µg/ml) was incubated with THP-1 cells for 24 
hours.  MIF levels released into the cell-free media were analysed by ELISA.  After 
24 hours, LPS significantly induced MIF release from THP-1 cells in a concentration-
dependent manner to a maximal enhancement of 237.6±23.4% of naïve (Figure 4.5). 
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Figure 4.4: LPS stimulation on MIF gene expression in THP-1 cells 
THP-1 monocytes were stimulated with increasing concentrations of LPS (1-20µg/ml) for 4 
hours.  Total RNA was extracted, reversed transcribed and analysed for MIF expression by 
RT-qPCR.  Data is normalised as a percentage of naïve control and expressed as 
mean±S.E.M. for four independent experiments. *p<0.05 vs. Naïve control as calculated by 
ANOVA with Dunns post-hoc test. 
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Figure 4.5: LPS-induced MIF release from THP-1 monocytes 
THP-1 cells were incubated with LPS (0.1-20µg/ml) for 24 hours.  LPS-induced MIF release 
was measured by ELISA.  Data is normalised as a percentage of naïve control and 
expressed as mean±S.E.M. for four independent experiments. **p<0.01 vs. naïve control as 
calculated by ANOVA with Dunns post-hoc test. 
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4.3.3 The pro-inflammatory effects of MIF in THP-1 cells 
To investigate the pro-inflammatory function of MIF, I studied the direct effect of 
human recombinant MIF (rhMIF) on changes in gene expression levels.  THP-1 
monocytes were treated with increasing concentrations of rhMIF (0.1-1000ng/ml) for 
4 hours before total RNA was extracted and RT-qPCR performed to analyse TNFA, 
IL8 and MIF gene expression.  Alternatively, in order to measure pro-inflammatory 
mediator release by ELISA, cells were treated with rhMIF for 1 hour prior to 24 hours 
LPS stimulation, or left untreated. 
After 4 hours treatment there was no significant effect of rhMIF on either TNFA 
(Figure 4.6A) or IL8 (Figure 4.6B) gene expression; however MIF expression levels 
were significantly inhibited in a concentration-dependent manner to a maximal 
suppression at 49.5±6.8%, p<0.001 of naïve control (Figure 4.6C).   
rhMIF-induced CXCL8 and TNF release in a concentration-dependent manner 
although this only reached statistical significance at the highest concentration of 
rhMIF for CXCL8 release (1.7-fold compared to naïve control, p<0.05, Figure 4.7A, 
C).  LPS significantly induced the release of both CXCL8 and TNF release.  There 
was no stimulatory effect seen on LPS-induced CXCL8 (Figure 4.7B).  No effect was 
seen on LPS-induced TNF by rhMIF either (Figure 4.7D).  
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Figure 4.6: rhMIF reduces MIF gene expression levels in THP-1 cells   
Cells were incubated with increasing concentrations of rhMIF (0.1-1000ng/ml) for 4 hours.  
Total RNA was extracted and reverse transcribed for  RT-qPCR.  Gene expression for TNFA 
(A), IL8 (B) and MIF (C) is normalised to the housekeeping gene 18S and then represented 
as a percentage of naïve cells as mean±S.E.M for at least four independent experiments for 
each gene. * p<0.05, ***p<0.001 vs. naïve control as calculated by ANOVA with Dunns post-
hoc test. 
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Figure 4.7: MIF activation shows pro-inflammatory mediator release in THP-1 cells 
THP-1 monocytes were stimulated with rhMIF (0.1-1000ng/ml) for 1 hour before stimulation 
with or without LPS (100ng/ml) for 24 hours.  Medium was removed and analysed for CXCL8 
release (A, B) and TNF release (C, D).  Data is normalised as a percentage of LPS control 
and expressed as mean±S.E.M. for at least 3 independent experiments.  Black line 
represents no stimulation (media alone) and Red line represents LPS stimulated. *p<0.05 
vs. naïve control, ***p<0.001 vs. naïve control as calculated by ANOVA with Dunns post-hoc 
test. 
 
4.3.4 Inhibition of MIF suppresses pro-inflammatory cytokine release in 
cells isolated from asthmatic patients 
MIF inhibition by ISO-1 has been shown to attenuate inflammation in mouse 
macrophages (Al-Abed et al., 2005) and also in ozone-induced (Chapter 3) and 
OVA-challenge mouse inflammation models (Chen et al., 2010).  ISO-1-suppressed 
inflammation has been reported in PBMCs from cystic fibrosis patients (Adamali et 
al., 2012).  I investigated this in LPS-stimulated PBMCs isolated from whole blood 
taken from non-severe and severe asthmatic patients (Table 4.6).  This study was 
approved by the Ethics Committee of the Royal Brompton & Harefield Hospitals National 
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Health Service Trust and all patients and healthy volunteers had given informed 
consent.   
Table 4.6 Demographics of asthmatic subjects for PBMCs isolation 
GROUP AGE 
SEX 
(M/F) 
N  
NUMBER 
FEV1 (% 
PRED) 
FEV1/FVC 
RATIO (%) 
Non-Severe 40.0±18.2 2/4 6 77.9±25.1 77.0±9.0 
Severe 50.8±13.8 2/7 9 64.5±27.3 62.8±18.3 
Normally distributed data is represented as mean±SD and data not normally distributed is 
represented as median (25-75 quartiles)  
 
4.3.4.1 Treatment of PBMCs from asthmatic patients with ISO-1 was 
cytotoxic at the highest concentrations 
PBMCs isolated from both severe and non-severe asthmatic patients were pre-
treated with the MIF inhibitor, ISO-1 (10-500µM) for 30 minutes and then stimulated 
with LPS (100ng/ml) for 24 hours (Figure 4.8) following this the cell viability was 
assessed by MTT.  The highest concentrations, 200µM and 500µM, caused 
significant cell death in the severe asthmatic PBMCs, cell viability was reduced by 
40.1±6.9%, p<0.001 at 200μM and 48.3±5.6%, p<0.01 at 500μM (Figure 4.8B).  This 
toxicity was not seen in the non-severe asthmatic PBMCs (Figure 4.8A). The 
concentrations of ISO-1, that were shown to be cytotoxic for the PBMCs taken from 
severe asthmatics, were not used in any subsequent experiments.  
4.3.4.2 Treatment with ISO-1 inhibits LPS-induced pro-inflammatory 
cytokine release in PBMCs from asthmatic patients 
Pro-inflammatory cytokine release (CXCL8, TNF and MIF) was measured in the 
supernatant from PBMCs isolated from both severe and non-severe asthmatics.  The 
cells were pre-treated with ISO-1 (10-100µM) for 30 minutes followed by stimulation 
with LPS (100ng/ml) for 24 hours (Figure 4.9).  CXCL8 and TNF release were both 
significantly induced by LPS stimulation in both patient groups.  The non-severe 
asthmatic PBMCs showed no ISO-1 effect on LPS-induced CXCL8 or TNF release 
(Figure 4.9A, C).  Pre-treatment with ISO-1 inhibited the enhanced cytokine release 
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in a concentration-dependent manner in PBMCs from the severe asthmatic subjects 
only.  LPS-induced CXCL8 and TNF release was suppressed to 55.4±11.0% 
(p<0.001) and 62.1±5.5% (p<0.001) of the LPS control with 50μM of ISO-1 
respectively and 36.0±6.3% (p<0.001) and 57.8±9.8% (p<0.001) respectively with 
100μM of ISO-1 (Figure 4.9B, D).  MIF release from PBMCs was not significantly 
enhanced by LPS stimulation for either severe or non-severe patient groups.  
However, LPS-induced MIF release was suppressed by 59.7±7.6%, p<0.001 with 
100μM of ISO-1 in non-severe asthmatic PBMCs (Figure 4.9E) and similarly, by 
59.4±6.2%, p<0.001 with 100μM of ISO-1 in the severe asthmatic patients (Figure 
4.9F).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The effect of MIF on inflammation 
108 
 
A) Non-Severe  
80
100
120
140
160
180
200
LPS (100ng/ml)
ISO-1 (M)-
-
-
+
10
+
50
+
100
+
200
+
500
+
M
T
T
 c
e
ll
 v
ia
b
il
ty
%
 o
f 
n
a
iv
e
 c
o
n
tr
o
l
 
 
B) Severe 
0
50
100
150
***
***
LPS (100ng/ml)
ISO-1 (M)-
-
-
+
10
+
50
+
100
+
200
+
500
+
M
T
T
 c
e
ll
 v
ia
b
il
ty
%
 o
f 
n
a
iv
e
 c
o
n
tr
o
l
 
 
Figure 4.8: The effect of ISO-1 and LPS on non-severe and severe asthmatic PBMC 
cell viability 
PBMCs were isolated from whole blood from non-severe and severe asthmatic patients and 
pre-treated with ISO-1 at concentrations ranging from 10µM to 500µM before being 
stimulated with LPS for 24 hours.  Cell viability was measured using MTT Assay, (A) non-
severe asthmatics (n=4) and (B) severe asthmatics (n=6). Data is normalised as % of naïve 
untreated cells and represented as mean±S.E.M. for 4-6 independent experiments.  
***p<0.001 vs. naïve cells as calculated by ANOVA with Dunns post-hoc test. 
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Figure 4.9: The ISO-1 effect on LPS-induced pro-inflammatory mediators in non-
severe and severe asthmatic PBMCs  
Isolated PBMCs from non-severe (A,C,E) and severe (B,D,F) asthmatics were pre-treated 
with ISO-1 (10µM-500µM) for 30mins followed by 24 hour LPS stimulation.  Pro-
inflammatory mediators, CXCL8 (A, B), TNF (C, D) and MIF (E, F) were measured in 
supernatants by ELISA.  Levels of release are expressed as % of LPS induced and 
represent mean±S.E.M. of six (non-severe asthmatics) and eight (severe asthmatics) 
independent experiments. ***p<0.001 vs. naïve control, $$p<0.01, $$$p<0.001 vs. LPS 
induced control as calculated by ANOVA with Dunns post-hoc test. 
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4.3.5 Inhibition of MIF suppresses pro-inflammatory cytokine release in 
lung tissue macrophages 
Lung tissue biopsies were taken and macrophages isolated from non-COPD and 
COPD patients.  Non-COPD patients were cancer patients undergoing lung 
resection surgery; tissue biopsies were taken away from cancer site.   
 
4.3.5.1 Effect of ISO-1 on lung tissue macrophage cytotoxicity 
Tissue macrophages were pre-treated with increasing concentrations of ISO-1 (10-
500µM) for 30 minutes followed by a 24hrs LPS (100ng/ml) stimulation.  MTT was 
used to evaluate the cell viability of the macrophages after these treatments in non-
COPD (Figure 4.10A) and COPD (Figure 4.10B) macrophages.  ISO-1 was less toxic 
in tissue macrophages compared to PBMCs.  The highest concentration of ISO-1 
tested (500µM) reduced viability in the non-COPD macrophages by 13.4±7.2% and 
in the COPD macrophages by 6.3±11.2%.  Therefore concentrations up to 500μM 
were used in subsequent experiments.   
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Figure 4.10: Cell viability after ISO-1 pre-treatment for tissue macrophages  
‘Healthy’ non-COPD (A) and COPD (B) lung tissue macrophages were pre-treated with MIF 
inhibitor, ISO-1 and then stimulated with LPS for 24 hours.  Cell viability is represented as % 
of mean naïve control of 2 independent experiments each. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
4.3.5.2 LPS-induced pro-inflammatory mediator release from tissue 
macrophages is inhibited by ISO-1 pre-treatment 
Tissue macrophages isolated from non-COPD and COPD patient lung tissue were 
pre-treated with ISO-1 for 30 minutes, before being stimulated with LPS for 24 hours. 
LPS significantly induced CXCL8 in both non-COPD and COPD macrophages.  Pre-
treatment with ISO-1 inhibited LPS-induced CXCL8 release from COPD 
macrophages by 30.3%±7.9, p<0.05 and 43.4%±8.3, p<0.01 at 200μM and 500μM 
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respectively (Figure 4.11A and B) but ISO-1 had no effect on LPS-induced CXCL8 
release from non-COPD macrophages.  Similarly, TNF release was also 
significantly induced by LPS stimulation in non-COPD and COPD macrophages.  
However, LPS-induced TNF release was significantly reduced by ISO-1 at 500μM 
by 49.7%±5.7, p<0.001 (Figure 4.11C) and 47.3%±8.3, p<0.01 (Figure 4.11D) in 
non-COPD and COPD macrophages respectively.  LPS had no effect on MIF 
release from either non-COPD or COPD macrophages, although ISO-1 significantly 
inhibited LPS-induced MIF release in a concentration-dependent manner for both 
non-COPD (Figure 4.11E) and COPD (Figure 4.11F) macrophages. 
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Figure 4.11: Effect of ISO-1 pre-treatment on LPS-induced pro-inflammatory mediators 
on tissue macrophages from ‘healthy’ non-COPD and COPD patients  
Tissue macrophages from ‘healthy’ non-COPD and COPD patients were pre-treated with 
ISO-1 for 30 minutes followed by 24 hours stimulation with LPS (100ng/ml).  Supernatants 
were measured for CXCL8 (A, B), TNF (C, D) and MIF (E, F) release by ELISA.  Levels of 
cytokine release are expressed as % of LPS-induced control and represent the 
mean±S.E.M. of four (non-COPD; A, C, E) and three (COPD; B, D, F) independent 
experiments.  ***p<0.001 vs. naïve control, $p<0.05, $$p<0.01, $$$p<0.001 vs. LPS induced 
control as calculated by ANOVA with Dunns post-hoc test.   
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4.3.6 Inhibition of MIF in THP-1 cells 
MIF inhibition by ISO-1 reduced LPS-induced inflammatory mediator production in 
two different primary cell types, PBMCs and lung tissue macrophages, from two 
inflammatory diseases, asthma and COPD.  I went on to investigate the role of MIF 
inhibition (pharmacological and biochemical) in the LPS-induced inflammation model 
in THP-1 monocytes as a model of primary cells. 
4.3.6.1 Pharmacological inhibition of MIF by ISO-1 in THP-1 cells 
4.3.6.1.1 Effect of ISO-1 pre-treatment on THP-1 cell viability 
THP-1 cells were pre-treated with the MIF inhibitor, ISO-1, ranging from 10µM to 
500µM for 30 minutes and then stimulated with LPS (100ng/ml) for a further 24 hours 
(Figure 4.12).  Cell viability after these conditions was then evaluated using MTT 
assay.  Cell viability was significantly reduced by 82.3±2.7 with 500µM ISO-1 and 
LPS stimulation; this combination was not used in further experiments.  
4.3.6.1.2 Pharmacological inhibition of MIF effects on inflammation 
THP-1 cells were pre-treated with ISO-1 for 30 minutes before 24 hours stimulation 
with LPS (100ng/ml).  LPS-induced CXCL8 and TNF release was analysed using 
ELISA.  The results show that LPS stimulation significantly induced the release of 
both CXCL8 (Figure 4.13A) and TNF (Figure 4.13B) by 99.1±1.6% and 84.9±5.8% 
respectively.  Pre-treatment with ISO-1 inhibited LPS-induced CXCL8 at 200µM by 
32.7±11.5% but had no effect at lower concentrations.  ISO-1 pre-treatment had no 
effect on LPS-induced TNF in THP-1 monocytes.   
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Figure 4.12: Cell viability of THP-1 cells after ISO-1 in combination with LPS treatment 
Cells were pre-incubated with ISO-1 (10µM-500µM) for 30 minutes prior to 24 hour 
stimulation with LPS (100ng/ml).  Cell viability was measured by MTT assay and data is 
represented as % of naïve control as mean±S.E.M. of five independent experiments.  
***p<0.001 vs. naïve control as calculated by ANOVA with Dunns post-hoc test. 
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Figure 4.13: ISO-1 reduces the LPS-induced pro-inflammatory mediator release 
Monocytes (THP-1) were pre-treated for 30 minutes with ISO-1 (10µM- 200µM) and then 
stimulated with LPS (100ng/ml) for 24 hours.  (A) CXCL8 and (B) TNF release into the 
media was analysed by ELISA.  The graphs are presented as % of LPS control as 
mean±S.E.M. for six independent experiments.  ***p<0.001 vs. naïve control and $p<0.05 
vs. LPS control as calculated by ANOVA with Dunns post-hoc test. 
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4.3.6.2 Knockdown of MIF expression by siRNA 
In order to confirm the effects of ISO-1 inhibiting MIF and attenuating LPS-induced 
inflammation I used On-Target MIF siRNA transfection in THP-1 cells. 
4.3.6.2.1 Effect of transfection with MIF siRNA on THP-1 cell viability 
Electroporation was used to transfer siRNA (200nM) into the nucleus of the THP-1 
cells, in the log phase of growth, at a cell density of 0.4×106/ml.  There were four 
experimental conditions for these experiments, untransfected (Naïve), transfected 
with no siRNA (Mock), Scramble siRNA and On-target MIF siRNA.  Cell viability was 
assessed using MTT assay 24 hours (Figure 4.14A), 48 hours (Figure 4.14B) and 72 
hours (Figure 4.14C) post-electroporation.  Electroporation alone caused significant 
cell death, around 50%, at all-time points; transfection with scramble and On-target 
siRNA had no additional effects on this cell viability at any time point.    
4.3.6.2.2 Knockdown of MIF gene expression and protein is time dependent 
Gene expression of MIF and intracellular MIF protein levels were evaluated after 
transfection as described above by RT-qPCR and Western blotting respectively.  
Levels of MIF expressed by the THP-1 cells, after the experimental conditions, were 
normalised to 18S mRNA for gene expression and to β-actin for protein expression.  
On-target MIF siRNA significantly reduced MIF mRNA gene expression at 24 hours 
(4-fold) and 48 hours (3-fold) post electroporation compared to scramble control 
siRNA (Figure 4.15A, C).  However, this effect was lost by 72 hours (Figure 4.15E).   
On-target siRNA also reduced intracellular MIF protein in a time-dependent manner.  
MIF protein was significantly reduced at 48 hours (1.75-fold) and 72 hours (1.85-fold) 
compared to scramble siRNA control post electroporation (Figure 4.15D, E). 
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Figure 4.14: Electroporation reduced THP-1 cell viability but siRNA had no additive 
impact on cell death 
THP-1 cells were electroporated without siRNA (Mock), with scramble siRNA (Scr) and On-
target MIF siRNA or left untransfected (naïve) and then incubated for (A) 24, (B) 48 and (C) 
72 hours. The cell viability post transfection was analysed using MTT assay.  Data is 
represented as mean±S.E.M. as a percentage of naïve (untransfected control) of at least 
four independent experiments. **p<0.01 vs. naïve control, ***p<0.001 vs. naïve control as 
calculated by ANOVA with Dunns post-hoc test.  
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Figure 4.15: Gene expression and protein levels of MIF after siRNA transfection  
THP-1 cells either naïve or electroporated alone (Mock), with scramble siRNA (Scr) or On-
target MIF siRNA were incubated for 24 hour (A, B), 48 hours (C, D) and 72 hours (E, F).  
Knockdown of MIF was analysed at gene expression level using RT-qPCR (A, C, E) or by 
measuring intracellular MIF protein by Western blot (B, D, F).  Data is presented as 
mean±S.E.M. as a fold change of naïve of at least four independent experiments for gene 
expression analysis and seven independent experiments for protein analysis.  Western blot 
images are representative of one independent experiment for each time point. **p<0.01 vs. 
scramble control ***p<0.001 vs. scramble control siRNA as calculated by ANOVA with 
Dunns post-hoc test. 
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4.3.6.2.3 Genetic inhibition of MIF on LPS-induced inflammation  
At each time point, 24, 48 and 72 hour post electroporation, THP-1 cells were 
incubated in 1% FBS RPMI media for 3 hours and then stimulated with LPS (1µg/ml) 
for 24 hours.  LPS-induced CXCL8 and TNF release were not affected by any 
treatments and the time points tested (Figure 4.16). 
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Figure 4.16: Reduced intracellular MIF has no effect on LPS-induced inflammation 
THP-1 cells were electroporated alone (Mock), with scramble siRNA (Scr) or On-target MIF 
siRNA (On-T) and incubated for 24 hours (black bars), 48 hours (grey bars) and 72 hours 
(white bars), following this the cells were stimulated with LPS (1μg/ml) and incubated for a 
further 24 hours.  LPS-induced CXCL8 (A) and TNF (B) secreted was analysed by ELISA.  
Data is normalised as mean±S.E.M. as a percentage of scramble siRNA control for each 
time point. Each condition at each time point is representative of three independent 
experiments. 
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4.3.7 MIF signalling 
4.3.7.1 CD74 activation 
Inhibition of MIF, in human primary cells and THP-1 cell lines, by pharmacological or 
genetical methods gave incompatible results in THP-1 cells.  MIF is thought to signal 
via binding to the membrane bound CD74 receptor (Leng et al., 2003).  I proceeded 
to elucidate the pro-inflammatory signalling of MIF in THP-1 cells with anti-CD74 (C-
16), an agonist for the putative MIF receptor.  THP-1 monocytes were treated with a 
concentration range of anti-CD74 (0.1-5μg/ml) for 4 hours before total RNA was 
extracted and RT-qPCR performed to analyse TNFA, IL8 and MIF gene expression.  
For pro-inflammatory mediator release measured by ELISA, cells were treated with 
the agonist for 1 hour prior to 24 hours LPS stimulation.   
In contrast to Section 4.3.3, activation of the putative MIF receptor, CD74, resulted in 
different gene expression profiles compared to stimulating with rhMIF.  TNFA gene 
expression was not affected by CD74 activation (Figure 4.17A) and IL8 and MIF 
gene expression increased in a concentration-dependent manner however did not 
reach statistical significance (Figure 4.17B, D). 
Activation of CD74 on pro-inflammatory mediator release evoked a similar response 
to that seen with rhMIF stimulation.  The CD74 agonist directly enhanced the release 
of CXCL8 3-fold at the highest concentration tested (5μg/ml, p<0.01) (Figure 4.18A).  
There was no effect on baseline TNF release with CD74 activation (Figure 4.18C).  
LPS significantly induced the release of both CXCL8 and TNF release.  
Furthermore, the CD74 agonist did not significantly enhance LPS-induced CXCL8 or 
TNF release (Figure 4.18B, D). 
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Figure 4.17: Activation of CD74 receptor affects gene expression levels in THP-1 cells  
Cells were incubated with a range of concentrations of CD74 agonist (0.1μg/ml to 5μg/ml) for 
4 hours.  Total RNA was extracted and gene expression was quantified by RT-qPCR.  Gene 
expression for TNFA (A), IL8 (B), MIF (C) is normalised to the 18S mRNA internal control 
and then represented as a percentage of naïve cells as mean±S.E.M for at least four 
independent experiments for each gene.  
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Figure 4.18: CD74 activation shows pro-inflammatory mediator release in THP-1 cells 
THP-1 monocytes were stimulated with CD74 agonist (0.1-5µg/ml) for 1 hour before 
stimulation with or without LPS (100ng/ml) for 24 hours.  Medium was removed and 
analysed for CXCL8 release (A, B) and TNF release (C, D).  Data is normalised as a 
percentage of LPS control and expressed as mean±S.E.M. for at least 3 independent 
experiments.  Black line represents no stimulation (media alone) and Red line represents 
LPS stimulated. **p<0.01 vs. naïve control, ***p<0.001 vs. naïve control as calculated by 
ANOVA with Dunns post-hoc test. 
 
4.3.7.2 Mitogen-activated protein kinases (MAPK)  
4.3.7.2.1 Transient induction of MAPK by MIF  
The ability of rhMIF to directly affect the phosphorylation states of p38, ERK 1/2 and 
JNK MAPKs was investigated in THP-1 monocytes, MIF signalling through MAPK 
has been shown in mouse and human fibroblasts cells via ERK1/2 (Lue et al., 2006), 
p38 (Santos et al., 2004) and JNK (Lue et al., 2011).  rhMIF at a concentration of 
100ng/ml was incubated with the cells for specified times up to 60 minutes and the 
phosphorylation of the MAPK proteins were analysed using an ELISA-based 
PhosphoTracer.  Phosphorylation of p38 MAPK on Thr180 and Tyr182, ERK1/2 
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(p44/42) at Thr202 and Tyr204 and JNK MAPK at Thr183 and Tyr185 
phosphorylation sites signify the activation of these kinases.  MIF reduced p-p38 and 
p-JNK MAPK at all time points studied.  This effect was significant at 60 minutes for 
p-p38 MAPK (60.1±8.6%, p<0.01) and at 40 minutes for p-JNK (38.4±11.0%, 
p<0.05) (Figure 4.19A, B).  There was no significant effect detected on the activation 
of ERK1/2 MAPK at any time point within the hour (Figure 4.19C).  
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Figure 4.19: rhMIF directly inhibits the baseline activation of p38 and JNK MAPK 
Monocyte THP-1 cells were treated with rhMIF (100ng/ml) for specified times over an hour 
period.  Phosphorylation of p38, JNK and ERK1/2, as a marker of activation, was analysed 
using an ELISA-based PhosphoTracer.  Data is represented as fold change of  
phosphorylation status from 0 minutes from five independent experiments. *p<0.05, **p<0.01 
vs. 0 minutes as calculated by ANOVA with Dunns post-hoc test. 
 
4.3.7.2.2 Sustained induction of MAPK by MIF 
In order to examine whether rhMIF induced or supressed kinase activity over a 
sustained period, THP-1 cells were incubated with rhMIF (100ng/ml) for 24 hours.  
Whole cell lysates were probed for phosphorylated kinase proteins using a kinase 
array; an increase in phosphorylated kinase is a marker of its activation.  The 
antibodies for the phosphorylated kinases were spotted in duplicate and pixel 
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densitometry was used to quantify changes in phosphorylation status.  The results 
were normalised as a percentage of naïve control.  Various kinases showed an 
increase in the phosphorylated state after 24hr treatment of rhMIF when compared 
to the relevant untreated (naïve) control, although none were significantly affected 
(Figure 4.20).               
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Figure 4.20: rhMIF has no direct sustained effect on MAPKs in THP-1 cells 
rhMIF was incubated with THP-1 cells for 24 hours, before whole cell protein lysates were 
prepared.  The lysates were used to identify the activated kinases by presence of the 
phosphorylated proteins; this is depicted by the dark spots on the kinase array (A).  The 
spots were used for pixel densitometry to graph activation status of the kinases (B).  The 
graph represents the average pixel densitometry signal (duplicate spots) normalised as a 
percentage of the same kinase on the naïve array (100% dotted line for naïve kinase). Data 
represents the mean±S.E.M of five independent experiments.  Data was non significant as 
calculated by individual Mann-Whitney t-tests against naïve control.     
 
4.3.7.3 Proliferation 
Proliferation of THP-1 cells was measured using a BrdU assay.  THP-1 cells (1×104 
total) were plated into 96-well plates and incubated with increasing concentrations of 
rhMIF (0.1-1000ng/ml) or with the MIF inhibitor ISO-1 (10-200μM) in 0.5% FBS 
media for 48 hours.  BrdU labelling reagent was added and allowed to incorporate 
into the DNA for 24 hours before the cells were fixed and analysed.  Cell proliferation 
The effect of MIF on inflammation 
125 
 
was determined by comparing the treatment with BrdU incorporation in THP-1 cells 
grown in 0.5% FBS.  rhMIF enhanced cell proliferation in a concentration-dependent 
manner, reaching a maximal increase of 123.6±5.3%, p<0.05 with 100ng/ml rhMIF 
compared to naïve control (Figure 4.21A).  ISO-1 inhibited cell proliferation in a 
concentration-dependent manner with a maximal suppression of 90.7±2.1%, 
p<0.001 of naïve control with 200µM ISO-1 (Figure 4.21B).  
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Figure 4.21: MIF is proliferative and essential for maintaining cell growth of THP-1 
cells 
Cells were incubated with increasing concentrations of rhMIF (0.1-1000ng/ml) (A) or 
increasing concentrations of ISO-1 (10-200μM) (B) for 48 hours before the cells were 
incubated with BrdU labelling reagent for 24 hours.  All media contained 0.5% FBS as a 
positive control for normal cell growth.  Proliferation of THP-1 cells was analysed using a 
chemiluminesence BrdU ELISA.  Data is represented as a percentage of the untreated naïve 
cells plotted as mean±S.E.M. of four independent experiments. *p<0.05, **p<0.01, 
***p<0.001 vs. naïve as calculated by ANOVA with Dunns post-hoc test. 
 
4.3.7.3.1 Proliferation control: p53 
The tumour suppressor protein p53 is known to control cell cycle arrest, apoptosis 
and DNA repair (Alberts et al., 2002a).  MIF and p53 were first shown to be 
associated in 1999 and since then much of the research into this relationship has 
been in animal models and cell systems (Hudson et al., 1999, Mitchell et al., 2002, 
Jung et al., 2008).  To further validate these findings I investigated MIF’s inhibitory 
effects on p53 in human cells, THP-1.  Monocytes were treated with rhMIF (0.1-
1000ng/ml) for 4 hours, total RNA was then extracted and the gene expression of the 
p53 protein, TP53 was determined.  The expression of TP53 mRNA was inhibited by 
rhMIF in a concentration-dependent manner at this time point; TP53 gene 
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expression was inhibited to 55.8±8.8%, p<0.05 and 50.3±6.6%, p<0.01 of the 
untreated control with 100ng/ml and 1000ng/ml respectively (Figure 4.22).       
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Figure 4.22: TP53 gene expression is inhibited by rhMIF  
THP-1 cells were incubated with a range of rhMIF (0.1ng/ml to 1000ng/ml) for 4 hours.  Total 
RNA was extracted and 0.5µg RNA was reverse transcribed before qPCR was performed.  
Data is normalised to the internal control 18S gene expression and then represented as a 
percentage of the naïve control as mean±S.E.M. for four independent experiments.  *p<0.05, 
**p<0.01 vs. naïve control as calculated by ANOVA with Dunns post-hoc test.. 
    
In addition to measuring TP53 gene expression levels I examined whether MIF 
directly affected p53 activity.  THP-1 cells were treated with rhMIF (100ng/ml) for a 
time course up to 24 hours.  Nuclear proteins were extracted and p53 DNA binding 
capacity measured by TransAM®.  rhMIF had no effect on the binding capacity of 
p53 to its promoter region (Figure 4.23).  
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Figure 4.23: p53 binding capacity to the response element over time  
THP-1 cells were incubated with 100ng/ml rhMIF for specified times during 24 hour period.  
Nuclear proteins were isolated and the amount of p53 translocated to the nucleus and able 
to bind the response element was measured, positive control (+; green bar) was included in 
kit (H2O2 -treated MCF-7 cells). Data is represented as fold change compared to 0 hours 
(mean±S.E.M.) for four independent experiments.   
 
4.3.7.3.2 Proliferation control: MAPK 
Proliferation and cell cycle control is not only modulated through p53 but also p38 
MAPK.  Activity of p38 may exert both stimulatory and inhibitory effects at certain 
stages of the cell cycle (Ono and Han, 2000).  Therefore the proliferative action of 
rhMIF was further investigated by the addition of a p38 MAPK inhibitor.  The 
experimental design was the same as before, however the THP-1 cells were pre-
treated with a p38 inhibitor (VX-745) (0.1nM-10µM) for 1 hour before being 
stimulated with rhMIF at a concentration of 100ng/ml.  As previously shown, rhMIF 
enhanced proliferation of THP-1 cells by ≈20% and pre-treatment with VX-745 
shows a concentration dependent inhibition of this rhMIF-induced proliferation.  The 
inhibitor, at concentrations greater than 10nM, suppressed proliferation to basal 
levels and the highest concentration (10µM) suppressed growth that THP-1 
proliferation was less than the naïve control (77.0±7.1% of naïve control, p<0.001) 
(Figure 4.24).        
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Figure 4.24: MIF-induced proliferation is suppressed with VX-745, a p38 inhibitor  
THP-1 cells were pre-treated with increasing concentrations of VX-745 (10-9-10-5M), before 
being stimulated with 100ng/ml rhMIF for 48 hours.  BrdU labelling reagent  was added for 
24 hours.  The amount of BrdU incorporated into the DNA on the cells was measured by 
ELISA.  Data is displayed as a percentage of naïve cells as mean±S.E.M for four 
independent experiments. **p<0.01 vs. naïve control, $p<0.05, $$p<0.01 and $$$p<0.001 vs. 
LPS control as calculated by ANOVA with Dunns post-hoc test. 
 
4.4 Discussion 
4.4.1 MIF expression profile in COPD 
In contrast to other chronic inflammatory diseases and the correlation between 
serum MIF and disease severity such as asthma (Rossi et al., 1998), RA (Morand et 
al., 2002) and atherosclerosis/cardiovascular disease (Burger-Kentischer et al., 
2002), systemic MIF measured in blood serum showed no difference between the 
COPD and control patient groups tested.  It is also worthy to note that serum MIF is 
present in relatively high concentration in normal individuals (0.1-100ng/ml) 
(Lubetsky et al., 2002, Kudrin and Ray, 2008), so large n numbers would be required 
for statistical power to detect small differences in expression.  
MIF detected in sputum supernatants was increased in COPD patients compared to 
healthy non-smokers.  The levels were non-significantly increased compared to 
smokers, suggesting that smoking may affect MIF levels released from cells in 
sputum.  This smoke-induced MIF increased is also seen in protein lysates from BAL 
macrophages, however there was no further enhancement with COPD compared to 
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smokers.  Correspondingly, there was also no significant difference in the MIF 
released from smokers and COPD cells into the BALF supernatant but there was no 
healthy non-smoking group to investigate the effect of smoking on MIF.  From this 
speculation, further investigation into the induction of MIF by LPS, a cigarette smoke 
component, was completed in THP-1 monocytes. 
MIF protein is stored within the cytoplasm of the cells (Calandra et al., 1994), 
however, there was no difference in MIF cellular content detected by 
immunohistochemistry in alveolar macrophages from smokers or COPD patients. 
Again, there was no healthy non-smoker group to investigate the effect of smoking.  
There was also no difference seen in the production of MIF at gene expression level 
between healthy non-smokers, smokers or COPD patients, this supports the lack of 
difference seen in the storage of intracellular MIF but the patient numbers are small 
and inconclusive.   
Having no healthy non-smoker group in some of the studies investigated has limited 
the understanding of the MIF profile within COPD patients.  Smoking is a significant 
risk factor in COPD development and therefore could induce or alter MIF function 
driving the inflammation and disease progression.  The effect of smoking on MIF in 
COPD should be further investigated. 
It is also noteworthy that the samples used in this study were collected from stable 
COPD patients that had relative control of the disease.  MIF may play a role during 
acute inflammation in disease, for example during an exacerbation.   There are 
complications with studying exacerbations as it can be difficult to collect samples 
from patients, to get comparable timings within the exacerbation and there are also 
the ethical considerations into patients’ well-being. 
4.4.2 Pro-inflammatory effects of MIF 
MIF signalling is unique among pro-inflammatory cytokines; the molecular 
mechanisms are complex, broad, cell type specific and have roles established in 
both innate and adaptive immunity.  MIF is understood to be pro-inflammatory 
although several reports give controversial results and this could be due to LPS 
contamination in bacterially expressed rhMIF (Kudrin et al., 2006) or cell specific 
functions. 
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At the gene expression level, MIF stimulation had no overall effect on baseline IL8 
production, however this did not correspond to protein release as MIF induced the 
baseline release of CXCL8 in a concentration-dependent manner from THP-1 cells.  
This is in support of the pro-inflammatory properties known for MIF (Bernhagen et 
al., 1994).  In contrast, MIF was shown to induce IL8 gene expression and CXCL8 
release from human gastric epithelial cells (Beswick et al., 2005) and in chronic 
lymphocytic leukaemia B-lymphocytes (Binsky et al., 2007).   
Similarly, MIF had no significant effects on TNFA gene expression although there 
was a non-significant concentration-dependent trend for MIF to enhance baseline 
TNF release from THP-1 cells.  This data is not in agreement with reports 
suggesting that MIF and TNF exist in a positive feedback loop and that MIF is 
essential for maximal induction of TNF in mouse in vivo and in vitro systems 
(Calandra et al., 1994).  However, my data is in support of results published by 
Kudrin, who also report the lack of TNF induction by MIF in THP-1 cells (Kudrin et 
al., 2006).   
The lack of gene production modulation by MIF seen in this study could be a time 
issue and a range of time points investigated would be needed to establish whether 
IL8 and TNFA gene expression was induced by MIF in THP-1 cells.  The small MIF 
stimulatory effects were not strong enough to significantly enhance the release of 
LPS-induced CXCL8 or TNF.  
rhMIF inhibited its own gene expression in a concentration-dependent manner.  
Interestingly, LPS induced MIF release from THP-1 cells in a concentration-
dependent manner; however, LPS also resulted in a concentration-dependent 
inhibition of MIF gene expression.  Suggesting that MIF is involved in a negative 
feedback loop and it may act in an autocrine fashion in these cells. 
MIF does not show potent pro-inflammatory functions in THP-1 cells as MIF-induced 
CXCL8 and TNF release is only seen at baseline and not in synergy with LPS and 
no pro-inflammatory action is seen at gene expression level.  The effects of MIF on 
cellular recruitment and phagocytosis may show more potent pro-inflammatory 
signals.  
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4.4.3 Inhibition of MIF on LPS-induced CXCL8 and TNF release 
As previously shown and discussed (Chapter 3), in vivo studies have shown the 
involvement of MIF in inflammation by using MIF knockout mice, anti-MIF antibodies, 
anti-MIF serum or ISO-1 in different inflammation models (Chen et al., 2010, 
Korsgren et al., 2000, Makita et al., 1998).  Different stimuli are used to model 
different aspects of disease, for asthma and COPD stimuli such as allergen-
challenge (OVA or house dust mite HDM), LPS instillation, smoke inhalation or 
ozone are used.  LPS is a component of cigarette smoke and induces inflammation.  
To translate this to humans I investigated the effects of ISO-1 on LPS-induced 
inflammation in human cells, firstly ex vivo and then in vitro to establish an 
inflammatory model. 
PBMCs isolated from severe asthmatic subjects showed an ISO-1 concentration-
dependent inhibition of LPS-induced CXCL8 and TNF but had no effect on PBMCs 
from non-severe asthmatics.  ISO-1 also had an inhibitory effect on LPS-induced 
MIF release from non-severe and severe asthmatic PBMCs although LPS alone had 
no effect on MIF release in either subjects’ cells.  This attenuation of LPS-induced 
inflammation by ISO-1 was also seen with regards to lung tissue macrophages.  
Macrophages isolated from both, non-COPD and COPD subjects showed a 
concentration-dependent inhibition by ISO-1 on LPS-induced TNF release, 
however the ISO-1 inhibition was only seen in COPD patient lung macrophages for 
LPS-induced CXCL8 release.  This data is in support of current findings; that ISO-1 
pre-treatment shows similar attenuation of inflammation with regards to LPS-induced 
TNF in PBMCs isolated from cystic fibrosis patients (Adamali et al., 2012).  
Overall this reduction in inflammation was more pronounced in the diseased cells, 
either severe asthmatic PBMCs or COPD macrophages compared to the controls.  
This difference supports the hypothesis that MIF is involved in the chronic 
inflammation, although with no clear difference in expression levels, MIF function or 
activity may be altered giving the distinct responses. 
In order to further examine this function of MIF on inflammation the immortalised 
monocyte THP-1 cell line was used.  THP-1 cells did not give comparable results to 
the lung tissue macrophages and asthmatic PBMCs and ISO-1 treatment showed no 
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attenuation of LPS-induced TNF release.  Nonetheless, the highest non-toxic 
concentration of ISO-1 (200μM) did reduce LPS-induced CXCL8 release.  Amano 
and colleagues also found that ISO-1 did not affect cytokine release associated 
inflammation but validated further the ISO-1 effect on recruitment of cells into the 
BALF in an allergic asthma mouse model (Amano et al., 2007).  
Due to this disparity of ISO-1 effect in THP-1 cells compared to primary cells, I 
wanted to confirm the lack of ISO-1 inhibition on LPS-induced inflammation in THP-1 
cells by using siRNA to genetically inhibit MIF.  At 24 hours post-electroporation, MIF 
gene expression was already reduced by 3-fold compared to scramble control; 
however this was not translated into the intracellular protein level.  At 48 hours, MIF 
gene expression remained suppressed and the intracellular protein level was also 
reduced (1.75-fold).  However at 72 hours post electroporation the reduced MIF 
gene expression was lost but the protein level was at its greatest reduction, 2-fold 
less compared to scramble control.  Due to the controversy in MIF function and roles 
within the cell, I continued to look at all time points to get a complete overview of the 
role of MIF in LPS-induced inflammation.  In support of the ISO-1 experiments in 
THP-1, siRNA-mediated reduction of MIF showed no modulation of LPS-induced 
CXCL8 or TNF release at any of the time points tested.   
The cell type specificity of ISO-1 has been reported; one study has shown LPS-
induced cytokine inhibition with ISO-1 in primary monocytes however not shown the 
same response in monocyte-derived macrophages (MDMs) (West et al., 2008).  
Primary cells would be a better model for human and disease state and showed a 
MIF inhibitory response, however due to the intensity of investigations needed to 
elucidate the function of MIF and its inhibition under specific conditions the cell line 
would be more appropriate at this stage.  The variations in responses between 
patients may hide/enhance any MIF modulatory effects when investigating its role 
and therefore result in difficulty in detecting functional outputs.  For these reasons, I 
continued with THP-1 cells and explored the direct modulatory effects of human 
recombinant MIF (rhMIF) on pro-inflammatory processes. 
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4.4.4 MIF signalling 
In order to confirm whether MIF signals through the putative receptor, CD74, an 
agonist for the receptor was used and the results compared with the direct 
stimulation with rhMIF. 
CD74 activation had a concentration-dependent trend towards increasing IL8 gene 
expression; however this did not reach statistical significance.  This corresponds with 
protein release as the CD74 agonist induced the baseline release of CXCL8 in a 
concentration-dependent manner in THP-1 cells.  This release of CXCL8 after CD74 
activation is comparable with the MIF stimulation seen in this study and others 
(Beswick et al., 2005, Binsky et al., 2007).   
CD74 activation had no significant effects on TNFA gene expression or baseline and 
LPS-induced TNF release from THP-1 cells.  This data is not in agreement with 
reports (Calandra et al., 1994). 
In contrast, MIF and CD74 activation had opposing effects on MIF expression in 
THP-1 cells; rhMIF inhibited its own gene expression whilst CD74 activation seemed 
to enhance MIF expression.  This data suggests that MIF may not be acting through 
CD74 in these cells or that the CD74 agonist has additional targets.   
In support of the published data on MIF and p53 (Bacher et al., 1996, Hudson et al., 
1999), MIF treatment induced THP-1 monocyte proliferation and inhibition of MIF-
suppressed cellular growth when compared to the positive control (0.5% FBS 
media).  rhMIF (100ng/ml) suppressed the baseline levels of TP53 gene expression, 
as p53 is a key regulator of proliferation, reduction of its levels would help drive the 
cell cycle and enhance proliferation.  I can speculate that the difference between the 
small induction of proliferation by exogenous MIF and large inhibition of proliferation 
by ISO-1 shows the importance of the intracellular MIF stores and constitutive 
production on maintaining regular cell growth and division.  This inhibition of p53 
production was not translated into reduced p53 transcriptional activity, as measured 
by TransAM® assay showing although MIF reduced expression levels it did not affect 
p53 DNA binding.  More selective p53 binding to specific target genes could be 
measured by chromatin immunoprecipitation (ChIP) assays.  
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A recent study noted that p53 was significantly higher in the lung of patients with 
emphysema secondary to smoking compared with tissue from smokers without 
emphysema (Morissette et al., 2008).  Another group investigated the association of 
p53 and MIF with cigarette smoke extract (CSE) and demonstrated that in human 
endothelial cells, CSE-induced MIF protein expression and the CSE-induced 
apoptosis was p53 dependent (Damico et al., 2011).  The authors also showed 
exogenous MIF prevented CSE-induced apoptosis.  It was therefore speculated that 
chronic smoking altered MIF function or expression in a way that prevented its 
cytoprotective function causing enhanced p53-dependent endothelial death and 
emphysema (Damico et al., 2011), my data supports this hypothesis.  
MIF is present in most cells, both structural and immune (Calandra and Roger, 2003) 
and therefore extending these investigations to other cell types, for example 
epithelial cells, may elucidate if MIF, within the lung, can contribute to the p53-
inhibited proliferation driven fibrosis and/or p53-dependent cell death driven 
emphysema.  One study also investigated the p53-dependent effects of MIF on cell 
growth/proliferation and demonstrated a direct link between MIF-mediated PI3K/Akt 
signalling and cell survival/growth and inhibition of apoptosis in mouse primary and 
immortalised fibroblasts (Lue et al., 2007).  In this study, rhMIF had no effect on the 
phosphorylation and hence activation status of Akt protein after 24 hours stimulation. 
Cell cycle control is critical for proliferation of cells and therefore further studies in to 
the effects of MIF on cyclins and cyclin-dependent kinases (Cdk) expressions and 
the stimulatory or inhibitory effects on MAPK activation may reveal the role of MIF in 
reducing apoptosis or enhancing proliferation and driving chronic inflammation. 
Proliferation, cell growth and apoptosis are not only driven via p53-dependent 
pathways but through the pro-inflammatory MAPK pathways. MIF has also been 
shown to signal through MAPK pathways; the direct modulation of the ERK 1/2 
pathway by MIF is most characterised (Lue et al., 2006, Mitchell et al., 1999).  
Although p38 activation and JNK activation by MIF has also been reported (Lue et 
al., 2011, Veillat et al., 2010).  Again most of these reports have been studied in 
rodent cells.  The proliferative effects of MIF via MAPK signalling have not been 
reported in THP-1 human monocytes. 
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As previously discussed, MIF enhanced cell growth in a concentration-dependent 
manner and this was abrogated by ISO-1.  This MIF-induced proliferation was also 
suppressed with pre-treatment of VX-745, again in a concentration-dependent 
manner, suggesting that the proliferative action of MIF may signal through p38 
MAPK cascade. Although, it could be possible that VX745 reduces the basal 
proliferation and thus too potent for MIF-induced proliferation to be seen. 
It has been demonstrated that MIF stimulates ERK1/2 MAPK in a sustained manner, 
(Mitchell et al., 1999) and in a transient manner (Lue et al., 2006) in murine 
fibroblasts and macrophages.  The effect of MIF on MAPK signalling in THP-1 cells 
was in contrast to these findings.  MIF did not directly affect ERK 1/2 activation within 
1 hour (transient) or at 24 hours (sustained) as measured by change in 
phosphorylation status of the kinase.  A dual role for MIF has been described, 
whereby MIF at physiological concentrations in an inflammatory context (50-
100ng/ml) stimulates resting cells, enhances proliferation and initiates an 
inflammatory response.  However, in an acute exacerbation, higher concentrations of 
MIF, in the upper ng/ml to μg/ml range, inhibits ERK1/2 MAPK and may activate a 
‘switch off’ mechanism (Lue et al., 2006).  Therefore, 100ng/ml rhMIF, as used in 
these experiments may be too high a concentration to activate MAPKs for prolonged 
periods and hence ‘switched off’ the activation of MAPKs detected in the array; there 
are a few MAPKs that have non-significant increases when compared to the naïve 
treated kinases, suggesting that the concentration of MIF is critical in initiating its 
signalling and functions.       
MIF directly inhibited serum-activated p38 and JNK MAPK in THP-1 cells, with the 
maximal suppression at 60 minutes for p38 MAPK and 40 minutes for JNK MAPK.  
This was slightly unexpected with regards to p38 MAPK, as VX-745 pre-treatment 
had suppressed the MIF-induced proliferation.  On the other hand, the BrdU assay, 
to analyse proliferation, was a 72-hour experiment and MIF-induced p38 MAPK 
inhibition was only seen transiently at 60 minutes and not sustained to 24 hours. 
The involvement of MIF in the chronic inflammation of COPD and severe asthma 
remains to be fully elucidated.  I have shown here, no distinct difference in MIF 
expression was seen between COPD patients and healthy smoking controls.  Also, 
that MIF signalling may not be through membrane-bound CD74, but that rhMIF 
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stimulation leads to inflammation and proliferation, reduced TP53 gene expression 
levels and inhibitory effects on MAPKs.  MIF signalling and its association with p53 
to either increase proliferation in airway fibrosis or to induce apoptosis and instigate 
emphysema and the relationship between MIF and smoking needs further 
investigation. 
Furthermore, MIF has been reported to override the immunosuppressive action of 
CSs (Calandra et al., 1995).  COPD and severe asthma patients show CS 
insensitivity and therefore in addition to the inflammatory effects of MIF, the counter-
regulatory effect of MIF on THP-1 cells as a model for COPD and asthma and its 
potential to be a therapeutic target is investigated in the next chapter.  Ideally these 
studies would have been conducted in primary cells from patients with COPD or 
severe asthma but limited cell availability prevented this approach. 
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5.1 Introduction 
The mainstay treatment for inflammatory diseases is CSs; they effectively suppress 
inflammation by reducing the recruitment of inflammatory cells, inhibiting the 
production of chemotactic mediators and adhesion molecules, inducing apoptosis of 
inflammatory cells and reducing the release of pro-inflammatory cytokines (Barnes, 
2006).  However, in some inflammatory diseases subsets of patients are relatively 
CS resistant whilst in other diseases like COPD, patients are generally CS resistant 
(Barnes and Adcock, 2009).  CS insensitivity leads to poor disease management and 
is a huge burden on NHS healthcare costs (Wenzel, 2006).  The precise 
mechanisms causing CS insensitivity are not completely understood, although many 
mechanisms have been suggested including genetic susceptibility (Carmichael et al., 
1981), defective GR binding and translocation (Matthews et al., 2004) and excessive 
activation of pro-inflammatory transcription factors such as AP-1 (Adcock et al., 
1995).  
The function of MIF within the immune system and inflammatory diseases is not fully 
understood (Bucala, 2000).  However, one action of MIF that potentially highlights its 
role in CS insensitivity is its potent anti-CS effects.  MIF has been shown to 
counteract the immunosuppressive effects of CSs (Calandra et al., 1995).   
The mechanisms by which MIF counteract CS actions are not fully elucidated but 
MIF has been shown to interact with some aspects of GR signalling pathways, such 
as via MKP-1 (Aeberli et al., 2006b, Roger et al., 2005) and via the inhibitor of NF-κB 
(IB) (Daun and Cannon, 2000).  However the majority of reports into MIF 
counteracting the immunosuppressive action of CSs are in rodent models and 
systems and therefore I aimed to confirm these responses in human cells.  I have 
chosen to use a human monocytic cell line THP-1 as a model to investigate the 
ability of MIF to interfere with dexamethasone actions as monocytes are a major cell 
type that responds to MIF.  A cell line rather than primary was selected as the 
number of cells required for some of the mechanistic studies would not be 
achievable in primary blood monocytes or BAL macrophages. 
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5.2 Chapter hypothesis and aims 
I hypothesise that MIF not only drives the inflammatory response in COPD but also 
reduces the effectiveness of steroids in monocytes/macrophages.   
1. Confirm that rhMIF counter-regulates the ability of dexamethasone to 
enhance a number of CS functions in human monocytic THP-1 cells. 
2. Investigate the possible mechanisms by which MIF modifies CS actions. 
 
5.3 Results 
5.3.1 Dexamethasone suppression of inflammation 
5.3.1.1 The anti-inflammatory function of dexamethasone  
Monocytic THP-1 cells were treated with dexamethasone (10-10-10-6M) and 
incubated for 2 hours (Figure 5.1) and inflammatory readouts either measured at 
baseline or following stimulation with LPS (1µg/ml) (Figure 5.2).  Total RNA was 
extracted and gene expression levels for IL8, MIF and DUSP1 measured.  
Dexamethasone significantly inhibited baseline levels of IL8 expression (Figure 5.1A) 
in a concentration-dependent manner with a plateau at 10-7M (66.0±7.0% 
suppression) and 10-6M (73.2±7.0% suppression).  The EC50 for dexamethasone-
suppression of basal IL8 mRNA expression was 5.6nM.  In contrast, DUSP1 gene 
expression (Figure 5.1B) was significantly induced by dexamethasone in a 
concentration-dependent manner with a 6-fold induction (653.2±111.2%) at the 
highest concentration (10-6M) tested.  The EC50 for DUSP1 induction was 12nM.  
Dexamethasone had no effect on baseline levels of MIF gene expression (Figure 
5.1C).   
LPS stimulated both IL8 (Figure 5.2A) and DUSP1 (Figure 5.2B) expression 
although the latter did not reach statistical significance; LPS had no effect on MIF 
(Figure 5.2C) gene expression levels.  Dexamethasone significantly inhibited LPS-
induced IL8 gene expression with a maximal effect of 55.4±8.0% at 10-6M (EC50 
7.6nM).  In contrast, dexamethasone significantly further enhanced LPS-induced 
DUSP1 expression 4-fold (395.4±26.8%) at the highest concentration tested (10-6M) 
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with an induction EC50 of 15nM (Figure 5.2B).  MIF gene expression was not affected 
by dexamethasone in combination with LPS.  
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Figure 5.1: Effect of dexamethasone on IL8, MIF and DUSP1 baseline gene expression 
levels 
THP-1 cells were incubated with dexamethasone (10-10-10-6M) for 2 hours before RNA was 
extracted and gene expression of IL8 (A), DUSP1 (B) and MIF (C) were evaluated by RT-
qPCR.  Data is normalised to the 18S internal control and calculated as a percentage of 
naïve control.  Results are presented as mean±S.E.M. for four independent experiments. 
*p<0.05, **p<0.01 and ***p<0.001 vs. naïve control as calculated by ANOVA with Dunns 
post-hoc test. 
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Figure 5.2: Effect of dexamethasone on LPS-induced IL8, MIF and DUSP1 gene 
expression levels 
THP-1 cells were pre-treated with dexamethasone (Dex) for 2 hours before being stimulated 
with LPS (1µg/ml) for 30 minutes.  Total RNA was extracted from the cells and then reverse 
transcribed before qPCR was performed.  18S gene expression was used as an internal 
control to normalise the gene expression of IL8 (A), DUSP1 (B) and MIF (C).  The data is 
presented as mean±S.E.M. of the percentage of LPS control (set at 100%) for three 
independent experiments. ***p<0.001 vs. naïve control, $p<0.05, $$p<0.01 and $$$p<0.001 vs. 
LPS control as calculated by ANOVA with Dunns post-hoc test. 
 
CSs have been shown to affect MIF release in a bell-shaped concentration response 
manner, with low levels inducing MIF release but high concentrations suppressing its 
secretion in mouse macrophages (Calandra et al., 1995).  In order to determine 
whether this may have affected earlier results I extended the dexamethasone 
concentration range.  Dexamethasone (10-13-10-6M) had no effect on MIF released 
from THP-1 cells (Figure 5.3).    
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Figure 5.3: Dexamethasone does not enhance MIF release in THP-1 cells 
Monocytic THP-1 cells were treated with increasing concentrations of dexamethasone (Dex, 
10-13-10-6M) for 24 hours before MIF secretion was analysed by ELISA.  Data is normalised 
as a percentage of naïve control and presented as the mean±S.E.M. for four independent 
experiments. 
 
Dexamethasone suppression of LPS (1µg/ml)-induced cytokine release was 
investigated in THP-1 cells following 1 hour pre-incubation and overnight stimulation.  
Supernatants were removed and the levels of inflammatory mediators measured by 
ELISA, measuring for pro-inflammatory mediator CXCL8 (Figure 5.4).  LPS 
significantly induced CXCL8 release 6-fold (653.3±97.3%, p<0.001) compared to 
naïve control cells.  Dexamethasone pre-treatment significantly inhibited LPS-
induced CXCL8 release in a concentration-dependent manner with the highest 
concentrations of dexamethasone (10-7 & 10-6M) reducing CXCL8 levels to basal 
levels (134.9±10.6, p<0.01 and 139.3±4.5, p<0.05) respectively (Figure 5.4).  
Dexamethasone suppression of CXCL8 release had an EC50 value of 6.4nM. 
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Figure 5.4: Dexamethasone inhibits LPS-induced CXCL8 release from THP-1 cells  
Cells were pre-incubated with dexamethasone (Dex, 10-13M to 10-6M) for 1 hour before being 
stimulated with 1µg/ml LPS for 24 hours. CXCL8 release into the supernatant was measured 
by ELISA.  Data is presented as mean±S.E.M. of the percentage of naïve control for four 
independent experiments. ***p<0.001 vs. naïve control, $p<0.05, $$p<0.01 vs. LPS control as 
calculated by ANOVA with Dunns post-hoc test.   
 
5.3.2 MIF effects on dexamethasone-induced gene expression 
THP-1 cells were stimulated with rhMIF (0.1-1000ng/ml) for 4 hours before total RNA 
was extracted and RT-qPCR used to analyse DUSP1 gene expression.  DUSP1 
gene expression levels were significantly inhibited in a concentration-dependent 
manner with a maximum suppression down to 35.84±6.8% of naïve control levels at 
1000ng/ml MIF (Figure 5.5).  The direct effect of MIF on pro-inflammatory IL8 gene 
expression was analysed previously in Chapter 4, Figure 4.6B. 
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Figure 5.5: MIF inhibits the expression of the anti-inflammatory DUSP1 gene in THP-1 
cells 
THP-1 monocytes were incubated with rhMIF (0.1-1000ng/ml) for 4 hours.  Total RNA was 
extracted and DUSP1 gene expression measured by RT-qPCR before being normalised to 
18S gene expression.  Data is presented as mean±S.E.M. of the percentage of naïve cells 
from at least four independent experiments *p<0.05 vs. naïve, **p<0.01 vs. naïve and 
***p<0.001 vs. naïve as calculated by ANOVA with Dunns post-hoc test. 
 
 
5.3.3 MIF counter regulation of dexamethasone actions 
The effect of dexamethasone, rhMIF and LPS on cell viability was measured.  THP-1 
cells were treated with rhMIF for 30 minutes and dexamethasone for a further 1 hour.  
Cells were subsequently stimulated with LPS (1g/ml) overnight and cytotoxicity 
measured using an MTT assay.  There was no significant effect on cell viability by 
any treatment alone or in any combination (Figure 5.6). 
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Figure 5.6: Dexamethasone and rhMIF have no effect on viability of LPS-stimulated 
THP-1 cells 
Cells were incubated with rhMIF (0.1-1000ng/ml) for 30 minutes followed by 1 hour pre-
treatment with dexamethasone (10-8M).  Cells were then stimulated with LPS (1g/ml) for 16 
hours and cytotoxicity measured by MTT assay.  Data is presented as the percentage of the 
naïve value and plotted as the mean±S.E.M of three independent experiments. 
 
5.3.3.1 rhMIF counter-regulates dexamethasone-induced DUSP1 gene 
expression at baseline  
To study whether rhMIF counteracts the action of dexamethasone at the gene 
expression level, THP-1 cells were pre-treated with rhMIF (0.1-1000ng/ml) for 1 hour 
and then incubated with dexamethasone (10-8M) for 2 hours.  DUSP1 and IL8 gene 
expression levels were measured.  Dexamethasone suppression of baseline IL8 
gene expression was not affected by rhMIF (Figure 5.7A).  In contrast, rhMIF 
significantly inhibited dexamethasone-induced DUSP1 gene expression in a 
concentration-dependent manner (Figure 5.7B).  The maximal inhibition reached 
50.9±11.9% of the dexamethasone control at 100ng/ml rhMIF. 
 
 
 
 
   
The effect of rhMIF on dexamethasone function in monocytes 
146 
 
A)          B) 
0
50
100
150
200
***
  Dex (10
-8
M)
rhMIF (ng/ml)
-
- -
+ + + + +
1 10 100 1000
IL
8
 g
e
n
e
 e
x
p
re
s
s
io
n


c
t 
IL
8
/1
8
S
(%
 o
f 
N
a
iv
e
 c
o
n
tr
o
l)
0
50
100
150
200
$
***
-
- -
+ + + + +
1 10 100 1000
D
U
S
P
1
 g
e
n
e
 e
x
p
re
s
s
io
n


c
t 
D
U
S
P
1
/1
8
S
(%
 D
e
x
 c
o
n
tr
o
l)
 
 
Figure 5.7: Effect of rhMIF on dexamethasone-controlled gene expression levels in 
THP-1 cells 
Cells were pre-incubated with rhMIF (0.1ng/ml to 1000ng/ml) for 30 minutes before 
stimulation for 2 hours with dexamethasone (Dex; 10-8M).  Total RNA was extracted, reverse 
transcribed and IL8 (A) and DUSP1 (B) gene expression levels measured by qPCR.  18S 
gene expression was used as an internal control and for normalisation of the gene 
expression.  Data is presented as the percentage of naïve control values and plotted as the 
mean±S.E.M. for four independent experiments. ***p<0.001 vs. naïve control, $p<0.05 vs. 
dexamethasone control as calculated by ANOVA with Dunns post-hoc test. 
       
 
5.3.3.2 rhMIF does not reverse dexamethasone function in the presence 
of LPS 
The opposing effects of rhMIF on dexamethasone function after LPS stimulation was 
investigated.  THP-1 cells were pre-treated with rhMIF for 30 minutes and 
dexamethasone (10-8M) for an additional 2 hours.  LPS was then used to induce an 
inflammatory response for 30 minutes and IL8 and DUSP1 gene expression was 
measured.  The release of TNF and CXCL8 into the culture medium was also 
investigated under essentially the same conditions as described above except that 
cells were stimulated overnight with LPS (1µg/ml) after an 1 hour pre-incubation with 
dexamethasone (10-8M).   
IL8 gene expression was significantly inhibited by dexamethasone after LPS 
stimulation (67.1±10.2% of LPS control, p<0.01) (Figure 5.8A).  The addition of 
rhMIF had no significant effect on dexamethasone inhibition of LPS-induced IL8 
gene expression (Figure 5.8A).   
DUSP1 expression was significantly enhanced by dexamethasone and LPS 
(261.9±26.7%, p<0.001) compared to the levels seen with LPS stimulation alone.  
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rhMIF had no effect on dexamethasone and LPS-induced DUSP1 gene expression 
(Figure 5.8B).  
LPS significantly induced the release of both CXCL8 (8-fold) and TNF (7-fold) and 
this induction was significantly inhibited by 10-8M dexamethasone in both cases. 
CXCL8 release inhibited by 54.0±2.9%, p<0.001 and TNF release was suppressed 
by 16.8±2.1%, p<0.001.  The addition of rhMIF had no significant effect on 
dexamethasone suppression of LPS-induced CXCL8 (Figure 5.9A) or TNF release 
(Figure 5.9B) in THP-1 cells.   
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Figure 5.8: rhMIF has no effect on dexamethasone modulation of LPS-induced IL8 and 
DUSP1 gene expression in THP-1 cells  
THP-1 cells were pre-treated with rhMIF (0.1-1000ng/ml) for 1 hour, followed by 2 hour 
incubation with dexamethasone (Dex; 10-8M) and 30 minutes stimulation with 1µg/ml LPS.  
RNA was extracted from the cells, reverse transcribed and IL8 (A) and DUSP1 (B) gene 
expression measured by qPCR.  18S gene expression was used as an internal control.  
Data is normalised as a percentage of LPS control and plotted as the mean±S.E.M. for four 
independent experiments.  **p<0.01, ***p<0.001 vs. naïve control, $$p<0.01, $$$p<0.001 vs. 
LPS control as calculated by ANOVA with Dunns post-hoc test. 
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Figure 5.9: The effect of rhMIF on dexamethasone suppression of LPS-induced TNF 
and CXCL8 release from THP-1 cells 
THP-1 cells were pre-treated with rhMIF (0.1-1000ng/ml) for 30 minutes followed by 1 hour 
exposure to dexamethasone (Dex; 10-8M) before stimulation with LPS (1µg/ml) for 16 hours. 
CXCL8 (A) and TNF (B) release was measured by ELISA.  Data is presented as the 
percentage of LPS control and plotted as the mean±S.E.M. of six independent experiments. 
***p<0.001 vs. naïve control, $$$p<0.001 vs. LPS control as calculated by ANOVA with 
Dunns post-hoc test. 
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5.3.4 Inhibition of MIF affects dexamethasone function in unstimulated 
THP-1 cells  
rhMIF inhibits dexamethasone-induced DUSP1 gene expression but not LPS and 
dexamethasone-induced DUSP1.  In order to confirm this MIF suppression I inhibited 
MIF with ISO-1 and siRNA.  
5.3.4.1 Effect of pharmacological inhibition of MIF by ISO-1 on 
dexamethasone-regulated gene expression 
THP-1 monocytes were pre-treated with rhMIF (100ng/ml) or the inhibitor ISO-1 
(100µM) for 30 minutes and then stimulated with dexamethasone (10-8M) for 2 
hours.  Total RNA was then isolated and gene expression for IL8 and DUSP1 
evaluated by qPCR.  Dexamethasone inhibited baseline IL8 gene expression by 
49.3±5.5% (p<0.001), whereas rhMIF and ISO-1 alone had no effect on basal IL8 
expression.  In addition, neither rhMIF (55.5±6.5%, p=NS) nor ISO-1 (57.3±10.4%, 
p=NS) had any effect on dexamethasone-suppression of IL8 gene expression 
(Figure 5.10A).   
DUSP1 gene expression was induced by dexamethasone (10-8M) by 70.9±6.0% 
above baseline (p<0.001).  In contrast to the previous set of experiments, rhMIF did 
not inhibit the baseline expression of DUSP1 (35.9±4.0% vs. 31.1±4.0%, p=NS); 
however pre-treatment with ISO-1 resulted in a 5.5-fold increase in DUSP1 gene 
expression compared to naïve levels (172.8±27.9% vs. 31.1±4.0%, p<0.001).  In 
support of previous results, rhMIF inhibited the dexamethasone-induced DUSP1 
gene expression by 44.0±9.9% (p<0.01) and ISO-1 enhanced dexamethasone-
induced DUSP1 gene expression by 22.3±20.5% although this did not reach 
statistical significance (Figure 5.10B). 
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Figure 5.10: ISO-1 attenuates MIF inhibition of dexamethasone-regulated gene 
expression 
THP-1 cells were pre-treated with ISO-1 (100µM) or rhMIF (100ng/ml) for 30 minutes 
followed by 2 hour stimulation with dexamethasone (Dex; 10-8M).  RNA was extracted and 
IL8 (A) and DUSP1 (B) gene expression evaluated using qPCR.  Data is normalised to 18S 
gene expression and plotted as a percentage of the naïve levels for IL8 expression and as a 
percentage of dexamethasone control for DUSP1 expression.  Data represent the 
mean±S.E.M. of four independent experiments. ***p<0.001 vs. naïve control and $$ p<0.05 
vs. dexamethasone control as calculated by ANOVA with Dunns post-hoc test. 
 
5.3.4.2 Effect of MIF knockdown on dexamethasone-regulated gene 
expression 
On-target MIF siRNA was used to knockdown MIF in THP-1 cells.  After 
electroporation the cells were incubated for 24, 48 and 72 hours and were then 
serum deprived using 1% FBS in phenol red free RPMI-1640 medium for 3 hours 
followed by treatment with dexamethasone (10-8M) for 2 hours.  Total RNA was 
extracted and IL8 and DUSP1 gene expression measured by RT-qPCR.  MIF 
knockdown using On-target MIF siRNA had no effect on the basal levels of IL8 
expression at any of the time points studied.  As seen in Figure 5.11A, 
dexamethasone inhibited the expression of IL8 in cells electroporated with scramble 
control siRNA at 24 hours (58.6±5.9% of scramble control, p<0.05).  However, this 
suppressive effect of dexamethasone on IL8 gene expression was lost in cells 
treated with On-target MIF siRNA (139.5±46.0% of scramble control, p=NS) at 24 
hours.  As the incubation times were extended the ability of dexamethasone to inhibit 
basal IL8 expression was reduced (41.4±5.9% at 24 hours compared to 12.9±9.8% 
at 72 hours).  Dexamethasone did not significantly affect IL8 gene expression in cells 
transfected with On-target MIF siRNA at any of the time points tested (Figure 5.11A).  
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Dexamethasone was able to induce DUSP1 gene expression at all-time points 
studied irrespective of whether cells were electroporated with scramble control 
siRNA or On-target MIF siRNA.  Reducing MIF levels in THP-1 cells had no effect on 
the baseline levels of DUSP1 gene expression when compared to scramble siRNA 
at any time point (Figure 5.11B).  However dexamethasone-induced DUSP1 was 
significantly greater in cells transfected with On-target siRNA compared to 
dexamethasone-treated scramble control siRNA at 24 hours (181.4±33.0% of 
scramble control, p<0.05), 48 hours (165.8±29.9% of scramble control, p<0.05) and 
72 hours (176.0±23.5% of scramble control, p<0.01) (Figure 5.11B). 
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Figure 5.11: The effect of MIF siRNA on dexamethasone regulation of IL8 and DUSP1 
gene expression at 24, 48 and 72 hours 
THP-1 monocytes were electroporated with scramble or On-target MIF siRNA and then 
incubated for 24, 48 or 72 hours.  Cells were then treated with or without dexamethasone 
(Dex; 10-8M) for 2 hours before total RNA was extracted and IL8 (A) and DUSP1 (B) mRNA 
measured by qPCR.  Results are normalised to 18S gene expression and presented as the 
percentage of scramble control for IL8 and of dexamethasone-treated scramble control for 
DUSP1 gene expression at each time point.  Data is presented as mean±S.E.M. of three 
independent experiments.  *p<0.05 vs. scramble control, **p<0.01 vs. scramble control, 
***p<0.001 vs. scramble control, ##p<0.01 vs. On-target MIF siRNA, ###p<0.001 vs. On-
target MIF siRNA, $p<0.05 vs. dexamethasone-treated scramble control, $$p<0.01 vs. 
dexamethasone-treated scramble control as calculated by ANOVA with Dunns post-hoc test. 
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5.3.4.3 Effect of MIF knockdown using siRNA on dexamethasone 
suppression of LPS-induced cytokine release 
In addition to gene expression cytokine release was also measured by ELISA.  At 
each time point post electroporation, THP-1 cells were incubated in 1% FBS/RPMI 
media for 3 hours followed by pre-treatment with dexamethasone (10-8M) for 1 hour 
and then stimulated with LPS (1µg/ml) for 24 hours.  Dexamethasone significantly 
suppressed LPS-induced CXCL8 release at 24 hours (25.0±2.4%, p<0.01), 48 hours 
(55.1±11.9%, p<0.01) and 72 hours (34.6±2.8%, p<0.001) in scramble siRNA 
transfected cells (Figure 5.12A).  Dexamethasone was still able to fully suppress 
LPS-induced CXCL8 at 24 hours (25.9±1.6% vs. 87.3±7.4%, p<0.01), 48 hours 
(57.9±12.7% vs. 111.1±5.8%, p<0.01) and 72 hours (47.8±4.6% vs. 164.4±25.5%, 
p<0.001) following transfection of cells with On-target MIF siRNA (Figure 5.12A).   
Similar trends are seen with LPS-induced TNF release with MIF knockdown having 
no significant effect on the ability of dexamethasone to inhibit TNF levels at any of 
the time points studied when compared to scrambled control siRNA (Figure 5.12B).  
However, the ability of dexamethasone to suppress LPS-induced TNF expression 
was reduced over time with scramble siRNA from 24 hours (49.2±3.7%, p<0.001) 
through 48 hours (19.0±8.1%, p<0.05) to 72 hours (14.1±2.3%, p=NS) (Figure 
5.12B).  This suggests that electroporation alone affects the efficacy of 
dexamethasone to regulate the expression of subsets of inflammatory genes.     
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Figure 5.12: MIF knockdown has no effect on dexamethasone suppression of LPS-
induced CXCL8 or TNF release 
THP-1 cells were electroporated with either scramble siRNA or On-target MIF siRNA and 
incubated for 24 (black bars), 48 (grey bars) and 72 hours (white bars).  The cells were pre-
treated with dexamethasone (10-8M) for 30 minutes and then stimulated with LPS (1μg/ml) 
for a further 24 hours.  CXCL8 (A) and TNF (B) released were measured by ELISA.  Data 
is normalised to the effect of scramble siRNA at each time point and plotted as the 
mean±S.E.M. of four independent experiments.    *p<0.05 vs. scramble control, **p<0.01 vs. 
scramble control, ***p<0.001 vs. scramble control, # p<0.05 vs. On-target MIF siRNA, ## 
p<0.01 vs. On-target MIF siRNA, ### p<0.001 vs. On-target MIF siRNA as calculated by 
ANOVA with Dunns post-hoc test. 
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5.3.5 The effect of rhMIF on dexamethasone suppression of LPS-
induced p38 MAPK phosphorylation 
MIF has been reported to modulate p38 MAPK activity (Santos et al., 2004), a known 
target of dexamethasone actions (Clark and Lasa, 2003).  THP-1 cells were pre-
treated with rhMIF (100ng/ml) for 1 hour and then with dexamethasone (10-8M) for 2 
hours.  The cells were subsequently stimulated with LPS (1µg/ml) for 30 minutes and 
p38 MAPK activation measured by ELISA-based PhosphoTracer analysis.  Total p38 
MAPK levels were not affected by any treatment conditions.  Phosphorylated p38 
MAPK (p-p38) was non-significantly enhanced by LPS (937.7±58.6% of naïve 
control, p<0.06) and neither dexamethasone (950.0±68.4%, p=NS) or 
dexamethasone and rhMIF (1147.0±109.4%, p=NS) significantly affected LPS-
induced p38 MAPK activation (Figure 5.13). 
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Figure 5.13: Neither dexamethasone nor rhMIF modulate LPS-induced p38 MAPK 
phosphorylation.   
Cells were pre-treated with 100ng/ml rhMIF for 1 hour followed by 2 hour treatment with 
dexamethasone (Dex;10-8M) and a final stimulation with LPS (1µg/ml) for 30 minutes.  Total 
p38 MAPK (black bars) and p-p38 MAPK (white bars) were measured using an ELISA-
based PhosphoTracer.  Data is plotted as fluorescent units normalised to naïve control 
samples.  Results for both total and p-p38 MAPK are reported as the mean±S.E.M for five 
independent experiments. 
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5.3.6 rhMIF on dexamethasone-induced glucocorticoid receptor-
glucocorticoid response element (GR-GRE) DNA binding 
THP-1 cells were pre-treated with rhMIF (1-1000ng/ml) for 1 hour before stimulation 
with dexamethasone (10-8M) for 30 minutes.  Nuclear proteins were isolated and GR 
DNA binding measured.  The ability of activated GR to bind to its consensus GRE 
sequence (5’-GGTACAnnnTGTTCT-3’) was determined by TransAM® assay.  The 
results showed that dexamethasone induced GR-GRE binding 4-fold (28.0±3.7% vs. 
100%, p=NS) but rhMIF had no effect on dexamethasone induced GR binding 
(Figure 5.14).   
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Figure 5.14: rhMIF has no effect on dexamethasone-induced glucocorticoid receptor 
binding to the glucocorticoid response element 
THP-1 cells were pre-treated with rhMIF (1-1000ng/ml) for 1 hour followed by 30 minutes 
stimulation with dexamethasone (Dex; 10-8M).  Nuclear proteins were immediately extracted 
and the binding capacity of GR to GRE was analysed using a TransAM® ELISA based 
assay.  Data is plotted as the mean±S.E.M. of the percentage of dexamethasone control for 
four independent experiments.   
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5.4 Discussion 
5.4.1 Counteracting the immunosuppressive actions of CSs 
As expected dexamethasone exerted anti-inflammatory effects in THP1 cells 
indicated by both suppressing IL8 and inducing DUSP1 gene expression, both at 
baseline and after LPS-induction.  Dexamethasone also suppressed LPS-induced 
CXCL8 and TNF release.  However, dexamethasone had no effect on MIF 
expression in these cells in contrast to the data of Calandra and colleagues who first 
demonstrated the biphasic control of CS on MIF release (Calandra et al., 1995).  
These authors suggested that CSs directly inhibit pro-inflammatory cytokine release 
at high concentrations of dexamethasone (10-8 to 10-6M) but at low steroid 
concentrations (10-14 to 10-12M), CSs are able to induce MIF release (Calandra et al., 
1995).  This results in a bell-shaped concentration response curve that has been 
reported in mouse macrophages (Calandra et al., 1995), mouse T lymphocytes 
(Bacher et al., 1996) and human fibroblasts (Leech et al., 1999).  This is in contrast 
to the data reported here where dexamethasone had no effect on MIF expression or 
release.  This conflicting result on MIF induction might be due to an immortalised cell 
line effect on MIF, as dexamethasone suppressed LPS-induced CXCL8 release at 
the concentrations expected.   
The relationship between MIF and CSs gave rise to new understandings of how 
endogenous CSs maintain a homeostatic environment in the healthy immune 
system.  Stress or inflammatory stimuli initiate an immune response and this up-
regulates the release of endogenous CSs to suppress this response.  To prevent the 
potential over-suppression of the immune system, MIF release is simultaneously 
induced by CSs to act as a ‘brake’ and to maintain a healthy immune response 
(Morand and Leech, 1999).  More recent studies also report that the presence of MIF 
can reduce CS responsiveness.  For example, the loss of MIF expression in a 
murine knockout model (Aeberli et al., 2006b) and in vitro using transfection of an 
anti-sense MIF plasmid in mouse RAW264.7 macrophages (Roger et al., 2005) 
resulted in increased CS sensitivity.  Correlations have also been shown between 
elevated MIF expression and the corresponding CS insensitivity in different diseases 
including juvenile RA (De Benedetti et al., 2003), children’s nephrotic syndrome 
(Berdeli et al., 2005), and ulcerative colitis (Ishiguro et al., 2006). 
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MIF counteracts the immunosuppressive effects of CSs on LPS-induced cytokine 
release in vitro and in vivo in a mouse model of endotoxic shock.  Importantly, rhMIF 
blocked the protective effect of CSs on LPS lethality (Calandra et al., 1995).  To date 
the association between MIF and CS insensitive COPD has not been explored.  In 
this thesis, the effects of MIF on dexamethasone regulation of cytokine production 
was investigated in THP-1 cells; to investigate transrepression, dexamethasone 
inhibition of IL8 (CXCL8) and TNFA (TNF) were evaluated and for transactivation, 
dexamethasone induction of DUSP1 (MKP-1) was analysed.  Baseline IL8 gene 
expression was suppressed by dexamethasone as expected and increasing 
concentrations of rhMIF had no effect on this inhibitory response.  Furthermore, MIF 
inhibition by ISO-1 had no effect on basal IL8 gene expression or on 
dexamethasone-suppressed IL8 gene expression.  This failure of ISO-1 to affect 
basal IL8 gene expression was supported, in part, by siRNA-mediated knockdown of 
MIF, whereby although MIF knockdown reversed dexamethasone-induced 
suppression of IL8 gene expression at 24 hours, this effect was lost at 48 and 72 
hours when MIF knockdown was greatest.  This result is in stark contrast to results 
demonstrated in mice peritoneal macrophages, whereby loss of MIF increased the 
sensitivity to dexamethasone and enhanced its suppressive action (Aeberli et al., 
2006b).  
Dexamethasone also suppressed LPS-induced IL8 production, which was not 
affected by the presence of rhMIF.  Similarly, rhMIF did not affect LPS-induced 
release of CXCL8 and TNF or the ability of dexamethasone to suppress this 
release.  The effects of reducing MIF protein content using siRNA was also 
investigated and again failed to show a clear modulation of basal or LPS-induced 
CXCL8 and TNF release or on the ability of dexamethasone to suppress LPS-
induced CXCL8 and TNF release.  However, with extended incubation times the 
ability of dexamethasone to suppress LPS-induced CXCL8 and TNF release was 
reduced suggesting that it was not the loss of MIF content within the cell that 
effected CS function but the electroporation method itself.  Although this lack of MIF 
ability to modulate dexamethasone function is in line with results seen at the gene 
expression level and with regards to reports on THP-1 monocytes (Kudrin et al., 
2006), these data are in conflict with results published in other cells types (Calandra 
et al., 1995, Santos et al., 2001, Aeberli et al., 2006b, Bacher et al., 1996, Kudrin et 
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al., 2006).  Another immortalised monocyte cell line, U937 cells were also 
investigated however these results were similar to those seen with THP-1 cells (data 
not shown).  It is also noteworthy that Kudrin and others used a lower concentration 
of LPS to stimulate CXCL8 and TNF release from cells (Kudrin et al., 2006) and 
that 1µg/ml LPS may have produced an overpowering response and masked the 
anti-CS effects of MIF. 
MIF reversed the dexamethasone induction of DUSP1 gene expression in this study; 
however this effect was not seen following stimulation of the cells with LPS.  The 
ability of dexamethasone to induce DUSP1 expression was significantly reversed by 
100ng/ml MIF and, although this is a fairly high concentration, it is possible to detect 
these levels in human samples from inflamed conditions.  The sensitivity of the cells 
to dexamethasone was also enhanced with MIF inhibition, resulting in a greater 
stimulation of DUSP1 gene expression with On-target MIF siRNA compared to 
scramble siRNA at all time points studied.  A similar result was also observed with 
ISO-1 pre-treatment however it did not reach statistical significance.   
MIF inhibition by siRNA transfection alone had no effect on baseline levels of DUSP1 
gene expression yet inhibition with ISO-1 alone, stimulated DUSP1 gene expression 
levels to a significantly greater extent than seen with dexamethasone.  This disparity 
between the effects seen with MIF inhibition using two different approaches is 
difficult to explain; I have shown that rhMIF inhibits the baseline levels of DUSP1 and 
that ISO-1 can enhance DUSP1 gene expression.  Nonetheless, this could be an 
ISO-1-specific effect as siRNA transfection is known to be highly specific and the 
reduced levels of intracellular MIF did not support the DUSP1 induction.  
Alternatively, only a small amount of intracellular MIF may be needed to ‘control’ the 
baseline expression levels of DUSP1. Transfection with siRNA did not abolish MIF 
levels completely with the maximal level of MIF knockdown achieved being 54% of 
the scrambled control level at 72 hours.  This opposing effect on the transactivation 
pathway of CS signalling could be further investigated by examining mRNA 
production and the release of the anti-inflammatory cytokine IL-10 (Rea et al., 2000) 
or on the expression of other CS-inducible genes such as GILZ (D'Adamio et al., 
1997) and GITR (Nocentini et al., 1997). 
The effect of rhMIF on dexamethasone function in monocytes 
161 
 
Further experiments will be required to fully elucidate all CS functions that MIF 
counteracts and to study this within COPD or asthma; primary cells such as PBMCs, 
bronchial epithelial cells or alveolar macrophages may give more disease relevant 
results. 
5.4.2 Mechanism of MIF counteraction of CS actions 
The mechanisms by which MIF counteracts the CSs’ action are not fully elucidated 
but MIF has been implicated to impact upon both transrepression and transactivation 
pathways of GR signalling.  However, MIF seems to have more dominant effects on 
GR transactivation functions. 
The ability of MIF to affect the function of MKP-1 was investigated in this study by 
analysing the ability of rhMIF to modify the actions of dexamethasone on LPS-
induced p-p38 MAPK.  MKP-1 is induced by dexamethasone and in turn deactivates 
MAPKs, preventing the signalling cascade to activate NF-B and AP-1 gene 
transcription.  However, I was unable to show an effect of dexamethasone on LPS-
induced p-p38 MAPK.  This may reflect the single time-point investigated here and 
therefore the timings for this specific event need to be further investigated.  LPS 
stimulates the activation of p38 MAPK within 30 minutes but the 2 hours pre-
treatment with the CS may be too long and the effect may have been missed.  This 
longer incubation time is needed to see a difference in DUSP1 gene transcription 
and therefore due to MAPK signalling occurring very transiently and quickly any 
effect may have been missed.  In other experiments I have shown that rhMIF directly 
inhibits the DUSP1 gene expression at 4 hours and this experiment had rhMIF in 
culture media for at least 3.5 hours.  In this case, MKP-1 levels will be low and 
dephosphorylation of the p-p38 will not occur.  Interestingly, there was a small non-
significant increase in p-p38 MAPK in my study, supporting the concept that lower 
MKP-1 levels may augment p38 MAPK-dependent inflammation due to hyper-
activation (Wu and Bennett, 2005).  
Alveolar macrophages from COPD and severe asthmatic patients have been shown 
to have higher levels of activated p38 MAPK compared to controls and p-p38 MAPK 
has been shown to correlate with CS insensitivity (Bhavsar et al., 2008, Renda et al., 
2008), these patients have also been shown to have hyper-activated NF-B and AP-
1 transcription factors (Barnes and Adcock, 1998).  MKP-1 can de-activate other 
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MAPK signalling pathways, JNK and ERK1/2 MAPK each of which can activate other 
transcription factors.  MIF, acting via MKP-1, has also been reported to affect other 
downstream targets such as JNK MAPK and AP-1 (Roger et al., 2005) and future 
studies may examine the effect of MIF on their activity. 
Another mechanism by which MIF can counteract CS transactivation function is via 
IB (Daun and Cannon, 2000, Roger et al., 2005).  CSs induce the synthesis of 
IB and it, in turn, inhibits NF-B translocation into the nucleus, preventing DNA 
binding and transcription of pro-inflammatory genes (Verma et al., 1995).  There is 
great controversy on this mechanism and no clear evidence for MIF effecting NF-B 
activation (Kleemann et al., 2000, Lacey et al., 2003).  In this study, IB was not 
evaluated but the downstream NF-B (p65 subunit) DNA binding activity was 
measured.  I was unable to show any effect of MIF on p65 DNA binding either on its 
own or in combination with dexamethasone.  To confirm that MIF had no effect on 
the NF-B pathway, further experiments including reporter gene assays and Western 
blotting for IB protein levels would be needed. 
CSs up-regulate the expression of the anti-inflammatory cytokine IL-10 via 
transactivation (Rea et al., 2000).  Interestingly IL-10 has been shown to inhibit MIF 
release (Wu et al., 1993) and conversely MIF can inhibit IL-10 (Stavitsky and Xianli, 
2002).  To date there are no reports on the effect of MIF on CS-induced IL-10. 
It is unlikely, that CS insensitivity with respect to the control of the inflammation seen 
in COPD and severe asthmatic patients will be wholly down to MIF interacting with 
the GR transactivation pathway and reducing MKP-1 levels.  GR transrepression 
mechanisms may also be important targets for MIF in these diseases.  Pro-
inflammatory gene expression is under the control of transcription factors such as 
NF-B in complexes with transcriptional co-activators, which have HAT activity.  This 
results in enhanced local histone acetylation and chromatin remodelling enabling 
greater transcriptional activity (Biddie et al., 2011).  This change in local chromatin 
structure can be reversed by CSs in a process that involves activated GR 
(transrepression) and AP-1 (Biddie et al., 2011).  For some genes, recruitment of GR 
to this remodelled chromatin may be affected by recruitment of co-repressor proteins 
that contain HDAC activity.  This may affect GR acetylation status and further 
interaction with NF-B and co-repressor complexes or play a role in altering the local 
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chromatin environment (Ito et al., 2006).  There are no reports on MIF modulation of 
GR-associated HAT activity or on the composition of GR-transactivation complexes 
or on local GR-associated chromatin complexes.  Although in this study, no 
modulation was seen by rhMIF on CS-suppressed LPS-induced pro-inflammatory 
mediator release it would be of interest to investigate this potential mechanism in 
other cells lines or PBMCs or alveolar macrophages to fully elucidate the CS sparing 
functions of MIF. 
CS insensitivity is a major issue in treating and controlling COPD and severe 
asthma.  Novel treatments are needed to either re-sensitise patients to the anti-
inflammatory effects of CSs or new anti-inflammatory drugs are required that differ 
mechanistically to CSs.  I have shown here that MIF interacts with CS function via 
the transrepression pathway.  Inhibiting the counter-regulatory effect of MIF may 
improve CS sensitivity however the potential immunosuppression and increased 
susceptibility to infections may be a greater risk as seen in MIF deficient mouse 
models (Rodriguez-Sosa et al., 2003, Satoskar et al., 2001).  Inhibiting the 
downstream functions of MIF, for example inducing MKP-1 expression and 
increasing its stability, would alleviate the infection risk and also increase the anti-
inflammatory effects of CSs. 
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6 The effect of MIF on global protein 
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6.1 Introduction 
As discussed in previous chapters, I have seen no clear functional output of rhMIF or 
MIF activation of pathways investigated in THP-1 monocytes.  In this chapter, I used 
two methods to investigate the global effect of MIF stimulation on protein and RNA 
expression.  The “Stable Isotope Labelled Amino acids in Cell culture” (SILAC) 
method (Ong et al., 2002) was performed to assess global changes in protein levels 
after MIF stimulation in THP-1 cells.  Furthermore, differentially regulated genes by 
MIF at the mRNA level in THP-1 cells were analysed by RNA microarray.   
SILAC is a novel quantitative proteomic approach for identifying changes in protein 
content (Ong et al., 2002).  Briefly, isotopically labelled arginine and lysine (13C6-Arg 
and 2H4-Lys) are added to amino acid deficient cell culture media and are 
incorporated into all synthesised proteins during regular cell proliferation/growth, 
producing ‘heavy’ proteins.  Control cells are cultured with non-labelled amino acids 
for ‘light’ proteins.  The labelled amino acids do not affect protein function in any way 
other than the protein mass.  Protein lysates from all samples are mixed together as 
the amino acids labels are incorporated directly into the amino acid sequence of the 
protein and the exact ratio of heavy to light amino acids will indicate differentially 
expressed or tagged proteins.  Where ratios do not alter it reflects a lack of protein 
differences.  Finally the peptides are analysed by liquid chromatography-mass 
spectrometry (LC-MS) and further quantitated by MS, Figure 6.1.   
Figure 6:1: Schematic of SILAC protocol  
THP-1 cells were grown in SILAC ‘light’ or ‘heavy’ media for five doublings.  Protein extracts 
from naïve (light-labelled) and rhMIF-treated (heavy-labelled) cells were mixed, separated by 
SDS-PAGE and digested using trypsin.  The peptides were analysed by LC-MS/MS.  A shift 
to the right for corresponding peptides shows incorporation of the ‘heavier’ amino acids and 
hence proteins from the ‘heavy’ cells and treatment.  The relative height of the 
protein/peptide peaks indicates a relative change in protein expression levels.  
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Genome-wide analysis of mRNA expression will provide a global analysis of gene 
expression changes following cell treatment with drug or between cells from different 
patient groups (Wheelock et al., 2013).  It is the most well described and validated 
‘omic’ technology currently used (Wheelock et al., 2013).  Briefly, the RNA samples 
were prepared and quality assessed before being reverse transcribed and labelled 
with cyanine fluorophores Cy3 or Cy5.  The labelled cDNA samples were then 
hybridised to the pre-defined probes captured onto the array (Agilent SurePrint G3 
Human Gene Expression microarrays).  The microarray was finally scanned and 
image analysis performed and subsequently the raw data was extracted from the 
microarray image files (Agilent Feature Extraction Image Analysis Software (Version 
10.7.3)).   
6.2 Chapter Aims 
1. Identify novel pathways, associations and targets that are involved in MIF 
signalling 
a. At the protein expression level using Stable Isotope Labelled Amino 
acids in Cell culture (SILAC) method 
b. At the gene expression level (mRNA) using RNA microarray 
2. Validate any findings from (1) above to confirm MIF involvement 
 
6.3 Chapter data analysis 
6.3.1 SILAC analysis 
Trypsin digest, LC-MS/MS and the following initial protein analysis was carried out 
by Dr K. Heesom from University of Bristol.  Raw data files were processed and 
quantified using Proteome Discoverer software v1.2 (Thermo Scientific, MA, USA).   
Briefly, data was searched against UniProt/SwissProt Human database release 
version 57.3 using the SEQUEST (ver.28 Rev. 13) algorithm.  Peptide precursor 
mass tolerance was set at 10ppm and MS/MS tolerance at 0.8Da.  Searches were 
performed with full tryptic digestion and a maximum of one missed cleavage was 
allowed.  Search criteria included fixed modifications (carbamidomethylation of 
cysteine) and variable modifications including oxidation of methionine and 
appropriate SILAC labels 2H4-Lys and 
13C6-Arg.  The reverse database search option 
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was enabled and all peptide data was filtered to satisfy a false discovery rate (FDR) 
of 5%.  The minimum cross-correlation factor filter was readjusted for each individual 
charge state separately to optimally meet the predetermined target FDR of 5% 
based on the number of random false positive matches, thus each data set has its 
own passing parameters.  Quantitation was performed using a mass precision of 
2ppm.  After extracting each ion chromatogram the Proteome Discoverer software 
runs several filters to check for interfering peaks and the presence of the expected 
isotope pattern amongst other parameters.  Peptides, which do not meet these 
criteria, are not used in calculating the final ratio for each protein.   
Protein values were then represented as the median of the raw measured peptide 
ratios of naïve (light media) for the corresponding protein.  I performed this second 
analysis.  Proteins that had a 2-fold increase or decrease in expression       ) or 
      were identified as significantly affected by the treatment and were included in 
the pathway analysis.  The significant protein set was transferred to the Database for 
Annotation, Visualisation and Integrated Discovery (DAVID) version 6.7 
(http://david.abcc.ncifcrf.gov/).  Pathway analysis was performed by KEGG within 
DAVID. 
 
6.3.2 Microarray analysis 
The array design was a direct two-colour experiment where Cy3 and Cy5 labelled 
signals were compared within the array.  Raw two-colour microarray data were 
quality assessed, normalised and log transformed using the limma (ver. 2.12) and 
MArray packages as implemented in RStudio (ver. 0.97.551) (RStudio, MA, USA).  
MA-plots were viewed to assess the quality of the data (Figure 6.2) and hence pre-
processing of the two-colour array data was performed.  Pre-processing included 
background correction and data normalisation, both within the same array and 
across different arrays (Figure 6.3 and 6.4). 
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Figure 6:2: MA-plots for two-colour array data 
An MA-plot is a plot of log 2-intensity ratios (M-values) versus log 2-intensity averages (A-
values).  The quality of the data and the necessity of data normalisation are assessed from 
these plots, in this experiment the data (n=4) required normalisation.   
 
 
 
 
A)      B) 
 
Figure 6:3: Colour densities pre and post normalisation 
Before normalisation there is considerable variation between red and green channels (A).  
Post-normalisation within (M-values) and between (A-values) arrays makes them more 
comparable and equally distributed (B). 
 
Pre Post 
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A) 
 
B)    
 
Figure 6:4: Post normalisation within arrays and between arrays 
Post-normalisation box and whisker plots for (A) green signal and (B) red signal provide a 
graphical view of the median, quartiles, maximum, and minimum for each experimental 
replicate (n=4).  MIFarray1-4 each represents a replicate.  Outliers for each box and whisker 
plot are shown.  This data has normalised showing equal distribution between the arrays for 
both colour signals. 
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6.4 Results 
6.4.1 Global protein expression 
THP-1 cells were stimulated with rhMIF (100ng/ml) for 24 hours, after which the 
proteins were isolated and sent for LC-MS/MS analysis. Figure 6.1 depicts the 
SILAC protocol.   
From a 10-slice in-gel tryptic digestion 6508 total proteins could have been detected, 
MIF treatment on THP-1 cells identified 3767 of these total proteins at varying 
expression levels.  A threshold of       ) and       was set and 235 proteins 
reached this criteria; 70 being up-regulated and 165 being down-regulated (see 
Appendix 1 for full differential protein lists and Figshare for full SILAC results 
(http://figshare.com/articles/SILAC_data_/840470).  Specific proteins of interest that 
were identified as being up-regulated in response to MIF stimulation included T-
lymphocyte surface glycoprotein CD4 and MAP kinase kinase kinase 1  (MAP3K).  
NAD+-dependent protein de-acetylase sirtuin-2 (SIRT2), bromodomain-containing 
protein-4 (Brd4), Melanoma Differentiation Associated Protein-5 (MDA5) and 
Retinoic Acid-Inducible Gene 1 Protein-1 (RIG-1) were significantly down-regulated. 
Pathway analysis, using the DAVID database, of the differentially expressed proteins 
in response to MIF stimulation identified the RIG-I-like receptor (RLR) signalling 
pathway as the biggest hit (Figure 6.5).  In addition, calcium (Ca2+) signalling was 
also identified as being regulated by MIF. 
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Figure 6:5: Schematic of RIG-I-like receptor (RLR) signalling pathway 
THP-1 cells were treated with rhMIF (100ng/ml) for 24 hours in specific SILAC media, intracellular proteins were extracted and the lysates were 
analysed by LC-MS-MS.  Five proteins and four processes were differentially expressed or affected by MIF stimulation as illustrated by the red 
stars.  Modified from KEGG pathway (www.genome.jp/kegg/pathway). 
 
The effect of MIF on global protein and gene expression 
172 
 
6.4.1.1 RLR signalling pathway validation 
The direct effect of MIF on in the RLR pathway was first investigated with regards to 
gene expression of proteins identified in the SILAC experiment.  THP-1 cells were 
stimulated with rhMIF (0.1-1000ng/ml) for 4 hours before total RNA was extracted 
and IFH1 (MDA5) and DDX88 (RIG-1) gene expression levels were analysed.  The 
gene expression of both IFH1 and DDX88 were not affected by MIF stimulation at 
the time point investigated (Figure 6.6). 
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Figure 6:6: MIF has no direct effect on RLR-associated gene expression 
THP-1 cells were stimulated with rhMIF (0.1-1000ng/ml) for 4 hours.  Total RNA was 
extracted and analysed by RT-qPCR.  Gene expression for (A) IFIH1 (MDA5) and (B) 
DDX88 (RIG-1) is normalised to 18S internal control and presented as the percentage of 
naïve control.  Results represent the mean±S.E.M. of four independent experiments. 
 
The protein levels of MDA5 and RIG-1 proteins were assessed in monocytic THP-1 
cells stimulated with rhMIF (0.1-1000ng/ml).  After 24 hours incubation MDA5 and 
RIG-1 proteins were measured in the whole cell protein lysates by Western blotting.  
Neither MDA5 nor RIG-1 protein content was directly affected by MIF stimulation 
(Figure 6.7). 
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A)      B)  
Protein           
β-Actin                          
 
Figure 6:7: MIF has no effect on RLR-associated protein content 
THP-1 monocytes were incubated with rhMIF (0.1-1000ng/ml) for 24 hours.  Total 
intracellular proteins were extracted and Western blotting and densitometry was used to 
quantify (A) MDA5 and (B) RIG-1 protein expression.  Each protein is normalised to β-actin 
as an internal control and the data is presented as fold change from naïve control.  Results 
represent the mean of two independent experiments. 
 
 
The involvement of MIF in the RLR pathway was further investigated using the RLR 
pathway activator, poly (I:C), a synthetic analogue of double-stranded RNA (dsRNA).  
THP-1 cells were stimulated with poly (I:C) (1-20µg/ml) for 4 hours, total RNA 
extracted and gene expression levels evaluated using qPCR.  IFNβ, a type 1 
interferon (IFNB1) was used as a positive control for the RLR pathway.  As 
expected, poly (I:C) stimulated the expression of IFN in a concentration-dependent 
manner (287.3±35.2%, p<0.05 at 10µg/ml and 417.8±133.0%, p<0.05 at 20µg/ml) 
(Figure 6.8A).  MIF gene expression was also increased in a concentration-
dependent manner; however this did not reach statistical significance (Figure 6.8B).     
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Figure 6:8: Poly (I:C) induces pro-inflammatory gene expression 
THP-1 cells were stimulated with poly (I:C) (1-20μg/ml) for 4 hours.  Total RNA was 
extracted and gene expression for (A) IFNB1 and (B) MIF was analysed by qPCR.  Gene of 
interest expression is normalised to 18S internal control and is presented as the percentage 
of naïve control.  Results represent the mean±S.E.M. of at least three independent 
experiments for each gene., **p<0.01 vs. naïve control as calculated by ANOVA with Dunns 
post-hoc test. 
 
MIF secretion from THP-1 cells was evaluated by ELISA after 24 hour poly (I:C) (1-
20µg/ml) stimulation.  MIF release was induced in a concentration-dependent 
manner, the two highest concentrations tested induced MIF release significantly, 
219.9±28.8%, p<0.05 at 10µg/ml and 226.9±24.3%, p<0.01 at 20µg/ml, (Figure 6.9).    
 
 
Figure 6:9: Poly (I:C) induces MIF secretion 
THP-1 monocytes were treated with poly (I:C) (1-20μg/ml) for 24 hours.  Conditioned 
medium was removed and MIF secretion was evaluated by ELISA.  Data is presented as 
mean±S.E.M of percentage of the naïve control for six independent experiments. *p<0.05, 
**p<0.01 vs. naïve control as calculated by ANOVA with Dunns post-hoc test. 
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After demonstrating the production and secretion of MIF by synthetic viral activation 
the effect of RV16 infection was evaluated in THP-1 cells.  Monocytic THP-1 cells 
were either incubated in media or infected with RV16 virus for a time course of up to 
96 hours.  At each time point, total RNA was extracted and MIF gene expression 
was analysed by qPCR.  MIF gene expression did not significantly change during the 
96 hour time course for the media control (Figure 6.10A); however RV16 infection 
significantly increased MIF gene expression in a time-dependent manner (Figure 
6.10B).  After 96 hours incubation time with RV16, MIF gene expression was 
significantly induced 4-fold (397.3±79.6%, p<0.01). 
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Figure 6:10: RV16 infection induces MIF expression 
THP-1 monocytes were infected with RV16 and incubated for up to 96 hours.  Total RNA 
was extracted and MIF expression analysed by qPCR from (A) media control and (B) RV16-
infected cells.  Data is presented as mean±S.E.M of the percentage of naïve control for each 
condition (n=3). **p<0.01 vs. naïve control as calculated by ANOVA with Dunns post-hoc 
test.  
 
To further explore the secretion and production of MIF induced by viral activation an 
in vivo approach was taken.  BALF was obtained by bronchoscopy as previously 
described (Mallia et al., 2013) at baseline and 7 days post experimental-induced 
RV16 infection of age-matched healthy non-smokers (n=18), healthy smokers (n=15) 
and COPD patients (n=17) (Table 6.1), the samples were provided by Dr. J. Footit.  
BAL macrophages were isolated from BALF and subsequently whole cell proteins 
were extracted and analysed for MIF content by ELISA.  Intracellular BAL 
macrophage MIF levels were not affected by RV16 infection in non-smokers.  
However, in smokers and COPD patients, there was a significant decrease in the 
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amount of intracellular MIF detected in BAL macrophages post-RV16 infection.  The 
average MIF content at baseline was 68.3±16.7ng/ml and 70.0±18.3ng/ml for 
smokers and COPD patients respectively compared to post-RV16 infection values of 
40.8±8.3ng/ml and 26.4±6.7ng/ml for smokers and COPD patients respectively, 
p<0.05 for both groups (Figure 6.11).   
 
Table 6:1: Patient demographics for RV16 infection 
GROUP AGE SEX (M/F) 
N 
NUMBER 
PACK 
YEARS 
FEV1 (% 
PRED) 
FEV1/FVC 
RATIO (%) 
Non 
smoker 
59(46-71) 9/10 19 N/A 106± 4 79± 1 
Smoker 54(41-66) 8/7 15 32(21-51) 99± 3 77± 2 
COPD 59(44-72) 13/5 18 39(25-57) 65± 2 58± 2 
COPD patients are GOLD Stage 2 as diagnosed by ATS guidelines.  Normally distributed 
data is represented as mean±SD and data not normally distributed is represented as median 
(25-75 quartiles)  
 
 
 
 
Figure 6:11: RV16 infection reduces intracellular MIF content in BAL macrophages 
BAL macrophages were isolated from BALF taken from non-smokers (n=18), smokers 
(n=15) and COPD patients (n=17) at baseline and 7 days post RV16 infection.  Intracellular 
MIF was measured by ELISA in protein lysates extracted from the BAL macrophages.  Data 
is presented as intracellular MIF protein levels (ng/ml) for each subject, pre- and post RV16 
infection. *p<0.05 as calculated by individual Mann-Whitney t-test. 
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6.4.1.2 Calcium signalling validation 
The association between calcium (Ca2+) signalling and MIF identified by the SILAC 
experiment was also assessed.  THP-1 cells were incubated with FURA-2 AM to 
fluorescently label intracellular Ca2+.  Cells were stimulated with rhMIF (0-1000ng/ml) 
and the Ca2+ released from intracellular stores was measured.  Ca2+ release from 
intracellular stores was concentration-dependent (Figure 6.12A and B).  To confirm 
the concentration-dependent induction of Ca2+ release I extended the concentration 
curve to include non-physiological concentrations of MIF (0-5000ng/ml).  This is 
because the MIF-induction of Ca2+ release was relatively small and it was possible 
that the diluent was having a small effect.  However, after controlling for an increase 
in diluent the rhMIF even at supra-physiological levels produced a concentration-
dependent induction of Ca2+ release (Figure 6.12C and D).    
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Figure 6:12: Calcium signalling is induced by MIF stimulation 
Intracellular calcium was fluorescently labelled in THP-1 cells.  rhMIF-induced calcium 
release was measured by detection of the fluorescence signal every 2.8 seconds. 
Physiological MIF concentrations (300-1000ng/ml) induced a time-dependent induction of 
Ca2+ release (A) which was quantified using the area under the curve (AUC) (B).  The time 
course results for all MIF concentrations (0-5000ng/ml) are shown in (C) and AUC 
quantification reported in (D). *p<0.05, **p<0.01 vs. naïve control as calculated by ANOVA 
with Dunns post-hoc test. 
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In resting cells, nuclear factor of activated T cells (NFAT) is phosphorylated and 
resides in the cytoplasm (Beals et al., 1997, Okamura et al., 2000).  An elevation of 
Ca2+ activates phosphatase calcineurin, which in turn dephosphorylates NFAT (Shaw 
et al., 1995).  NFAT then translocates to the nucleus to bind to its gene promoter 
region (Shibasaki and McKeon, 1995).  The expression/activation of the calcium 
dependent transcription factor NFAT was assessed to investigate the downstream 
effects of MIF-induced calcium release.  THP-1 monocytes were stimulated with 
rhMIF (100ng/ml) for up to 60 minutes.  Nuclear proteins were extracted and the 
binding capacity of NFAT to the canonical DNA response element was evaluated by 
TransAM® assay.  rhMIF had no effect on the binding capacity of NFAT to its DNA 
consensus motif (Figure 6.13). 
 
Figure 6:13: NFAT binding capacity to response element over time  
THP-1 cells were incubated with 100ng/ml rhMIF for up to 60 minutes.  Nuclear proteins 
were isolated and the capacity of NFAT to bind to DNA was measured, positive control (+; 
green bar) was included in kit (PHA-treated Jurkat cells).  Data is reported as the fold 
change compared to 0 hours and presented as the mean±S.E.M. of four independent 
experiments.   
 
 
6.4.2 Global RNA expression 
THP-1 monocytes were stimulated with or without rhMIF (100ng/ml) for 4 hours 
(n=4), after this time total RNA was extracted and quantified.  A concentration of 
17ng/μl total RNA for both naïve and MIF treated samples were sent for microarray 
analysis.  Raw data was pre-processed and normalised as previously described; 
differential gene expression by MIF stimulation was assessed using an Empirical 
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Bayes linear model approach.  The default method to adjust p-values for multiple 
testing was the Benjamini-Hochberg (BH) method, the BH method controls for the 
FDR (Benjamini and Hochberg, 1995).  FDR was set to 5% in this array experiment.  
The results for this array experiment indicated that no genes were directly affected 
by 4 hours stimulation of MIF.  A table of the top 20 genes with the lowest adjusted 
p-value (FDR) are shown in Table 6.2.  As no significant hits were seen I did not 
perform qPCR validation on these samples. 
Non-significant genes and long non-coding RNA (lncRNA) with fold change         
or         were extracted from the array results to generate new hypotheses.  This 
resulted in 27 up-regulated and 210 down-regulated genes and lncRNAs (Appendix 
2); the top 10 hits for up and down regulated genes are shown in Table 6.3.  A full list 
of genes and lncRNAs detected from the RNA array are available on Figshare 
(http://figshare.com/articles/RNA_microarray_results/840472).  Even though the 
expression changes were non-significant pathway analysis was performed on these 
biggest hits to identify new areas of research that could warrant further investigations 
with regards to MIF stimulation.  The pathway analysis program (DAVID) recognised 
191 genes and identified glycolysis/gluconeogenesis, vascular endothelial growth 
factor (VEGF) signalling and B-cell receptor signalling as pathways involving the 
biggest hit genes.  All 23 non-significant lncRNAs were searched against the 
Ensembl database (http://www.ensembl.org/index.html) and any known lncRNAs 
were then further investigated by internet searches and LNCipedia 
(http://lncipedia.org/). 
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Table 6:2: Top 20 non-significant genes with lowest adjusted p-value 
UP-REG 
GENE ID 
GENE NAME GENE 
P-
VALUE 
ADJ. P-
VALUE 
FOLD 
CHANGE 
NR_024244 Small ILF3/NF90-associated RNA G2 small nuclear RNA SNAR-G2 0.032 0.479 1.39  
A_33_P3402773 Uncharacterised  0.027 0.479 1.36  
NM_014977 Apoptotic chromatin condensation inducer 1 transcript variant 1 ACIN1 0.023 0.479 1.24  
NM_006887 ZFP36 ring finger protein-like 2  ZFP36L2 0.015 0.479 1.23  
NR_003016 Small nucleolar RNA, H/ACA box 26 SNORA26 0.031 0.479 1.28  
XM_003119593 Hypothetical protein  0.011 0.479 1.47  
NM_001031847 Carnitine palmitoyltransferase 1A CPT1A 0.029 0.479 1.24  
NM_138459 Nuclear undecaprenyl pyrophosphate synthase 1 homolog  NUS1 0.041 0.479 1.21  
NM_003760 Eukaryotic translation initiation factor 4 gamma, 3  EIF4G3 0.017 0.479 1.21  
DOWN-REG 
GENE ID 
GENE NAME GENE 
P-
VALUE 
ADJ. P-
VALUE 
FOLD 
CHANGE 
NM_021177 LSM2 homolog, U6 small nuclear RNA associated LSM2 0.008 0.479 0.78 
NM_002661 Phospholipase C, gamma 2  PLCG2 0.042 0.479 0.85 
A_24_P401090 Uncharacterised  0.031 0.479 0.85 
NM_001127320 Ubiquitin associated protein 2-like transcript variant 2 UBAP2L 0.023 0.479 0.81 
NM_003104 Sorbitol dehydrogenase transcript variant 1 SORD 0.005 0.479 0.75 
NM_014845 FIG4 homolog FIG4 0.010 0.479 0.72 
NR_003267 Gamma-glutamyltransferase 3 pseudogene  GGT3P 0.027 0.479 0.83 
NM_021130 Peptidylprolyl isomerase A   PPIA 0.027 0.479 0.81 
NM_005692 ATP-binding cassette, sub-family F member 2 ABCF2 0.011 0.479 0.66 
NM_052916 Ring finger protein 157  RNF157 0.006 0.479 0.78 
NM_001042416 Zinc finger protein 596  ZNF596 0.027 0.479 0.83 
Up-regulated (top) and down-regulated (bottom) genes 
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Table 6:3: Top 10 non-significant greatest fold change  
UP-REG 
GENE ID 
GENE NAME GENE P-VALUE 
ADJ. P-
VALUE 
FOLD 
CHANGE 
NR_003271 Small nucleolar RNA, C/D box 3B-1 SNORD3B-1 0.001 0.479 2.00 
NM_020535 
Killer cell immunoglobulin-like receptor, two domains, long 
cytoplasmic tail, 5A 
KIR2DL5A 0.091 0.522 1.92 
NR_040108 Uncharacterized LOC728175 non-coding  0.066 0.500 1.89 
NR_004400 RNA variant U1 small nuclear 18 RNVU1-18 0.001 0.479 1.79 
NM_004113 Fibroblast growth factor 12 FGF12 0.010 0.479 1.68 
NR_034143 Cancer susceptibility candidate 14 non-protein coding CASC14 0.114 0.543 1.60 
ENST00000419440 ^^ Lnc-C11orf39-3 0.010 0.479 1.60 
TCONS_00009863 ^^ Lnc-ADCY2-4 0.105 0.535 1.59 
NR_027030 Uncharacterized protein MGC34034  0.058 0.490 1.57 
NM_153267 MAM domain containing 2 MAMDC2 0.001 0.479 1.55 
DOWN-REG 
GENE ID 
GENE NAME GENE P-VALUE 
ADJ. P-
VALUE 
FOLD 
CHANGE 
NM_016536 Zinc finger protein 571 ZNF571 0.062 0.493 0.37 
AJ276510 Partial mRNA for hypothetical protein ORF1 0.066 0.500 0.38 
TCONS_00029565 ^^ Lnc-CRYBA4-8 0.076 0.509 0.40 
ENST00000441356 ^^ Lnc-RND3-1 0.193 0.614 0.40 
NM_001822 Chimerin 1 CHN1 0.040 0.479 0.41 
NM_004797 Adiponectin, C1Q and collagen domain containing  ADIPOQ 0.166 0.590 0.42 
TCONS_00022613 ^^ 
Lnc-RP11-
1070N10.3.1-1 
0.100 0.531 0.43 
TCONS_00019700 ^^ Lnc-STARD10-1 0.112 0.541 0.43 
XR_109045 Hypothetical LOC100507282  0.044 0.479 0.45 
NM_018711 SV2 related protein homolog SVOP 0.110 0.540 0.45 
Up-regulated (top) and down-regulated (bottom) genes (≥1.5 or ≤0.7)  
^^ Represents long non-coding (lnc) RNAs 
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6.5 Discussion 
6.5.1 SILAC proteomic analysis 
There were 70 up-regulated proteins and 165 down-regulated proteins that were 
identified through the SILAC experiment.  Differentially expressed proteins that were 
of interest with regards to COPD research include the up-regulation of CD4+ T-
lymphocytes (Hogg et al., 2004) and MAP3K involvement in chronic pro-
inflammatory cytokine release (Tudhope et al., 2008) and down-regulation of the 
SIRT2, a protein that has been associated with aging (Wang et al., 2007, North et 
al., 2003) and BRD4, a protein involved in the recruitment and function of 
transcription factors (e.g. NF-B) on chromatin (Huang et al., 2009).  
6.5.1.1 RIG-I-Like Receptor (RLR) pathway 
RIG-1, melanoma differentiation-associated protein 5 (MDA5) and RIG-I -like 
receptor LGP2 (LGP2) belong to the RLR family of intracellular pattern recognition 
receptors (PRR) (Yoneyama et al., 2005, Yoneyama et al., 2004, Andrejeva et al., 
2004).  Both RIG-1 and MDA5 were reduced by MIF stimulation as detected by the 
SILAC experiment.  These particular RLRs are involved in the recognition of viral 
double-stranded RNA (dsRNA) and contain DExD/H box RNA helicase domains.  
However only RIG-1 and MDA5 possess two caspase recruiting domain (CARD)-like 
domains and these induce the cellular response (Saito et al., 2007, Yoneyama et al., 
2005, Rothenfusser et al., 2005).  The recognition of viral dsRNA by RLRs is cell-
type and viral-specific (Wang et al., 2009).  Initiating the RLR pathway leads to the 
production of Type 1 IFNs including IFN and subtypes, IFNβ, IFNω and IFNε as 
well as pro-inflammatory cytokines IL-6 and TNF via NF-B or IRF3 transcription 
factors (Honda et al., 2006).  RLR activation also results in natural killer cell 
activation, the production of antibodies and the stimulation of viral-specific cytotoxic 
T-lymphocytes, which leads to the activation of the adaptive immune response 
(Longhi et al., 2009).  Mice deficient in RIG-1 or MDA5 are more susceptible to viral 
infections compared to wild type mice (Kato et al., 2006, Errett et al., 2013).  
However, in some strains of mice RIG-1 deficiency is not viable and they show 
embryonic lethality due to liver degeneration (Kato et al., 2005).  
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The SILAC experiment identified five proteins and four processes within the RLR 
pathway as being differentially expressed and hence affected by MIF stimulation.  
MIF stimulation had no direct effect on the gene expression or protein levels of 
IFIH1/MDA5 or DDX88/RIG-1 in THP-1 cells as measured by qPCR and Western 
blotting respectively.  The discrepancy between the Western blotting and SILAC 
experiments could be due to the mass spectrometry being more sensitive and thus 
detecting smaller changes that would not be seen with the Western blotting 
technique.  Alternatively, the SILAC approach may be detecting protein hits due to 
alterations in post-translational modifications (PTMs) and changes in protein-protein 
interactions (PPI).  Further investigations of the effects of MIF on PPI in the RIG-I 
pathway may yield additional interesting areas of research. 
Similar to RLRs, TLR3 is a PRR that recognises viral dsRNA and induces the 
activation of transcription factors (NF-B and IRF3) to produce type 1 IFNs.  In 
contrast to the RLRs, TLR3 can be expressed on the cell surface (Matsumoto et al., 
2003) or as an endosomal receptor (Alexopoulou et al., 2001).  Poly (I:C) is a 
synthetic dsRNA analogue that activates TLR3 and induces the production of type 1 
IFNs, if transfected into cells, poly (I:C) can also be recognised by intracellular 
sensors RIG-1 and MDA5 (Gitlin et al., 2006, Kato et al., 2005).  In support of 
previous reports showing poly (I:C)-induced MIF production in uterine epithelial cells 
(Schaefer et al., 2005), stimulating THP-1 monocytes with poly (I:C) also induced 
MIF secretion and increased MIF gene production.  Further supporting the 
association with MIF, RLR and TLR stimulation and viral infection.  Future 
experiments examining the ability of MIF to modify the poly (I:C)-induced RIG-I 
pathway may also give insight as to how MIF affects cellular function. 
There is a growing body of evidence that the lungs are not sterile as previously 
thought and characterisation of the lung microbiome has generated great interest 
(Erb-Downward et al., 2011, Sze et al., 2012).  Viral nucleic acid has been detected 
in COPD lung tissue, BALF and sputum samples in stable and exacerbating 
(episodes of worsening symptoms and may require the patient to seek medical help) 
COPD patients (Seemungal et al., 2001, Rohde et al., 2003, Wedzicha, 2004, Macek 
et al., 1999, Papi et al., 2006, Utokaparch et al., 2013). Viral infection is an 
associated factor for initiating an exacerbation in COPD patients, with rhinovirus 
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(RV) being the most common and accounting for 58% of the viruses detected during 
an exacerbation (Seemungal et al., 2001, McManus et al., 2008).  
To date there are no publications reporting on MIF and RV infection however there 
have been reports on the association between MIF and Influenza virus.  Elevated 
levels of MIF induced by infection with H5N1 influenza virus were reported in a 
mouse model (Hou et al., 2009).  MIF content in primary NHBE cells reduced in a 
time-dependent manner post infection with Influenza Virus A, this was paralleled with 
an increase in secreted MIF (Arndt et al., 2002).  
RV16 infection can be recognised by RIG-1, MDA5 or TLR3 (Slater et al., 2010) and 
THP-1 cells infected with RV16 showed a time-dependent induction of MIF gene 
expression.  Furthermore, RV16 infection reduced the intracellular MIF levels in BAL 
macrophages isolated from smokers and COPD patients and I propose that the MIF 
has been secreted from the macrophages in response to the viral infection.  
However, MIF levels in the BALF supernatant were not measured in these patients 
due to no sample remaining for analysis and so this hypothesis needs to be 
confirmed in a separate study.  It is not known whether the RV16-induced MIF 
production is via RIG-1, MDA5, TLR3 or all of them and this would need further 
investigations to elucidate.  It would also be of interest to look at the direct effects of 
MIF on TLR3 production, when stimulating cells with bacterial LPS, there is a 
positive loop of cytokine production and production of TLR4 (Roger et al., 2001).  
From these studies, I would speculate that MIF is involved in viral-induced 
exacerbations instead of in a stable disease state.  RV16 infection induces MIF 
release which may in turn drive a pro-inflammatory response and effect CS 
sensitivity.  Patients with stable COPD do not have elevated levels of MIF and so a 
direct effect of MIF on the enhanced sensitivity of COPD bronchial epithelial cells to 
respond to viral infection compared to controls (Professor Donna Davies, 
Southampton University, personal communication) is unlikely to reflect an effect of 
these MIF levels.  Further investigations will be needed to elucidate this exciting 
novel area of MIF function within COPD research.  
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6.5.1.2 Calcium signalling 
Ca2+ is major intracellular secondary messenger that can regulate many cellular 
functions including cell proliferation (Lu and Means, 1993, Berridge, 1995), gene 
transcription (Crabtree, 1999) and apoptosis (Kass and Orrenius, 1999).  It was 
previously understood that Ca2+ signalling was a rapid response such as during 
neurotransmission (Douglas and Rubin, 1961) yet it is now understood to have 
functions that occur after some substantial delay, for example the regulation of gene 
transcription (Bading et al., 1997).  In this study, MIF induces Ca2+ release in THP-1 
cells in a concentration-dependent manner, which is supported by data published in 
rat testicular peritubular cells (Wennemuth et al., 2000).  In this latter study however, 
the concentrations of MIF-induced Ca2+ reached ≈1100nM compared to 25nM with 
50ng/ml rhMIF, this difference may be cell-specific, species-specific or the rhMIF 
used.  Wennemuth and colleagues produced their own rhMIF (Wennemuth et al., 
2000) but previous studies have shown LPS contamination in some bacterially 
expressed rhMIF (Kudrin et al., 2006, Wennemuth et al., 2000) whereas a 
commercially available rhMIF was used in this study.  Moreover, an earlier 
publication had shown that MIF did not alter Ca2+ uptake in guinea pig macrophages 
(Block et al., 1978).  
Ca2+ cannot transduce a transcriptional signal in its own right and therefore requires 
intermediate messenger proteins.  These act by transducing the Ca2+ activation 
signal into a protein cascade to signal to transcription factors and co-activators such 
as CREB, NFAT and NF-B and cause increased gene expression.  There are three 
main Ca2+ signalling pathways each involving different kinase proteins, 1) 
calmodulin-dependent kinases 2) MAPK proteins specifically Ras (Cullen and 
Lockyer, 2002) lead to transcription regulated by CREB and NF-B (Hardingham et 
al., 2001, Lilienbaum and Israël, 2003) and 3) phosphatase calcineurin leads to 
NFAT regulation (Feske et al., 2003, Hogan et al., 2003).  I further investigated the 
THP-1 MIF-induced Ca2+ release by assessing the downstream transcription factor 
NFAT and its DNA binding capacity to consensus region.  However at the times 
studied, there was no MIF-enhanced DNA binding of NFAT.   
The limitations with this study include the restricted number of time-points studied; 
future work could include ChIP analysis to detect specific NFAT binding to inducible 
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genes.  NFAT is expressed and activated in monocytes and myeloid cells, however, 
its expression in these cells is low and it often requires a strong inducer such as 
RANKL, a TNF family member, to activate NFAT (Yarilina et al., 2011).  NFAT 
function is also much better understood in T-lymphocytes (Hogan et al., 2003).  The 
other Ca2+ signalling pathways will need to be investigated to fully understand and 
confirm the MIF-induced Ca2+ release described.  
It is possible that several other pathways may be important in MIF function in these 
cells.  The pathway analysis database identifies pathways containing known proteins 
and therefore any unknown or undiscovered proteins/peptides detected during the 
mass spectrometry analysis will not be recognised and will fail to flag a potential 
MIF-modulated pathway.   
6.5.2 RNA microarray- mRNA analysis 
In this study, there were no genes that were significantly differentially expressed 
after 4 hour MIF stimulation.  This is in contrast to MIF-modulated genes assessed 
by qPCR at the same time point, such as DUSP1, TP53 and MIF itself, as shown in 
previous chapters.  If the MIF-induced gene expression modulations are small then 
these may not be detected in an array analysing ≈62000 genes and lncRNAs and 
therefore using a more focussed array might identify smaller but significant gene 
changes induced by MIF.  It is also noteworthy that significant gene modulations may 
not have been detected by the microarray due to a lack of statistical power and 
therefore increasing the n number of experiments would alleviate this issue.  Gene 
expression changes occur at different times after stimulation for different genes and 
investigating one time point (4 hours) will only snapshot a specific moment.  
Investigating different time points using a time course will give a more accurate result 
into the role of MIF regulating genes.   
Even though no significant genes were detected within the FDR cut-off, microarrays 
can still be used as a hypothesis-generating tool.  Usually a cut off of fold change 
(>1.5) is the final criteria to identify differentially expressed genes.  For hypothesis-
generating microarray analysis the FDR cut-offs can also be changed, either to a 
less restrictive value or a more restrictive value if many genes are identified for 
example 0.01 or 1%.  The genes that are detected using these less restrictive 
analyses can then be further analysed using pathway analysis to identify potential 
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signalling pathways.  In this experiment, non-significant genes with a fold change 
        or         were investigated and pathway analysis competed to identify 
potential new research areas.   
To date, specific lncRNAs have not been associated with COPD or severe asthma 
and their functions still remain to be fully understood.  Many mechanisms of lncRNAs 
functions have been described, including acting as an RNA decoy by preventing 
transcription factors binging to promoter regions (Kino et al., 2010) and recruiting 
chromatin-modifying complexes to their DNA target (Wang et al., 2011b).   Another 
suggested role for lncRNAs is acting as a microRNA sponge and preventing the 
microRNAs binding to their mRNA targets (Cesana et al., 2011).  The expression of 
a number of lncRNAs were modulated by MIF, including the down regulation of Lnc-
RND3-1.  Information on Lnc-RND3-1 is very limited however hsa-miR-3148, hsa-
miR-211-3p and hsa-miR-629-3p are known to be targeting microRNAs and could be 
mopped up by the lncRNAs.  Investigating this microRNA further may elucidate a 
function for Lnc-RND3-1 and association with MIF.  Interestingly hsa-miR-3148 has 
been shown to negatively regulate TLR7 expression in SLE patients (Deng et al., 
2013).  In this case, MIF-reduced expression of Lnc-RND3-1 would result in more 
available hsa-miR-3148 and hence lower TLR7 expression.  Viral infection is 
recognised by TLR7 (Lund et al., 2004).  This is in support of the new viral and MIF 
hypothesis I have speculated in this thesis as viral susceptibly may be increased due 
to reduced expression of TLR7 in a similar fashion to reduced RLRs.  Further 
investigations would be needed to confirm the MIF-modulated lncRNAs and viral 
susceptibility.   
From the ‘biggest hit’ genes, the glycolysis and gluconeogenesis pathway was 
identified as ‘active’ during MIF stimulation; interestingly this is a major area of 
research for COPD patients.  COPD severity has been associated with increased 
muscle loss and weakness (Maltais et al., 2000) and alterations in macronutrient 
metabolism (Franssen et al., 2011).  Alterations to insulin sensitivity and diabetes are 
well-established clinical implications for increased risk of CVD that in turn is a major 
co-morbidity of COPD (Sin et al., 2005) there has been no reports on the 
involvement of MIF.  Another pathway that was suggested through pathway analysis 
was the VEGF pathway.  Both MIF and VEGF are understood to be monocytes’ 
chemo-attractants and their expression is positively correlated in human 
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glioblastomas (Munaut et al., 2002).  It has been reported that MIF directly induces 
VEGF gene expression in a concentration- and time-dependent manner in human 
endometrial cells (Bondza et al., 2008).  VEGF is induced in hypoxic conditions 
caused by cigarette smoke, a risk factor of COPD, and has been shown to be 
elevated in COPD patients (Pavlisa et al., 2010).  
However, it must be strongly emphasised that these gene and lncRNA changes were 
not statistically significant and the pathways identified by the proteomic and 
transcriptomic approaches are not comparable.  Therefore the significance of the 
RNA microarray results, including the gene and lncRNA expression changes are 
uncertain.   
Even though there were proteins that had enhanced or reduced levels after MIF 
stimulation, as detected by the SILAC technique, this was not paralleled by an 
increase or decrease in the corresponding gene production measured by the array.  
However this discrepancy may be due to the presence of PTMs.  PTMs are chemical 
modifications of a protein after it has been translated, there are many different PTMs 
such as phosphorylation, glycosylation, ubiquitination, methylation and proteolysis; 
there are ≈200 different types of PTMs (Krishna and Wold, 1993). 
A PTM that may explain the discrepancy between the SILAC experiment and the 
RNA microarray could be ubiquitination.  Proteins tagged with the 8kDa polypeptide 
ubiquitin are targeted for degradation (Ciechanover et al., 1980, Hershko et al., 
1980, Goldstein et al., 1975).  If transcription levels are constant but there is reduced 
ubiquitination (degradation rate) this would lead to an increase in protein content and 
hence give the results shown here but this would need to be confirmed.    
Studies have shown that PTMs including methylation and acetylation occur on 
histones and subsequently controlling gene transcription (Adcock et al., 2006).  
Regulation of gene transcription involves the acetylation of histones by enzymes with 
HAT activity.  HDAC enzymes reverse the acetylation and increase chromosomal 
condensation preventing gene transcription.  Oxidative and nitrative stress for 
example from cigarette smoking can also cause PTMs, effecting protein levels and 
activity, for example reducing HDAC2 by increasing proteasomal degradation (Ito et 
al., 2005, Osoata et al., 2009).  COPD has also been associated with PTMs on 
transcription factors GR (Bodwell et al., 1998, Matthews et al., 2011) and NF-B 
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(Gloire and Piette, 2009) that are either in response to oxidants from cigarette 
smoking or effect sensitivity to CSs.  To date, the regulation of PTMs on HDAC or 
HAT proteins by MIF has not been investigated.  However it must be emphasised 
that from the RNA array data, MIF did not affect the transcription of any genes or 
lncRNAs and so these PTMs are not likely to be MIF mechanisms of action.  The 
disconnect between the proteomic and transcriptomic data maybe due to the times 
chosen and the effects of MIF may need longer than 4 hours to show any 
transcriptional control.  The optimal time at which MIF may control transcription will 
need extensive investigations.      
Phosphorylation is a common PTM that controls and regulates the activity of the 
protein, for example kinases during signal transduction.  MIF is not a kinase, as it 
does not have phosphorylation ability however MIF may have a PTM role via its 
enzymatic function.  Although to date no physiological substrate is known.  PTMs 
would need to be investigated to elucidate if MIF has a role in this mechanism.  
Furthermore, the potential of MIF to regulate proteins by PTMs in viral exacerbations 
of COPD and other chronic inflammatory diseases should be investigated. 
Proteomic and transcriptomic studies were an effective way to identify potential new 
interactions and pathways modulated by MIF stimulation.  The downstream functions 
of MIF have yet to be fully elucidated; however the methods described here have 
identified new targets of MIF.  The involvement of MIF in the viral RLR pathway and 
the Ca2+ signalling needs further confirmation although the results are encouraging.  
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7.1 General Discussion 
The hypothesis, that elevated MIF drives chronic inflammation and CS insensitivity in 
COPD, was first tested in vivo, in a 6-week chronic ozone-induced mouse model of 
COPD airway inflammation (Triantaphyllopoulos et al., 2011, Wiegman et al., 2013).  
The model used here was CS insensitive and showed chronic lung inflammation with 
increased recruitment of immune cells, increased pro-inflammatory mediators in 
BALF and increased pulmonary resistance and airway hyper-responsiveness.  The 
levels of MIF in BALF were elevated in the COPD model compared to controls.  
Concordant with the literature and in support of the hypothesis, inhibition of MIF does 
reduce and prevent inflammation in in vivo models of inflammation (Chen et al., 
2010, Korsgren et al., 2000, Makita et al., 1998).  Overall, cellular recruitment to the 
lung was significantly reduced after ISO-1 pre-treatment as was airway hyper 
reactivity; further supporting the hypothesis that MIF is a key driver of inflammation in 
COPD.  However, in contrast to the attenuation of inflammation, CS sensitivity was 
not restored by MIF inhibition in the ozone-induced model.  To date, the restoration 
of CS sensitivity by MIF inhibition has not been reported in this or any other in vivo 
COPD model.  Different doses of dexamethasone will need to be assessed in the 
model to determine whether the dose of CS used here was too powerful for the MIF 
effect to be detected.  In addition, another MIF inhibitor such as the more potent 4-
IPP (Winner et al., 2008), should be used to confirm the findings shown with ISO-1.  
The results demonstrated here were in support of the hypothesis (in vivo results 
summarised in Figure 7.1) and I went on to investigate and translate the expression 
of MIF in human patient samples with MIF function in human cells. 
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Figure 7.1: Illustration summarising the results from in vivo ISO-1 pre-treated ozone-
induced inflammatory model (chapter 3) 
Inhibition of MIF by ISO-1 resulted in attenuation of some aspects of inflammation in an 
ozone-induced mouse model.  Cytokine and chemokine release in BALF, total cellular 
recruitment and pulmonary resistance was reduced after pre-treatment with ISO-1 compared 
to no ISO-1 treatment before ozone exposure.  CS insensitivity and airway hyper-
responsiveness was not affected by ISO-1 pre-treatment before ozone exposure. 
 
Results in the human experiments were less supportive of the hypothesis that MIF is 
a key driver of inflammation in the airway.  MIF was characterised in samples taken 
from age-matched healthy non-smokers, healthy smokers and stable COPD 
patients.  There was no clear difference in MIF expression between healthy controls 
and patient groups in serum and lung biopsy samples or protein lysates isolated from 
BAL macrophages.  This was in contrast to the reported differences in serum MIF 
expression in a disease-severity dependent manner for asthmatics (Rossi et al., 
1998) and RA patients (Morand et al., 2002).  MIF expression increased in a 
stepwise fashion in induced sputum samples from age-matched non-smokers, 
smokers and COPD.  However, only the difference between non-smokers and 
COPD patients was significant.  Unfortunately, due to the lack of BALF and 
immunohistochemistry samples from healthy non-smoker controls it is not possible to 
conclude whether MIF was elevated due to smoking or other COPD-associated 
factors. 
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As MIF was elevated in the mouse model of COPD and is frequently described in 
literature as a potent pro-inflammatory cytokine the role of MIF driving inflammation 
was investigated.  The immortalised cell line THP-1 and PBMCs and tissue 
macrophages from age-matched non-severe and severe asthmatics, COPD patients 
and controls were used in a LPS-induced inflammatory model.   Initial experiments in 
the primary cells showed an attenuation of LPS-inflammation by MIF inhibition.  This 
was more pronounced in the diseased cells and therefore may indicate an alteration 
in the MIF function or activity.  The ISO-1 attenuation of LPS-induced cytokine 
release was supported by previous reports by Adamali and colleagues in PBMCs 
isolated from cystic fibrosis patients (Adamali et al., 2012).  In stark contrast, MIF 
inhibition had no effect on LPS-induced CXCL8 or TNF release in THP-1 cells.  
Stimulation with rhMIF confirmed the lack of effect in the LPS-stimulated 
inflammatory model.  MIF stimulation did not further enhance the release of LPS-
induced CXCL8 or TNF, which is supported by earlier studies (Amano et al., 2007).  
As previously discussed, continuing the experiments in primary cells would have 
been advantageous, but with the intensity of the investigations needed to elucidate 
the role of MIF in COPD and the numbers of patients to reduce the natural variation, 
THP-1 cells were used.  Nevertheless MIF stimulation and the inhibition of MIF on 
LPS-induced mediators should be investigated in different human primary cell types 
such as epithelial or ASMCs as CD74 and MIF staining was also detected in these 
cells (data not shown).  MIF functions seem to vary between cells and are dependent 
on the role of that specific cell-type in the immune system. 
Activation of CD74, the putative MIF receptor (Leng et al., 2003), was investigated to 
act as a positive control for rhMIF activity.  Stimulation with rhMIF and α-CD74 
antibodies both induced the baseline levels of CXCL8 but not TNF release in THP-
1 cells, which is comparable to current literature (Beswick et al., 2005, Binsky et al., 
2007), supporting the notion that the rhMIF was biologically active and signals via 
CD74 activation.  However the slight pro-inflammatory function on CXCL8 release 
was not investigated in primary cells and due to the disconnect between primary and 
THP-1 cells seen previously, future work will need to be completed in order to 
confirm this finding.  It is also worth noting that rhMIF, ISO-1 and α-CD74 gave 
inconsistent results on the expression and release of MIF itself.  Further investigation 
into baseline rhMIF-induced cytokine release would confirm whether ISO-1 
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specifically inhibits MIF and/or signals through the CD74 receptor.  Moreover, these 
effects were not seen in the LPS model and therefore the importance of the 
modulations at baseline is questionable when investigating the role of MIF in 
inflammatory diseases. 
My original hypothesis also stated that MIF modulates the CS sensitivity seen in 
COPD patients and severe asthmatics.  The lack of modulation of CS sensitivity in 
the murine model is comparable to the results found in THP-1 cells, showing no MIF 
modulation of the CS transrepression mechanism with regards to IL8 and TNFA 
gene expression or CXCL8 or TNF release in THP-1 cells.  However with regards 
to the CS transactivation mechanisms, MIF counter-acts the CS-induced DUSP1 
gene expression, which is in agreement with other reports (Aeberli et al., 2006a, 
Aeberli et al., 2006b, Roger et al., 2005).  Moreover, MIF inhibition by ISO-1 and MIF 
siRNA knockdown increased the sensitivity of THP-1 cells to dexamethasone shown 
by an enhanced induction of DUSP1 gene expression at baseline and in the LPS-
stimulated model.  This finding supports the hypothesis of MIF potentially being a 
mechanism of inducing CS insensitivity.  To assess whether the LPS concentration 
used here was too high and hence overpowered the MIF counteraction, lower 
concentrations of LPS should be investigated.  Further evidence to support the 
assumption that MIF counteracts CSs via the GR-transactivation pathway instead of 
the GR-transrepression pathway is also required.  For example, additional 
investigation into CS-inducible genes (IL10 and GILZ) (Nocentini et al., 1997, 
D'Adamio et al., 1997) and GR transcriptional activity is needed to validate the role of 
MIF in the transactivation mechanism.  Investigations on MIF-modulation of the GR-
transrepression pathway are also needed to confirm that MIF is not involved in this 
mechanism.  I also demonstrated that MIF enhanced THP-1 proliferation through an 
effect on TP53 expression and activation of the p38 MAPK pathway.  Further 
experimental work is needed to confirm this data in primary cells and potentially see 
if this could interfere with CS actions on cell proliferation. 
Studying the control of CSs by MIF in other cell types will also be essential as MIF 
will not only effect monocytes but other cell types for example epithelial or T-
lymphocytes.  Finally, investigating whether MIF can counteract different clinically 
relevant CSs such as fluticasone propionate or budesonide would further confirm this 
unique role of MIF and confirm that it is not a dexamethasone-specific effect.  MIF 
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seems to be a very cell-specific cytokine that may have differing roles at higher and 
lower concentrations.  Future work to enable this would include, investigating the 
modulation of CS-transactivation by MIF in animal models of COPD and in primary 
cell experiments.  Much more research is required to understand the outcomes of 
MIF signalling, how MIF drives inflammation and how MIF can restore CS sensitivity 
(MIF-modulated inflammatory results are summarised in Figure 7.2).  
 
 
Figure 7.2: Illustration summarising main results from MIF stimulation (chapters 4-6) 
MIF stimulation resulted in cell-type specific cytokine release.  THP-1 cells released no 
CXCL8 or TNF in response to MIF stimulation.  However cells from severe asthmatics and 
COPD patients showed a more pronounced ISO-1-suppressed LPS-induced cytokine 
release than in cells from non-severe asthmatics and non-COPD patients respectively.  MIF-
induced proliferation could be via MIF-suppressed TP53 expression or through p38 MAPK 
activation.  MIF reverses the dexamethasone-induced DUSP1 production and in turn 
increases MAPK signalling, this could be a potential mechanism for CS insensitivity.  MIF 
induced Ca2+ release however did not signal through NFAT.  RV16 Infection induced the 
production and release of MIF in THP-1 and RV16 infection of healthy smokers and COPD 
patients resulted in reduced intracellular MIF in BAL macrophages.   
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Overall, from the data presented here I am rejecting my original hypothesis.  In 
contrast to the murine models MIF is not generally elevated in human COPD patients 
and MIF is not a potent inflammatory mediator in the human cells studied here.  
Even though I have demonstrated that MIF reverses the transactivation mechanism 
of CSs in THP-1 cells.  It is unlikely that sensitivity of CSs is modulated by MIF 
enough to cause the characteristic CS insensitivity in COPD.  
One important result from this thesis is the discrepancy between the in vivo murine 
ozone-induced inflammatory model and the subsequent translation into humans. 
Interestingly much of the inflammatory and mechanistic MIF research has been 
completed in vivo or in rodent cells ex vivo and therefore whether the same 
mechanisms and functions occur in human cells and models will need to be 
investigated.  Rodent but especially mouse models are the basis of biomedical 
research and aid in identifying candidate agents for clinical trials and investigating 
the effects of drugs in an organism.  However, there are many examples were drugs 
work well in mice but fail to show an efficacious effect once tested in humans for 
sepsis (Hotchkiss and Opal, 2010, Mitka, 2011).  
Animal models of disease differ greatly to that of the human disease. Firstly they 
have to be induced ‘artificially’ and are usually modelled on a disease phenotype.  
Therefore, the animal model of disease may not reproduce the same disease at the 
molecular level.  Ultimately, this could be a different disease being modelled.  MIF 
may have a role in chronic inflammation, as elevated levels have been shown in 
many chronic inflammatory diseases including, RA (Morand et al., 2002), 
atherosclerosis (Burger-Kentischer et al., 2002), SLE (Rovensky et al., 1975) and 
asthma (Rossi et al., 1998), however the mechanism and stimulus may not be 
precisely the same to the mouse model of disease.  Ozone-induced inflammation 
shows COPD-associated features such as inflammatory markers and CS 
insensitivity (Triantaphyllopoulos et al., 2011, Wiegman et al., 2013).  However 
compared to COPD patients the diseases differ in complexity and no model has all 
the characteristics of the disease.  COPD is not caused by the presence of one 
single stimulus or inducer alone (ozone, cigarette smoke or pollutants) but is a 
complex disease associated with many risk factors (Mannino and Buist, 2007); 
therefore it is very difficult to model in animals.  The genomic sequence of MIF differs 
between mice and human, there is 90% homology between the human MIF gene 
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and the mouse mif gene (Bozza et al., 1999).  This could affect the function, the 
activity and/or the binding ability of MIF.  For these reasons, the discrepancy 
between the ozone-induced COPD model and the MIF profiles in human samples 
can be explained.  Different in vivo models of COPD, for example cigarette-induced 
inflammation or LPS-instillation will need to be investigated to confirm that MIF drives 
airway inflammation.  It would also be of interest to examine ISO-1 attenuation in 
asthma mouse models using either OVA or HDM/CFA challenge, this would also 
assess whether the stimulus/challenge-method directly effects MIF induction or if 
MIF release is controlled by the immune response.  It is also possible that ISO-1 is 
having off-target effects in the mouse and therefore showing a different response to 
that in humans. 
Single-cell in vitro assays are also difficult to compare to in vivo models that contain 
multiple cells types, tissues and organs.  Cells signal to activate different cells/cell 
types and to initiate multiple responses and/or signalling cascades.  The presence of 
the liver, that metabolises drugs and agents into more or less active metabolites, 
may have a greater or lesser effect on attenuating or augmenting a response is also 
potentially crucial in affecting drug efficacy and drug interactions.  These changes 
would not be seen in vitro and would be difficult to assess without animal models.  In 
single-cell experiments these interactions between cells and tissues are lost due to 
the simplicity of the model and therefore are not taken into account.  However the 
effects on the single cell type and the signalling pathways activated by the stimuli 
can be investigated much easier without these complications in simplified models.  
Monocytes were chosen as the single cell to investigate in this thesis as 
macrophages have been shown to predominantly express MIF (Calandra et al., 
1994), however investigating other cell types, both immune and structural for 
example T-lymphocytes and epithelial cells, is essential and future work could 
include co-culturing different cell types to assess the role of MIF in a multiple cellular 
model.  An alternative approach would be to culture biopsy samples with ISO-1 to 
examine its effects in a complex disease-relevant tissue. 
Human primary cells (PBMCs and tissue macrophages) and the human immortalised 
cell line (THP-1) gave different responses to stimuli and MIF inhibition.  There are 
advantages and disadvantages to both primary and immortalised cells however 
mechanisms and functions should be confirmed in both to validate the finding.  
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Primary cells are a better model for humans and disease state, however getting the 
samples and appropriate cell numbers can be difficult, especially in severe 
subgroups of disease.  Primary cells also have a short life span and can change 
phenotype as they divide.  Whereas immortalised cell lines are better characterised 
with less variation and do not change with passages.  However different 
immortalised cells of the same cell type can give different responses, therefore most 
mechanistic work is initially done in immortalised cells and then confirmed in primary 
cells.  Much of the data demonstrated here in the THP-1 cells, especially the 
counteraction of MIF on CS-transactivation mechanisms should be confirmed in 
primary cells such as tissue or BAL macrophages or PBMCs. 
Proteomic and transcriptomic methods were used to generate new hypotheses and 
identify novel associations between MIF and COPD and severe asthma.  The SILAC 
experiment reported numerous proteins that had been significantly affected by MIF 
stimulation however the RNA microarray gave no significant differentially expressed 
genes.  Although, there were no MIF-modulated gene changes detected by my RNA 
microarray, pathway analysis identified glycolysis/gluconeogenesis, VEGF signalling 
and B-cell receptor signalling as pathways involved.  Pilot experiments could be 
performed to establish any modulation by MIF, as these pathways are associated 
with COPD.  Nonetheless, it must be noted that the changes were not significant in 
the array and therefore the relevance is uncertain.  Repeating the experiment with 
greater n numbers would increase the statistical power of the experiment and may 
detect changes.  MIF-induced no differential gene expression changes after multiple 
testing.  Using more focussed arrays or using RNA-seq as a more sensitive 
technique (Sirbu et al., 2012) may detect smaller but significant changes induced by 
MIF stimulation.  The MIF effects after multiple time points should also be assessed 
as MIF could affect gene expression very transiently or in a delayed response. 
One main issue with the proteomic and transcriptomic studies was the discrepancy 
between the results.  Changes detected at the protein level did not correlated with 
corresponding gene changes; this could be due to PTMs, most likely to be caused by 
changes in the stability or degradation of the proteins.  Confirmation of this 
speculation would be needed and could include investigating PTMs by MIF on 
associated proteins and assess the functional effect on either protein activity or 
ability to bind and complex.  Furthermore, modulation of PTMs present on 
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transcriptional co-activators and co-repressors associated with GR function and on 
GR itself by MIF could affect CSs functions and should be investigated. 
The SILAC method identified the RLR pathway as interacting with MIF, which was 
further investigated in THP-1 cells as well as human samples.  Whilst MIF did not 
seem to play a role in LPS driven inflammation or stable COPD, the role of MIF 
during viral infection and associated pathways should be further examined.  Western 
blotting, pharmacological inhibitors, siRNA and co-immunoprecipitation could be 
used to assess the specific roles and activity status of MDA5 and RIG-1 proteins and 
the respective associations with MIF.  This would elucidate the role these proteins 
play in the viral-induced MIF pathway.  There are very few published reports on MIF 
and viral infection, however in a mouse model of alphavirus-induced arthritic 
inflammation, deficiency of the MIF receptor CD74, leads to attenuation of tissue 
inflammation and disease severity (Herrero et al., 2013).  Studying the attenuation of 
inflammation, the CS action and the potential restoration of CS sensitivity by MIF 
inhibition in an in vivo viral-infected model of COPD would confirm the role of MIF in 
exacerbating COPD-associated inflammation.  COPD patients can have many 
exacerbations per year and during any stage of disease, from mild to severe, 
however they become more frequent as the disease severity increases (Hurst et al., 
2010).  Exacerbations lead to a sudden decline in health and an increase in disease 
severity (Donaldson et al., 2002, Burge and Wedzicha, 2003) and either early 
detection or preventative treatment would help in controlling COPD progression.  
Measuring MIF in patients’ samples collected during an acute viral exacerbation 
would confirm this viral induction of MIF.  Future experiments to investigate this viral-
MIF association could be to assess a viral exacerbation on top of an inflammatory-
induced model in vivo.  Moreover, the effect of MIF inhibition (ISO-1 and 4-IPP) or 
MIF knockout mice in this exacerbating COPD inflammatory model would further 
validate the previous findings, and again validate findings and further investigations 
in primary cells.  The proteomic approach of SILAC was effective and integral in 
identifying a novel pathway associated to MIF. 
The aim of this thesis was to investigate whether MIF has a role in COPD and 
severe asthma inflammation and to assess if MIF was a mechanism for inducing the 
disease characteristic CS insensitivity.  The in vivo murine model supported the 
hypothesis however this was not true in LPS-induced human cell models.  MIF was 
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shown to modulate the CS transactivation mechanism by counteracting 
dexamethasone-induced DUSP1 gene expression but had no effect on genes 
regulated via the CS transrepression mechanism.  Overall I have rejected my original 
hypothesis; MIF has no role in stable COPD.  However, the SILAC results indicate 
that MIF may be involved in response to viral infection.  Therefore, I propose a new 
hypothesis that viral-induced MIF and not bacterial-induced MIF may drive the 
inflammation during exacerbations and/or heighten the immune response to the viral 
infection; this may lead to or worsen the CS insensitivity seen in COPD patients. 
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Appendix 1 
** Unknown proteins 
 
SILAC: Up-regulated proteins in response to MIF stimulation 
Entry name Protein names Gene names Length Ratio 
A6NCQ5 Methionine sulfoxide reductase B2 MSRB2  159 2.173 
A6NGR9 Maestro heat-like repeat-containing protein family member 6 MROH6  719 100 
A6NMY6 Putative annexin A2-like protein  ANXA2P2  339 100 
A8MVM3 ** 
  
100 
A8MY34 ** 
  
8.215 
A8MYY3 ** 
  
100 
B3KSZ7 cDNA FLJ37361  
 
697 100 
B3KVZ3 Centromere protein H  CENPH  228 100 
B3KY83 Retinoic acid receptor RXR-alpha  RXRA 365 9.076 
B4DEU5 L-fucose kinase FUK 180 100 
B7Z3B9 GRB2-associated-binding protein 1 GAB1 591 100 
B7ZKT6 Son of sevenless homolog 2 SOS2 1,299 100 
C9IYU0 ** 
  
100 
C9J1C1 Cysteine protease ATG4B ATG4B 66 100 
C9J6U6 ** 
  
100 
C9J7Y4 Cytoskeleton-associated protein 2 CKAP2 97 100 
C9JID5 Transmembrane protein 40  TMEM40  157 100 
C9JYM0 Ribonuclease P protein subunit p20 POP7 137 100 
C9K0J2 Uridine phosphorylase 1 UPP1 29 100 
D6RB81 Alpha-methylacyl-CoA racemase AMACR 367 100 
E2QRG7 4-hydroxybenzoate polyprenyltransferase, mitochondrial COQ2 328 100 
E7ETX8 ** 
  
100 
E7EUC5 ** 
  
100 
E9PE41 ** 
  
100 
E9PEZ1 Cullin-9 CUL9 2,489 100 
F1D8N3 Estrogen nuclear receptor beta variant b NR3A2 495 49.843 
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F5GWQ7 ** 
  
11.065 
F5H3Y6 ** 
  
83.851 
F5H480 T-cell surface glycoprotein CD4 CD4 148 100 
O60486 Plexin-C1  PLXNC1  1,568 100 
O94888 UBX domain-containing protein 7 UBXN7 489 100 
O95394 Phosphoacetylglucosamine mutase (PAGM)  PGM3  542 100 
O95801 Tetratricopeptide repeat protein 4  TTC4 387 3.258 
P12931 Proto-oncogene tyrosine-protein kinase Src  SRC 536 81.132 
P13196 5-aminolevulinate synthase, nonspecific, mitochondrial  ALAS1  640 100 
P28749 Retinoblastoma-like protein 1 RBL1 1,068 10.077 
Q13233 Mitogen-activated protein kinase kinase kinase 1  MAP3K1  1,512 9.443 
Q13362 Serine/threonine-protein phosphatase 2A 56kDa regulatory subunit gamma isoform  PPP2R5C  524 100 
Q14814 Myocyte-specific enhancer factor 2D MEF2D 521 100 
Q15818 Neuronal pentraxin-1  NPTX1 432 9.619 
Q2TAM9 Tumor suppressor candidate gene 1 protein  TUSC1 212 100 
Q4G0J3 La-related protein 7  LARP7  582 8.955 
Q5HYC2 Uncharacterized protein KIAA2026 KIAA2026 2,103 100 
Q5I2W7 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial  CYP24  372 100 
Q5T0N5 Formin-binding protein 1-like  FNBP1L  605 100 
Q702N8 Xin actin-binding repeat-containing protein 1  XIRP1 1,843 100 
Q86WS4 Uncharacterised protein C12orf40 C12orf40 652 100 
Q8IVG5 Sterile alpha motif domain-containing protein 9-like  SAMD9L  1,584 7.949 
Q8IWR0 Zinc finger CCCH domain-containing protein 7A ZC3H7A  971 19.816 
Q8N655 Uncharacterised protein C10orf12 C10orf12 1,247 100 
Q8NFC6 Biorientation of chromosomes in cell division protein 1-like 1  BOD1L1  3,051 10.325 
Q96JG9 Zinc finger protein 469 ZNF469  3,925 100 
Q96L73 Histone-lysine N-methyltransferase, H3 lysine-36 and H4 lysine-20 specific  NSD1  2,696 100 
Q99797 Mitochondrial intermediate peptidase  MIPEP  713 100 
Q99961 Endophilin-A2  SH3GL1  368 9.119 
Q9BQE5 Apolipoprotein L2  APOL2 337 100 
Q9BRH9 Zinc finger protein 251 ZNF251 671 100 
Q9H5Q4 Dimethyladenosine transferase 2, mitochondrial  TFB2M  396 8.013 
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Q9NPD8 Ubiquitin-conjugating enzyme E2 T  UBE2T 197 7.832 
Q9NQP4 Prefoldin subunit 4 PFDN4  134 8.430 
Q9NTZ6 RNA-binding protein 12  RBM12  932 100 
Q9NUQ2 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon  AGPAT5 364 9.544 
Q9UIS9 Methyl-CpG-binding domain protein 1  MBD1  605 10.580 
Q9UJ71 C-type lectin domain family 4 member K) CD207  328 100 
Q9UPW5 Cytosolic carboxypeptidase 1  AGTPBP1  1,226 5.344 
Q9Y2U9 Kelch domain-containing protein 2  KLHDC2  406 100 
Q9Y512 Sorting and assembly machinery component 50 homolog  SAMM50  469 7.386 
Q9Y6I9 Testis-expressed sequence 264 protein TEX264  313 9.750 
 
SILAC: Down-regulated proteins in response to MIF stimulation 
Entry name  Protein names  Gene names  Length Ratio 
A2A3F3 Transient receptor potential cation channel subfamily M member 3 TRPM3 1,566 0.01 
A2AB27 Guanine nucleotide-binding protein-like 1 GNL1 264 0.418 
A6NHL2 Tubulin alpha chain-like 3 TUBAL3 446 0.094 
A6QL64 Ankyrin repeat domain-containing protein 36A ANKRD36 1,941 0.01 
A8K968 cDNA FLJ77757  756 0.049 
A8MWV3 Osteoclast-associated immunoglobulin-like receptor OSCAR 161 0.01 
B0QY86 MICAL-like protein 1 MICALL1 210 0.093 
B1AH77 Ras-related C3 botulinum toxin substrate 2 RAC2 148 0.01 
B4DE86 Protein NDRG2  NDRG2 367 0.01 
B4DH53 MAP1S light chain  MAP1S 1,033 0.420 
B4DI70 cDNA FLJ53509, highly similar to Galectin-3-binding protein  413 0.496 
B4DJX9 Syntaxin 16 STX16 139 0.01 
B4DK85 Glutaryl-CoA dehydrogenase, mitochondrial  GCDH 394 0.359 
B4DP52 HCG2005638 DDX39B 350 0.01 
B4DPV4 Graves disease carrier protein  SLC25A16 234 0.01 
B4DSZ9 E3 ubiquitin-protein ligase TTC3  TTC3 612 0.01 
B4DUI8 cDNA FLJ52761, highly similar to Actin, aortic smooth muscle  332 0.01 
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B4E2Q6 Regulation of nuclear pre-mRNA domain-containing protein 2  RPRD2 934 0.075 
B4E2X3 Methyltransferase-like protein 13 (cDNA FLJ56024) METTL13 698 0.086 
B5MDE0 Protein RFT1 homolog RFT1 502 0.432 
B7Z207 3-phosphoinositide-dependent protein kinase 1 PDK1 281 0.01 
B7Z6M1 Plastin-3  PLS3 585 0.01 
B7Z8H8 ADP-ribosylation factor GTPase-activating protein 1  ARFGAP1 293 0.01 
B7ZM37 PDE3B protein  PDE3B 1,061 0.01 
C9JGW8 **  
 
0.092 
C9JKR2 Albumin, isoform CRA_k  ALB 417 0.01 
C9JN15 Peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8) PPIG 246 0.390 
C9JR33 NAD-dependent protein deacetylase sirtuin-2 SIRT2 73 0.171 
C9JRE4 Tudor domain-containing protein 1 TDRD1 717 0.01 
C9JS68 Thromboxane-A synthase TBXAS1 150 0.01 
C9JSP5 **  
 
0.1 
C9JUG1 5'-AMP-activated protein kinase subunit gamma-2 PRKAG2 163 0.474 
D6RBS5 ELMO domain-containing protein 2 ELMOD2 168 0.455 
E5RJV7 Serine/threonine-protein kinase Sgk3 SGK3 109 0.01 
E7EMU3 **  
 
0.01 
E7EMV0 Protein diaphanous homolog 1 DIAPH1 863 0.01 
E7ENF8 RalA-binding protein 1 RALBP1 207 0.01 
E7EPR3 Gamma-interferon-inducible protein 16 IFI16 733 0.085 
E7EQS7 **  
 
0.01 
E7ERA4 **  
 
0.01 
E7ESA8 U4/U6 small nuclear ribonucleoprotein Prp31 PRPF31 450 0.097 
E7ETY2 Treacle protein TCOF1 1,488 0.429 
E7EU54 **  
 
0.064 
E7EWJ5 **  
 
0.01 
E9PBK4 Protein NRDE2 homolog NRDE2 933 0.491 
E9PE69 **  
 
0.368 
E9PEW8 Haemoglobin subunit delta HBD 104 0.01 
E9PGY2 HEAT repeat-containing protein 2 HEATR2 280 0.079 
E9PS71 Peroxisomal biogenesis factor 19 PEX19 166 0.01 
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F2Z2C3 Bcl-2-like protein 13 BCL2L13 78 0.083 
F2Z2M1 Solute carrier organic anion transporter family member 1B1 LST1 66 0.425 
F5GWB8 **  
 
0.01 
F5H196 **  
 
0.01 
F5H2U6 **  
 
0.01 
F5H456 RRP12-like protein RRP12 1,015 0.094 
F5H4N7 **  
 
0.01 
F5H696 **  
 
0.01 
F5H721 WW domain-binding protein 11 WBP11 607 0.01 
F5H7W4 Sterol O-acyltransferase 2 SOAT2 310 0.01 
O14879 Interferon-induced protein with tetratricopeptide repeats 3  IFIT3 490 0.152 
O15381 Nuclear valosin-containing protein-like  NVL 856 0.098 
O60885 Bromodomain-containing protein 4  BRD4 1,362 0.01 
O76039 Cyclin-dependent kinase-like 5  CDKL5 1,030 0.01 
O94822 E3 ubiquitin-protein ligase listerin  LTN1 1,766 0.01 
O95716 Ras-related protein Rab-3D RAB3D 219 0.486 
O95758 Polypyrimidine tract-binding protein 3   PTBP3 552 0.086 
O95786 Retinoic Acid-Inducible Gene 1 Protein-1 (RIG-1) DDX58 925 0.01 
P02533 Keratin, type I cytoskeletal 14  KRT14 472 0.01 
P02647 Apolipoprotein A-I  APOA1 267 0.01 
P02765 Alpha-2-HS-glycoprotein  AHSG 367 0.01 
P02788 Lactotransferrin  LTF 710 0.01 
P04004 Vitronectin VTN 478 0.01 
P04264 Keratin, type II cytoskeletal 1 KRT1 644 0.01 
P05161 Ubiquitin-like protein ISG15  ISG15 165 0.08 
P05787 Keratin, type II cytoskeletal 8  KRT8 483 0.01 
P08779 Keratin, type I cytoskeletal 16  KRT16 473 0.01 
P09601 Heme oxygenase 1  HMOX1 288 0.244 
P09913 Interferon-induced protein with tetratricopeptide repeats 2  IFIT2 472 0.01 
P0CG38 POTE ankyrin domain family member I POTEI 1,075 0.01 
P10606 Cytochrome c oxidase subunit 5B, mitochondrial  COX5B 129 0.498 
P11678 Eosinophil peroxidase   EPX 715 0.01 
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P13645 Keratin, type I cytoskeletal 10  KRT10 584 0.01 
P13647 Keratin, type II cytoskeletal 5  KRT5 590 0.01 
P16455 Methylated-DNA--protein-cysteine methyltransferase  MGMT 207 0.450 
P20591 Interferon-induced GTP-binding protein Mx1  MX1 662 0.01 
P20592 Interferon-induced GTP-binding protein Mx2  MX2 715 0.01 
P29400 Collagen alpha-5(IV) chain COL4A5 1,685 0.01 
P34931 Heat shock 70kDa protein 1-like  HSPA1L 641 0.466 
P35527 Keratin, type I cytoskeletal 9  KRT9 623 0.01 
P35908 Keratin, type II cytoskeletal 2 epidermal  KRT2 639 0.01 
P42858 Huntingtin  HTT 3,142 0.342 
P47914 60S ribosomal protein L29  RPL29 159 0.078 
P48200 Iron-responsive element-binding protein 2  IREB2 963 0.092 
P53674 Beta-crystallin B1 CRYBB1 252 0.487 
P53779 Mitogen-activated protein kinase 10   MAPK10 464 0.087 
P57105 Synaptojanin-2-binding protein  SYNJ2BP 145 0.490 
P62699 Protein yippee-like 5 YPEL5 121 0.133 
P69905 Hemoglobin subunit alpha  HBA1 142 0.01 
Q00653 Nuclear factor NF-kappa-B p100 subunit  NFKB2 900 0.489 
Q13393 Phospholipase D1  PLD1 1,074 0.477 
Q14213 Interleukin-27 subunit beta  EBI3 229 0.01 
Q14344 Guanine nucleotide-binding protein subunit alpha-13 GNA13 377 0.490 
Q15417 Calponin-3  CNN3 329 0.01 
Q2TAL8 Glutamine-rich protein 1 QRICH1 776 0.09 
Q32N00 DNA polymerase delta subunit 3  POLD3 360 0.081 
Q4KMP7 TBC1 domain family member 10B  TBC1D10B 808 0.099 
Q4W5H2 Putative uncharacterized protein BMP2K  BMP2K 662 0.01 
Q53EL6 Programmed cell death protein 4  PDCD4 469 0.098 
Q58FF6 Putative heat shock protein HSP 90-beta 4 HSP90AB4P 505 0.01 
Q5JV73 FERM and PDZ domain-containing protein 3 FRMPD3 1,810 0.01 
Q5SNV9 Uncharacterised protein C1orf167 C1orf167 1,468 0.01 
Q5T0A6 Dehydrodolichyl diphosphate synthase DHDDS 169 0.342 
Q5TH58 Uncharacterised protein C6orf106 C6orf106 224 0.477 
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Q68CZ6 HAUS augmin-like complex subunit 3 HAUS3 603 0.01 
Q6ZNK6 TRAF-interacting protein with FHA domain-containing protein B  TIFAB 161 0.01 
Q7Z2Y8 Interferon-induced very large GTPase 1  GVINP1 2,422 0.01 
Q86TB9 Protein PAT1 homolog 1  PATL1 770 0.098 
Q86U10 60kDa lysophospholipase  ASPG 573 0.01 
Q8IXQ6 Poly [ADP-ribose] polymerase 9  PARP9 854 0.01 
Q8IY21 Probable ATP-dependent RNA helicase DDX60  DDX60 1,712 0.01 
Q8N4A0 Polypeptide N-acetylgalactosaminyltransferase 4  GALNT4 578 0.01 
Q8N6G6 ADAMTS-like protein 1  ADAMTSL1 1,762 0.01 
Q8NBT2 Kinetochore protein Spc24  SPC24 197 0.092 
Q8NGU2 Olfactory receptor 9A4  OR9A4 314 0.01 
Q8NHZ6 Mannose phosphate isomerase isoform  267 0.315 
Q8NI60 Chaperone activity of bc1 complex-like, mitochondrial  ADCK3 647 0.01 
Q8TAD4 Zinc transporter 5  SLC30A5 765 0.01 
Q8WTU0 Protein DDI1 homolog 1 DDI1 396 0.01 
Q8WVD3 E3 ubiquitin-protein ligase RNF138  RNF138 245 0.01 
Q8WWI1 LIM domain only protein 7  LMO7 1,683 0.122 
Q96AH8 Ras-related protein Rab-7b RAB7B 199 0.033 
Q96AZ6 Interferon-stimulated gene 20kDa protein  ISG20 181 0.265 
Q96JB5 CDK5 regulatory subunit-associated protein 3  CDK5RAP3 506 0.422 
Q96KN8 Ca2+-independent N-acyltransferase  HRASLS5 279 0.124 
Q96PP9 Guanylate-binding protein 4  GBP4 640 0.450 
Q96SI9 Spermatid perinuclear RNA-binding protein STRBP 672 0.01 
Q9BRX2 Protein pelota homolog  PELO 385 0.08 
Q9BSL1 Ubiquitin-associated domain-containing protein 1  UBAC1 405 0.081 
Q9BV86 N-terminal Xaa-Pro-Lys N-methyltransferase 1   NTMT1 223 0.092 
Q9BVP2 Guanine nucleotide-binding protein-like 3 GNL3 549 0.096 
Q9BVS4 Serine/threonine-protein kinase RIO2  RIOK2 552 0.498 
Q9BYF1 Angiotensin-converting enzyme 2  ACE2 805 0.01 
Q9BYK8 Helicase with zinc finger domain 2  HELZ2 2,649 0.401 
Q9BYX4 Melanoma Differentiation Associated Protein-5 (MDA5) IFIH1 1,025 0.497 
Q9BZE2 tRNA pseudouridine(38/39) synthase  PUS3 481 0.01 
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Q9H1K6 Mesoderm development candidate 1 MESDC1 362 0.01 
Q9H444 Charged multivesicular body protein 4b  CHMP4B 224 0.484 
Q9H4L7 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily A containing DEAD/H box 1 
SMARCAD1 
1,026 0.01 
Q9H974 Queuine tRNA-ribosyltransferase subunit QTRTD1  QTRTD1 415 0.089 
Q9H9L3 Interferon-stimulated 20kDa exonuclease-like 2  ISG20L2 353 0.01 
Q9HC10 Otoferlin  OTOF 1,997 0.01 
Q9NQX4 Unconventional myosin-Vc MYO5C 1,742 0.078 
Q9NRK6 ATP-binding cassette sub-family B member 10, mitochondrial  ABCB10 738 0.180 
Q9NRX1 RNA-binding protein PNO1 PNO1 252 0.086 
Q9NS37 CREB/ATF bZIP transcription factor  CREBZF 354 0.01 
Q9NYL9 Tropomodulin-3  TMOD3 352 0.403 
Q9UDY2 Tight junction protein ZO-2  TJP2 1,190 0.098 
Q9UID3 Vacuolar protein sorting-associated protein 51 homolog  VPS51 782 0.01 
Q9UII4 E3 ISG15--protein ligase HERC5 HERC5 1 0.01 
Q9UK61 Protein FAM208A  FAM208A 1,670 0.481 
Q9UN19 Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide  DAPP1 280 0.450 
Q9Y3I1 F-box only protein 7 FBXO7 522 0.084 
Q9Y3Q8 TSC22 domain family protein 4  TSC22D4 395 0.01 
Q9Y6N7 Roundabout homolog 1  ROBO1 1,651 0.420 
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Appendix 2 
^^ LncRNAs 
** Unknown Transcript 
 
RNA microarray: Up-regulated genes in response to 4 hour MIF stimulation (fold change ≥1.5) 
Entry Name  Gene Name Gene ID Fold change 
NR_003271 Small nucleolar RNA, C/D box 3B-1 SNORD3B-1 2.00 
NM_020535 Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5A KIR2DL5A 1.92 
NR_040108 Uncharacterised LOC728175 non-coding  1.89 
NR_004400 RNA variant U1 small nuclear 18 RNVU1-18 1.79 
NM_004113 Fibroblast growth factor 12  FGF12 1.68 
NR_034143 Cancer susceptibility candidate 14 non-protein coding  CASC14 1.60 
ENST00000419440 ^^ LncC11orf39-3 1.60 
TCONS_00009863 ^^ Lnc-ADCY2-4 1.59 
NR_027030 Uncharacterised protein MGC34034  1.57 
NM_153267 MAM domain containing 2 MAMDC2 1.55 
NR_023343 RNA, U4atac small nuclear U12-dependent splicing RNU4ATAC 1.55 
NM_000230 Leptin LEP 1.55 
TCONS_00006780 ^^ Lnc-THUMPD3-1 1.54 
NR_003064 Peptide YY, 2 (pseudogene) non coding PYY2 1.54 
NM_178466 BPI fold containing family A, member 3 BPIFA3 1.54 
TCONS_00004035 ^^ Lnc-SLC4A3-8 1.53 
NM_175868 Melanoma antigen family A, 6 (MAGEA6)  1.53 
NM_001004695 Olfactory receptor, family 2, subfamily T, member 33 (OR2T33  1.53 
NR_000020 Small nucleolar RNA, C/D box 33 (SNORD33  1.52 
TCONS_00023084 ^^ Lnc-STXBP6-1 1.52 
NR_030737 Tetratricopeptide repeat domain 3 pseudogene 1 (TTC3P1  1.52 
NM_183062 Protease, serine, 38 (PRSS38  1.52 
XM_001719518 Hypothetical protein  1.51 
NR_002575 Nucleolar RNA, H/ACA box 27 (SNORA27  1.51 
TCONS_00022841 ^^ Lnc-SERPINA12-1 1.51 
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ENST00000428157 ^^ Lnc-ZAP70-2-2 1.51 
XR_132564 Hypothetical LOC100652913  1.51 
 
RNA microarray: Down-regulated genes in response to 4 hour MIF stimulation (fold change ≤0.7) 
Entry Name Gene Name Gene ID Fold change 
NM_016536 Zinc finger protein 571 ZNF571 0.37 
AJ276510 Partial mRNA for hypothetical protein ORF1 0.38 
TCONS_00029565 ^^ Lnc-CRYBA4-8 0.40 
ENST00000441356 ^^ Lnc-RND3-1 0.40 
NM_001822 Chimerin 1 CHN1 0.41 
NM_004797 Adiponectin, C1Q and collagen domain containing ADIPOQ 0.42 
TCONS_00022613 ^^ 
Lnc-RP11-
1070N10.3.1-1 0.43 
TCONS_00019700 ^^ Lnc-STARD10-1 0.43 
XR_109045 Hypothetical LOC100507282  0.45 
NM_018711 SV2 related protein homolog SVOP 0.45 
BC047507 Solute carrier family 2 (facilitated glucose transporter), member 13, mRNA  0.47 
BC034958 Hypothetical protein LOC283665  0.48 
NM_001080451 
Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 11 
SERPINA11 
0.49 
XR_109658 Uncharacterised LOC100505973  0.51 
TCONS_l2_00012321 ^^  0.51 
ENST00000430672 ^^ Lnc-HDDC2-2 0.51 
NM_001024227 ADP-ribosylation factor 1 ARF1 0.51 
NM_005566 Lactate dehydrogenase A  LDHA 0.53 
NM_032704 Tubulin, alpha 1c TUBA1C 0.53 
NM_006793 Peroxiredoxin 3 PRDX3 0.54 
ENST00000458017 ^^ Lnc-SLC35D3-1 0.54 
NM_032551 KISS1 receptor KISS1R 0.55 
NM_001950 E2F transcription factor 4, p107/p130-binding E2F4 0.55 
NM_001402 Eukaryotic translation elongation factor 1 alpha 1 EEF1A1 0.55 
NM_014214 Inositol(myo)-1(or 4)-monophosphatase 2 IMPA2 0.55 
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NM_002629 Phosphoglycerate mutase 1 PGAM1 0.56 
NM_206956 Preferentially expressed antigen in melanoma PRAME 0.56 
TCONS_00026344 ^^ Lnc-MALT1-1 0.56 
NM_001042465 Prosaposin PSAP 0.56 
NM_033198 Phosphatidylinositol glycan anchor biosynthesis, class S PIGS 0.56 
NM_014045 Low density lipoprotein receptor-related protein 10 LRP10 0.57 
NM_001006617 Mitogen-activated protein kinase associated protein 1 MAPKAP1 0.57 
NM_021932 RIC8 guanine nucleotide exchange factor A RIC8A 0.57 
NM_032985 Sec23 homolog B SEC23B 0.57 
NM_006009 Tubulin, alpha 1a TUBA1A 0.57 
NM_000687 Adenosylhomocysteinase AHCY 0.57 
NM_006839 Inner membrane protein, mitochondrial  IMMT 0.57 
NM_020679 MIF4G domain containing MIF4GD 0.57 
NM_030752 T-complex 1 TCP1 0.57 
NM_020531 Adipocyte plasma membrane associated protein APMAP 0.58 
NM_000820 Growth arrest-specific 6 GAS6 0.58 
NM_006029 Paraneoplastic Ma antigen 1 PNMA1 0.58 
NM_153824 Pyrroline-5-carboxylate reductase 1 PYCR1 0.58 
NM_001012732 dCMP deaminase DCTD 0.58 
ENST00000417260 ^^ 
Lnc-RP3-
377D14.1.1-1 0.58 
NM_005265 Gamma-glutamyltransferase 1 GGT1 0.58 
NM_015171 Exportin 6 XPO6 0.58 
NM_004550 NADH-coenzyme Q reductase NDUFS2 0.58 
NM_001012662 Solute carrier family 3 (amino acid transporter heavy chain), member 2 SLC3A2 0.58 
NM_001004356 Fibroblast growth factor receptor-like 1  FGFRL1 0.59 
NM_032539 SLIT and NTRK-like family, member 2 SLITRK2 0.59 
NM_003331 Tyrosine kinase 2 TYK2 0.59 
NM_023075 Metallophosphoesterase 1 MPPE1 0.59 
NM_000532 Propionyl CoA carboxylase, beta polypeptide PCCB 0.59 
NM_002631 Phosphogluconate dehydrogenase PGD 0.59 
NM_002755 Mitogen-activated protein kinase kinase 1 MAP2K1 0.60 
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NM_020414 DEAD (Asp-Glu-Ala-Asp) box helicase 24 DDX24 0.60 
NM_001067 Topoisomerase (DNA) II alpha 170kDa TOP2A 0.60 
NM_201222 Melanoma antigen family D, 2 MAGED2 0.60 
NM_001039619 Protein arginine methyltransferase 5 PRMT5 0.60 
NM_053045 Transmembrane protein 203 TMEM203 0.60 
NM_014003 DEAH (Asp-Glu-Ala-His) box polypeptide 38 DHX38 0.60 
NM_002194 Inositol polyphosphate-1-phosphatase INPP1 0.60 
NM_014230 Signal recognition particle 68kDa SRP68 0.60 
ENST00000466304 ^^   0.60 
NM_014669 Nucleoporin 93kDa NUP93 0.60 
NM_198976 Negative elongation factor complex member C/D NELFCD 0.60 
NM_001184768 Armadillo repeat containing, X-linked 6  ARMCX6 0.61 
NM_014889 Pitrilysin metallopeptidase 1 PITRM1 0.61 
NM_144699 ATPase, Na+/K+ transporting, alpha 4 polypeptide ATP1A4 0.61 
ENST00000490216 ^^   0.61 
NR_001562 Annexin A2 pseudogene 1 ANXA2P1 0.61 
NM_012401 Plexin B2 PLXNB2 0.61 
NM_153201 Heat shock 70kDa protein 8 HSPA8 0.61 
NM_003575 Zinc finger protein 282  ZNF282 0.61 
NM_053052 Synaptosomal-associated protein, 47kDa SNAP47 0.61 
NM_002115 Hexokinase 3  HK3 0.61 
NM_014063 Drebrin-like DBNL 0.61 
NM_005120 Mediator complex subunit 12  MED12 0.61 
NM_006677 Ubiquitin specific peptidase 19 USP19 0.61 
NM_021095 
Solute carrier family 5 (sodium/multivitamin and iodide cotransporter), 
member 6 
SLC5A6 
0.61 
NM_001206710 Protein kinase, AMP-activated, gamma 1 non-catalytic subunit PRKAG1 0.61 
NM_005850 Splicing factor 3b, subunit 4, 49kDa SF3B4 0.61 
NM_001017405 Macrophage erythroblast attacher MAEA 0.61 
TCONS_l2_00014935 ^^   0.62 
NM_014845 FIG4 homolog FIG4 0.62 
NM_003626 Protein tyrosine phosphatase, receptor type, f polypeptide PTPRF 0.62 
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NM_001686 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide ATP5B 0.62 
NM_004581 Rab geranylgeranyltransferase, alpha subunit RABGGTA 0.62 
NM_017617 Notch 1 NOTCH1 0.62 
NM_003730 Ribonuclease T2 RNASET2 0.62 
ENST00000375713 ^^   0.62 
NM_020944 Glucosidase, beta (bile acid) 2 GBA2 0.62 
NM_004946 Dedicator of cytokinesis 2 DOCK2 0.63 
NM_004281 BCL2-associated athanogene 3 BAG3 0.63 
NM_005186 Calpain 1, (mu/I) large subunit CAPN1 0.63 
NM_006453 Transducin (beta)-like 3  TBL3 0.63 
NM_003680 Tyrosyl-tRNA synthetase  YARS 0.63 
NM_002110 Hemopoietic cell kinase  HCK 0.63 
ENST00000380291 ^^   0.63 
NM_004879 Etoposide induced 2.4  EI24 0.63 
NM_173717 ElaC ribonuclease Z 2  ELAC2 0.63 
A_24_P246963 **   0.63 
A_33_P3357227 **   0.63 
NM_052853 aarF domain containing kinase 2 ADCK2 0.63 
NM_007011 Abhydrolase domain containing 2 ABHD2 0.63 
NM_031229 RanBP-type and C3HC4-type zinc finger containing 1 RBCK1 0.63 
NM_002601 Phosphodiesterase 6D PDE6D 0.63 
NM_001693 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 ATP6V1B2 0.64 
NM_001127 Adaptor-related protein complex 1, beta 1 subunit  AP1B1 0.64 
NM_025204 TraB domain containing TRABD 0.64 
NM_005174 
ATP synthase, H+ transporting, mitochondrial F1 complex, gamma 
polypeptide 1 
ATP5C1 
0.64 
NM_145805 ISL LIM homeobox 2 ISL2 0.64 
NM_033296 Morf4 family associated protein 1 MRFAP1 0.64 
NM_004793 lon peptidase 1, mitochondrial LONP1 0.64 
NM_006357 Ubiquitin-conjugating enzyme E2E 3 UBE2E3 0.64 
NM_017547 FAD-dependent oxidoreductase domain containing 1 FOXRED1 0.64 
NM_014230 Signal recognition particle 68kDa  SRP68 0.64 
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NM_001428 Enolase 1, (alpha)  ENO1 0.64 
NM_015160 Peptidase (mitochondrial processing) alpha PMPCA 0.64 
ENST00000435049 ^^  Lnc-WRAP73-1 0.64 
XR_110047 Uncharacterised LOC389102  0.64 
NM_024068 Nucleic acid binding protein 2 NABP2 0.64 
NM_130475 MAP-kinase activating death domain MADD 0.64 
NM_138793 Calcium activated nucleotidase 1 CANT1 0.64 
NM_015374 Sad1 and UNC84 domain containing 2 SUN2 0.64 
NM_001077351 RNA binding motif protein 23 RBM23 0.64 
NM_173165 Nuclear factor of activated T-cells,  NFATC3 0.65 
NM_015440 Methylenetetrahydrofolate dehydrogenase1-like  MTHFD1L 0.65 
NM_005337 NCK-associated protein 1-like  NCKAP1L 0.65 
TCONS_00012632 ^^ Lnc-FAM120B-6 0.65 
NM_000026 Adenylosuccinate lyase ADSL 0.65 
NM_058004 Phosphatidylinositol 4-kinase, catalytic, alpha PI4KA 0.65 
NM_015913 Thioredoxin domain containing 12 TXNDC12 0.65 
NM_007024 Transmembrane protein 115 TMEM115 0.65 
NM_000938 Polymerase (RNA) II (DNA directed) polypeptide B, 140kDa  POLR2B 0.65 
NM_006230 Polymerase (DNA directed), delta 2, accessory subunit POLD2 0.65 
NM_001042388 Protein phosphatase 4, regulatory subunit 1 PPP4R1 0.65 
NM_005098 Musculin MSC 0.65 
NM_020362 PITH domain containing 1 PITHD1 0.65 
NM_006325 RAN, member RAS oncogene family RAN 0.65 
NM_002738 Protein kinase C, beta PRKCB 0.65 
NM_001002878 THO complex 5 THOC5 0.65 
NM_016176 Stromal cell derived factor 4 SDF4 0.65 
NM_020190 Olfactomedin-like 3 OLFML3 0.65 
NM_005701 Snurportin 1 SNUPN 0.65 
NM_005015 Oxidase (cytochrome c) assembly 1-like OXA1L 0.65 
NM_001099668 HIG1 hypoxia inducible domain family, member 1A HIGD1A 0.65 
NR_015434 Uncharacterized LOC148413  0.65 
NM_013335 GDP-mannose pyrophosphorylase A GMPPA 0.65 
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NM_022765 
Microtubule associated monooxygenase, calponin and LIM domain 
containing 1 
MICAL1 
0.65 
NM_002086 Growth factor receptor-bound protein 2 GRB2 0.65 
NM_033296 Morf4 family associated protein 1 MRFAP1 0.65 
NM_153611 Cytochrome b561 family, member A3 CYB561A3 0.65 
NM_001114618 
Mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase 
MGAT1 
0.65 
NM_015941 ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H ATP6V1H 0.65 
A_33_P3358347 **   0.65 
NM_002953 Ribosomal protein S6 kinase, 90kDa, polypeptide 1 RPS6KA1 0.65 
NM_014287 NODAL modulator 1 NOMO1 0.65 
NM_000969 Ribosomal protein L5 RPL5 0.65 
NM_014338 Phosphatidylserine decarboxylase PISD 0.65 
NM_017719 SNF related kinase SNRK 0.65 
NM_001087 Angio-associated, migratory cell protein AAMP 0.65 
NM_032508 Transmembrane protein 185A TMEM185A 0.65 
NM_001127695 Cathepsin A  CTSA 0.66 
NM_006819 Stress-induced-phosphoprotein 1 STIP1 0.66 
NM_005390 Pyruvate dehydrogenase (lipoamide) alpha 2 PDHA2 0.66 
NM_002872 Ras-related C3 botulinum toxin substrate 2 RAC2 0.66 
NM_006369 Leucine rich repeat containing 41 LRRC41 0.66 
NM_000294 Phosphorylase kinase, gamma 2 (testis) PHKG2 0.66 
NM_176096 CDK5 regulatory subunit associated protein 3 CDK5RAP3 0.66 
NM_005788 Protein arginine methyltransferase 3 PRMT3 0.66 
NM_152293 Transcriptional adaptor 2B  TADA2B 0.66 
NM_139279 Multiple coagulation factor deficiency 2 MCFD2 0.66 
NM_001040033 CD53 molecule CD53 0.66 
NM_000183 Hydroxyacyl-CoA dehydrogenase hydratase beta subunit HADHB 0.66 
NM_007065 Cell division cycle 37 CDC37 0.66 
A_33_P3283167 **   0.66 
NM_002168 Isocitrate dehydrogenase 2 mitochondrial  IDH2 0.66 
NM_005692 ATP-binding cassette, sub-family F member 2  ABCF2 0.66 
Appendix 
249 
 
NM_007001 Solute carrier family 35 member D2 SLC35D2 0.66 
NM_130803 Multiple endocrine neoplasia I  MEN1 0.66 
NM_001077351 RNA binding motif protein 23 RBM23 0.66 
NM_006357 Ubiquitin-conjugating enzyme E2E 3 UBE2E3 0.66 
NM_000918 Prolyl 4-hydroxylase, beta polypeptide P4HB 0.66 
NM_178819 1-acylglycerol-3-phosphate O-acyltransferase 6 AGPAT6 0.66 
NM_032985 Sec23 homolog B SEC23B 0.66 
NM_021822 Apolipoprotein B mRNA enzyme, catalytic polypeptide-like 3G APOBEC3G 0.66 
A_24_P603890 **   0.66 
NM_019015 Chondroitin polymerizing factor 2 CHPF2 0.66 
NM_007067 K(lysine) acetyltransferase 7 KAT7 0.66 
NR_003226 AFG3 ATPase family member 3-like 1 pseudogene AFG3L1P 0.66 
NM_014771 Ring finger protein 40, E3 ubiquitin protein ligase RNF40 0.66 
NM_006831 Cleavage and polyadenylation factor I subunit 1 CLP1 0.66 
NM_032272 MAF1 homolog MAF1 0.66 
NM_001243646 CD2 (cytoplasmic tail) binding protein 2 CD2BP2 0.66 
NM_000918 Prolyl 4-hydroxylase, beta polypeptide P4HB 0.66 
NM_002969 Mitogen-activated protein kinase 12 MAPK12 0.66 
NM_024419 Phosphatidylglycerophosphate synthase 1 PGS1 0.66 
NM_001961 Eukaryotic translation elongation factor 2 EEF2 0.66 
TCONS_l2_00005546 ^^   0.66 
NM_006066 Aldo-keto reductase family 1, member A1  AKR1A1 0.66 
NM_033446 Multivesicular body subunit 12B MVB12B 0.66 
NM_016238 Anaphase promoting complex subunit 7 ANAPC7 0.67 
NM_004393 Dystroglycan 1  DAG1 0.67 
NM_015274 Mannosidase, alpha, class 2B, member 2 MAN2B2 0.67 
NM_032564 Diacylglycerol O-acyltransferase 2 DGAT2 0.67 
NM_004168 Succinate dehydrogenase complex, subunit A SDHA 0.67 
A_33_P3361817 **   0.67 
NM_024833 Zinc finger protein 671 ZNF671 0.67 
 












